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Aim 
 
The aim of this PhD work was to develop micro- and nano-carriers for some drugs derived 
from plants. Vegetal world is a big box, containing numerous potential therapeutic 
molecules but many of them suffer of poor biopharmaceutical properties which affect their 
effectiveness. Micro- and nano-carriers represent formulation technologies which can 
hugely modify drug release profile, absorption, distribution and elimination for the benefit of 
improving product efficacy and safety, as well as patient convenience and compliance. 
The molecules investigated in the present project were artemisinin, isolated from Artemisia 
annua L., verbascoside, purified from Lippia citriodora H.B.K. and resveratrol, derived from 
Vitis vinifera L. 
 
Artemisinin is a sesquiterpene lactone having an unusual endoperoxyl moiety which is 
essential for the activity. The molecule has a poor bioavailability due to its little solubility 
both in oil and water and it is not stable decomposing by the opening of the lactone ring or 
lacking the endoperoxide moiety (Klayman DL, 1985).  
Verbascoside is a phenylpropanoid molecule represented by two sugar moieties (glucose 
and rhamnose), a phenylpropanoid structure (caffeic acid) and a phenylethanol moiety. It 
is very water soluble (up to 30 mg/mL) but in aqueous media it is unstable and it 
undergoes to degradation which is correlated to the pH (Sinico C, 2008). The main 
reaction involved in this process is the hydrolysis of the caffeic acid moiety which led to the 
formation of an inactive molecule. 
Resveratrol is a stilbenoid molecule having a low solubility in aqueous media, with a poor 
bioavailability and high propensity to oxidize (Walle T, 2004; Trela BC, 1996; Wenzel E, 
2005). Resveratrol exists as two possible geometric isomes: cis- (Z) and trans- (E). The 
trans- form can undergo isomerisation to the cis- form when exposed to ultraviolet 
irradiation but this isomer is inactive. (Prokop J, 2006). This isomerization is very fast and 
represent a very huge problem for the use of trans-resveratrol in pharmaceutical and 
cosmetic applications (Wang Y, 2002).  
 
These three molecules having very different structures and as a consequence distinctive 
problematics related to their scarce solubility and/or poor stability were chosen to solve 
some practical aspects related to their therapeutically use but also as model structures to 
substantiate how pharmaceutical technology may deeply affect bioavailability profile of 
drugs.  
Carriers with different characteristics were developed and tested for evaluating their 
efficacy and versatility as Troy’s horses. It is clear that making new formulations without 
trying their real application or therapeutic capability seems only a style exercise. 
Many efforts were done in order to test in vivo the innovative formulations. So, many links 
and collaborations with other researchers’ groups were created, believing deeply in an 
international sharing of knowledge.  
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I.   Artemisinin 
 
 
 
 
 
 
 
 
 
I.1.  Introduction 
 
I.1.1.  Artemisinin: Hystory 
 
Artemisinin (qinghaosu), an endoperoxide sesquiterpene lactone isolated from Artemisia 
annua L. a plant derived from Traditional Chinese Medicine, which was used for at least 
2000 years to treat fever and malaria (Klayman DL, 1985; Duffy PE, 2004; Meshnick SR, 
1998). Its earliest recorded use dates as far back as  340 BC when Ge Hong of the East 
Jin dynasty described this herbal medicine in The Handbook of prescription for 
emergencies. In 1596, The Chinese herbalist Li Shizhen recommended that patients with 
fever take a handful of qinghaosu , soak it in a sheng (about 1 liter) of water, squeeze out 
the jouice and drink it all (Efferth T, 2009). 
Nowadays, artemisinin is considered one of the most important secondary metabolite and 
bioactive constituent (Klaiman DC, 1985; van Agtmael MA, 1999; Heppner DG, 1998). 
Now is available commercially in China, Vietnam and other countries as an antimalarial 
drug. 
 
I.1.2.  Artemisinin: Source 
 
Malaria continues to be a major global killer disease despite continuous efforts to reduce 
its toll. Each year at least a million people die with more than 80% of these in Africa south 
of the Sahara. Within this number, pregnant women and children under five years of age 
account for the majority of the victims (WHO, UNICEF, 2005). 
The widespread development of resistance in malaria parasites against the cheapest 
antimalarials such as chloroquine and to a lesser extent quinine has prompted a search for 
alternative treatments. In remote regions patients often first consult traditional herbalists 
and healers before visiting the nearest clinic or hospital (usually only when symptoms 
worsen). Because of its efficacy against both uncomplicated and severe malaria, there is a 
global demand for artemisinin and its derivatives, which are the active compounds against 
falciparum malaria. The increased demand has led to fears of a future shortage if  
increased cultivation of Artemisia annua L., the source of artemisinin is not pursued. The 
non-governmental organisations Anamed (Action for Natural Medicine) and Medicos 
Descalzos (Barefoot doctors) have set up programs for small scale cultivation and local 
utilization of herbal formulations of A. annua L. (Hirt HM, 2000). 
Artemisia annua L. (sweet or annual wormwood, member of Asteraceae family) is an 
annual herbaceous plant with a strong fragrance endemic to the northern parts of Chahar 
and Suiyuan Provinces in China, at 1000-1500 m above sea level (Wang CW, 1961) 
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where it is known as qinghao  (green herb) and used as a remedy for chills and fevers 
since more than 2000 years (Klaiman DC, 1985; Hien TT, 1993). Artemisia is now growing 
in many European countries and has also become naturalized in North America. A. annua 
is an interesting source of essential oils (Simon JE, 1990), however, its economical 
importance is mainly determined by being probably the only species of genus Artemisia 
able to synthesize artemisinin (Baraldi R, 2008). In 1972, the active ingredient was isolated 
and first named qinghaosu (essence of qinghao), and then later renamed artemisinin 
(Meshnick SR, 2002). In the 1979 its structure was fully elucidated. 
 
I.1.3.  Artemisinin: Chemical properties 
 
Artemisinin presents many problems due to its poor biopharmaceutical properties. First of 
all, it has low bioavailability due to its low solubility. Artemisinin metabolizes quickly in vivo 
and has an initial burst effect and high peak plasma concentration (Chen Y, 2009). It is not 
very stable and easly decomposes, most probably by the opening of the lactone ring, due 
to its unusual peroxy group (Klayman DL, 1985). It is difficult for drug crystals to disperse 
homogeneously because of their hydrophobicity in solution or blood. In addition, a greater 
number of injections is necessary because of the short-duration effect (Chen Y, 2009). 
 
I.1.4.  Artemisinin: Antimalarian activity 
 
Artemisinin is considered a potent antimalarial drug, even against chloroquine- and 
quinine-resistant Plasmodium falciparum and other malaria-causing parasites (Meshnick 
SR, 1998; Baraldi R, 2008). At the moment, artemisinin is the basis of a large family of 
drugs recommended by the World Health Organization to fight malaria in the countries 
where highly resistant strains of the protozoan have been certified (Baraldi R, 2008). 
Its chemical action on the human organism has not yet completely clarified. The theory 
more realistic seems that in Plasmodia species, the cleavage of the endoperoxide moiety 
of artemisinin is facilitated by haeme-iron. Erythrocyte haemoglobin serves as an amino 
acid source for Plasmodium trophozoites and schizonts. The parasites take up 
haemoglobin and degrade it in their food vacuoles (Shenai BR, 2000). The release of 
haeme-iron during haemoglobin digestion facilitates the cleavage of the endoperoxide 
moiety of artemisinin by an iron(II) Fenton reaction. Thereby, reactive oxygen species, 
such as hydroxyl radicals and superoxide anions, are generated. They damage the 
membranes of food vacuoles and lead to auto-digestion (Krishna S, 2004). 
Artemisinin offers impressive effects including characteristics of ‘high efficacy, fast-action 
and low-toxicity’, and is regarded as ‘a breakthrough in the history of antimalarial drugs’ 
(Heppner DG, 1998). It is a potent blood schizonticide with a minimum inhibitory 
concentration of 0.1 µM (De Vries PJ, 1996). 
 
I.1.5.  Artemisinin: Pharmacological effects 
 
It has been found to be effective also against other infectious diseases including hepatitis 
B (Romero MR, 2005) and parasites that cause schistosomiasis (Bormann S, 2001; 
Utzinger J, 2001). More recently, artemisinin and its derivatives (expecially its water 
soluble derivative artesunate) have been shown to be effective also against numerous 
types of tumors, including breast cancer, human leukemia, colon, and small-cell lung 
carcinomas (Efferth T, 2001; Singh NP, 2001). Artemisinin is a therapeutic molecule to 
control human cancers with reduced side-effects (Firestone GL, 2009). Artemisinin is also 
selectively toxic to cancer cells because of their high iron content; in vitro in the presence 
of iron, induces apoptosis (Singh NP, 2004), and is lethal towards human leukaemia (Lai 
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H, 1995) and breast cancer cells (Singh NP, 2001). Normal cells pick up less iron and 
have better intracellular regulation of iron content, they are significantly less susceptible to 
artemisinin (Lai H, 2006). Artemisinin is able to prevent breast cancer development in rats. 
In addition, breast tumors in artemisinin-fed rats were significantly fewer and smaller in 
size when compared with controls. These data indicate that artemisinin may be a potent 
cancer-chemoprevention agent (Lai H, 2006). 
 
Curcumin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I.1.6.  Curcumin: Source 
 
Curcumin, diferuloylmethane isolated from the rhizomes of the Curcuma longa L. 
(Zingiberaceae family) plant, a perennial herb widely cultivated in tropical regions of Asia 
and extensively used for imparting colour and flavour to food (Shoba G, 1998).  
 
I.1.7.  Curcumin: Antimalarian activity 
 
Studies both in vitro with P. falciparum and in vivo with a rodent model of malaria (P. 
berghei) have indicated that curcumin has also an antimalarial activity against sensitive 
and multidrug resistant parasites (Reddy RC, 2005; Nandakumar DN, 2006).  
The target of curcumin is not known, although it has been suggested to be the PfATP6 
protein (Reddy RC, 2005), which has already been implicated as a potential candidate of 
artemisinin-resistance in malaria (Eckstein-Ludwig U, 2003). 
 
I.1.8.  Curcumin: Pharmacological activity 
 
Curcumin has been shown to regulate a number of biological responses (Araujo CC, 
2001). Curcumin has been shown to have antitumoral properties (Kuttan G, 2007). 
Additionally, curcumin and, to a lesser extent, its  metabolites have been shown to have 
immunomodulatory activities which may also contribute to the beneficial effects of 
curcumin against autoimmune diseases and cancer (Jagetia GC, 2007; Sandur SK, 2007). 
In addition to its anti-tumorigenic, anti-oxidant, and antinflammatory effects, curcumin has 
been shown to possess anti-microbial activity (Araujo CC, 2001; Rasmussen HB, 2000). 
Curcumin has been shown to hinder Leishmania (Koide T, 2002) and Trypanosoma (Nose 
M, 1998) viability.  
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I.1.9.  Artemisinin-based combination therapy (ACT) 
 
Malaria continues to be one of the major public problems in Africa, Asia and Latin America. 
The World Health Organisation (WHO) has racommended that all the antimalarians must 
be combined with an artemisinin component (artemisinin-based combination therapy ACT) 
for use as first line treatment against malaria. This class is now first line policy in most 
malaria-endemic countries (Ioset JR, 2009; Eastman RT, 2009).  
 
 
 
Fig 1. (a) The worldwide incidence of malaria and (b) the rapid adoption of ACT across the sub-
Saharan Africa (Nature Review Microbiology, 2009). 
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In the figure 1 (a), incidence of malaria worldwide in 2006, stratified per 1000 population, 
was estimated. Cases in Africa constituted 86% of the global total, Southeast Asia 
accounted for 9% and the eastern of Mediterranean regions had 3%. Plasmodium 
falciparum was found to be responsible for over 75% of the cases in most of sub-Saharan 
African countries but was second to Plasmodium vivax in most countries outside of Africa 
(WHO, 2008). In the figure 1 (b), the official first-line antimalarian policy in Africa in 2003 
and 2007, demonstrating the dramatic shift from a diversity of first line antimalarials 
(typically chloroquine or sulphadoxine-pyrimethamine) towards the adoption of artemisinin-
based combination therapies (UNICEF, 2007). 
It is now widely accepted that the emergence of artemisinin resistance in natural parasite 
populations of P. falciparum may be only a question of time. In order to delay the 
development of resistance and thus prolong the efficacy of artemisinin and its derivatives, 
artemisinins have been paired with other drugs in so-called artemisinin combination 
therapies (ACT) (Martinelli A, 2008). These have however been criticized due to the 
pharmacokinetic  mismatches between the two drugs within the combination and to the 
fact that resistance versus the non-artemisinin component of the combination is commonly 
present (Hastings IM, 2006).  
Curcumin has been recently proposed as an attractive partner drug for artemisinins, due to 
its short half-life (1–2 h), closely matching that of artemisinin, its relative abundance and 
cost effectiveness (Reddy RC, 2005; Nandakumar DN, 2006). Artemisinin and curcumin 
show an additive interaction in killing P. falciparum in culture with; IC50 for artemisinin and 
curcumin are 45-50 nM and 15-18 µM, respectively (Nandakumar DN, 2006).  
In view of its abundance, non-toxic nature and demonstrated therapeutic effects in a 
variety of human diseases, it will be useful to further investigate the potential of curcumin 
in developing low-cost antimalarial therapies (Reddy RC, 2005). 
 
I.2.  Materials and methods 
 
I.2.1.  Chemicals and standards 
 
All the solvents used for the extraction and HPLC analysis (MeOH, n-hexane, 
dichloromethane, and acetonitrile) were HPLC grade from Merck (Darmstadt, Germany); 
85% formic acid was provided by Carlo Erba (Milan, Italy). Water was purified by a Milli-
Qplus system from Millipore (Milford, MA). Solution NaCl 0.9%, Fresenius Kabi, Italy. 
Artemisinin was purchased from Sigma (Sigma-Aldrich srl, Milan, Italy). Curcumin 
purchased from Extrasynthese (Milan, Italy). 18:0/18:0 PEG 2000 was purchased by 
Spectra2000 srl (Rome, Italy), italian seller for Avanti Polar (Canada). Egg 
phosphatidylcholine (Phospholipon90G, P90G) were kindly obtained from Natterman 
Phospholipids, Gmb. Cholesterol, dicetylphosphate and stearylamine were analytical 
grade and were purchased from Aldrich (Milan, Italy). Phosphotungstic acid and copper 
grids with carbon film 150 mesh were purchased from Società Italiana Chimici (Rome, 
Italy). 
Artemisinin reference standard (ST3105, batch no. C005641) which was used for the 
quantification of artemisinin, was kindly provided by Sigma-tau (Pomezia, Rome, Italy). 
Rutin trihydrate reference standard (batch no. K12408717, standard purity 88.17%, 
considering the content of residual solvents, moisture and amount of impurities) which was 
used for the quantification of polymethoxylated flavonoids, was kindly provided by Indena 
Research Laboratories (Settala, Milan, Italy). 
Curcumin standard was used for the quantification of curcumin, was kindly provided by 
Extrasynthese (Milan, Italy). 
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I.2.2.  Plant material and growth condition 
 
Seeds of Artemisia annua L. (a gift from a private collection site near Bologna, Italy) were 
sown in 1x1 m nursery beds in April and germinated in greenhouse. One month old 
seedlings were then transplanted into pots containing peat and the obtained plantlets were 
then transferred outside where they were allowed to acclimate for 4 weeks before planting 
in the experimental field located in a flat land site 11°37’ E and 44°300’ N in the Po Valley, 
Italy, with an intra-row and inter-row spacing of 0.2 and 1 m, respectively. The plants were 
sampled randomly and the different parts of the flowering tops (leaves and inflorescences) 
were harvested at different time during the vegetative phase (pre-flowering, full bloom and 
post-flowering), separated manually, weighted and stored frozen at -20°C until analysis to 
check the artemisinin and flavonoid concentrations. Plant dried material used for the 
analyses at pre-flowering, full bloom and post-flowering were 24.17, 3.7 and 20.30 g, 
respectively, for the inflorescence and 14.20, 3.4 and 8.20 g for leaves. 
 
I.2.3.  Preparation of the extracts 
  
Leaves and inflorescences at different developmental stages were lyophilized and cut into 
small pieces with an Osterizer. The samples were exhaustively extracted at room 
temperature by maceration with 100 mL of hexane for 72 h. The eluates were 
subsequently taken to dryness under reduced pressure to obtain the crude extracts. 
 
I.2.4.  Preparation of the samples for HPLC/DAD/ESI MS analysis 
 
Three samples of 10 mg of dried n-hexane extract (accurately weighed) were suspended 
in 2 mL acetonitrile in a volumetric flask and sonicated for 30 min. The suspensions were 
filtered and each of the sample solutions was injected three times. Quantification of 
artemisinin was performed by the MS detection while flavonoids were quantified by UV 
detection at 280 nm. Calibration curves were obtained from a methanolic solution of the 
reference standards containing artemisinin or rutin with the concentrations ranging 
between 0.01 and 2.0 mg/mL. All calibration levels (n=5) were measured six times. Results 
were calculated using the peak areas. 
 
I.2.5.  Analytical HPLC/DAD characterization 
 
The HPLC analyses were performed using a HP 1100 Liquid Chromatograph (Agilent 
Technologies, Palo Alto, CA, USA) equipped with a HP 1040 Diode Array Detector (DAD), 
an automatic injector, an auto sampler and a column oven and managed by a HP 9000 
workstation (Agilent Technologies, Palo Alto, CA, USA). Separations were performed on a 
reversed phase column Purospher® Star RP-18, namely Hibar® Prepacked column RT 
(250 x 4.6 mm) with particle size 5 mm (Merck, Darmstadt, Germany).  
The eluents were H2O at pH 3.2 by formic acid and acetonitrile. The following multi-step 
linear gradient was applied:  
 
Time 
(min.) 
CH3CN 
(%) 
H2O/HCOOH 
pH=3.2 
(%) 
0.1 50 50 
15 50 50 
20 100 0 
23 100 0 
28 50 50 
 8 
 
 
 
The system was operated with a flow of 1 mL/min and with the oven temperature at 26°C; 
the injection volume was 20 µL. Before HPLC analysis, each sample was filtered through a 
cartridge-type sample filtration unit with a polytetrafluoroethylene (PTFE) membrane (d=13 
mm, porosity 0.45 µm, Lida manufacturing Corp.) and immediately injected. 
Chromatograms were recorded at 240, 280, 350 nm to detect flavonoids and any other 
constituents and at the wavelength of 420 nm in order to detect the amount of curcumin in 
combined liposomes. 
 
I.2.6.  Analytical HPLC/ESI MS characterization 
 
The HPLC system described above was interfaced with a HP 1100 MSD API-electrospray 
(Agilent Techologies, Palo Alto, CA, USA). The interface geometry, with an orthogonal 
position of the nebulizer with respect to the capillary inlet, allowed use of analytical 
conditions similar to those used for HPLC/DAD analysis in order to achieve the maximum 
sensitivity of ESI values. The same column, time period and flow rate were used during the 
HPLC/ESI MS analyses. Mass spectrometry operating conditions were optimised in order 
to achieve maximum sensitivity values: negative and positive ionisation mode, scan 
spectra from m/Z 100 to 800, was used with a gas temperature of 350°C, nitrogen flow 
rate of 10 L min-1, nebulizer pressure 30 psi, quadrupole temperature 30°C, Capillary 
voltage 3500V. The applied fragmentors were in the range 80–180 V. Full scan spectra 
from m/z 100 to 800 in the positive ion mode were obtained (scan time 1 s).  
Identification of constituents was carried out by HPLC/DAD and HPLC/ESI MS analysis, 
and/or by comparison and combination of their retention times, UV-Vis and mass spectra 
of the peaks with those of authentic standards when possible, or isolated compounds or 
characterised extracts as well as based on literature data. 
 
I.2.7.  Statistical analysis 
 
Data of physiological variables were analyzed by ANOVA using PC SAS version 8.2 (SAS 
Institute Inc., Cary, NC, USA). Means and standard errors are presented. The 
concentrations were compared using the General Linear Model Procedure with the LSD 
test. Differences referred to as significant had a P value less than 0.05. 
 
I.2.8.  Formulations 
 
I.2.8.1. Production  of liposomes  
 
Multilamellar vesicles were prepared according to the film hydratation method (Bangham 
AD, 1965). P90G, cholesterol and artemisinin were dissolved in chloroform. The organic 
solvent were vacuum evaporated and the dry lipid film was hydratated by addition of 
bidistilled water or physiological solution (Buffer at pH=7.4 or NaCl 0.9% v/v). The 
dispersion was stirred with a mechanical stirrer for 30 minutes with a waterbath at the 
constant temperature of 38°C. In order to reduce the dimensions of the vesicles from MLV 
to LUV, an high pressure homogenizer Emulsiflex C3® was used at the applied pressure 
of 150000 kPa for 60 seconds. Then the liposomes were characterized by different 
techniques. 
 
I.2.8.2. Production  of liposomes with superficial charge 
 
Multilamellar vesicles were prepared according to the film hydratation method (Bangham 
AD, 1965), as described above. Negatively and positively charged vesicles were prepared 
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by using either dicetylphosphate (dihexadecylphosphate) or stearylamine, respectively, as 
a charge inducer. Dicetylphospahate or stearylamine was weighted together with P90G, 
cholesterol and artemisinin. In order to reduce the dimensions of the vesicles, an high 
pressure homogenizer Emulsiflex C3® was used, as described above. 
 
I.2.8.3. Production of PEGylated liposomes  
 
Multilamellar vesicles were prepared according to the film hydratation method (Bangham 
AD, 1965), as described above. 18:0/18:0 PEG 2000 was weighted together with P90G, 
cholesterol and artemisinin in order to obtain stealth liposomes. In order to reduce the 
dimensions of the vesicles, an high pressure homogenizer Emulsiflex C3® was used, as 
described above. 
 
I.2.8.4. Production  of artemisinin-curcumin loaded  liposomes  
 
Multilamellar vesicles were prepared according to the film hydratation method (Bangham 
AD, 1965), as described above. Artemisinin, curcumin, P90G, and cholesterol were 
weighted together with the perspective of combined therapy. In order to reduce the 
dimensions of the vesicles, an high pressure homogenizer Emulsiflex C3® was used, as 
described above. 
 
I.2.9.  Characterization of liposomes 
 
I.2.9.1. Dynamic Light Scattering (DLS) 
 
Dynamic Light Scattering is an ALV CGS-3 system (Malvern Instruments, Malvern, UK) 
equipped with a JDS Uniphase 22 mW He–Ne laser operating at 632.8 nm, an optical 
fiber-based detector, a digital LV/LSE-5003 correlator and a temperature controller 
(Julabowater bath) set at 25 °C. Time correlation functions were analyzed to obtain the 
hydrodynamic diameter of the particles (Zh) and the particle size distribution (polydispersity 
index, PDI) using the ALV-60X0 software V.3.X provided by Malvern. Autocorrelation 
functions were analyzed by the cumulants method (fitting a single exponential to the 
correlation function to obtain the mean size (Zave) and polydispersity index (PDI)) and 
CONTIN (to fit a multiple exponential to the correlation function to obtain particle size 
distributions). The diffusion coefficients calculated from the measured autocorrelation 
functions were related to the hydrodynamic radius of the particles via the Stokes–Einstein 
equation 
     Zh = (kBTq2)/(3piηΓ) 
 
where Zh is the hydrodynamic radius of the particles,  
 kB is the Boltzmann constant,  
 T is the absolute temperature,  
 η is the solvent viscosity,  
 Γ is the decay rate,  
 q is the scattering vector  
     q = [4pinsin(Ф/2)]/λ 
 
in which  n is the refractive index of the solution,  
  Ф is the scattering angle,  
  λ is the wavelength of the incident laser light.  
Scattering was measured in an optical quality 4 mL borosilicate cell at a 90° angle.  
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I.2.9.2. Electrophoretic mobility 
 
Zeta potentials (ζ-potentials) of the liposome systems were measured using a Malvern 
Instruments Zetamaster 5002. For all samples, an average of three measurements at 
stationary level was taken. The cell used was a 5 × 2 mm rectangular quartz capillary. The 
temperature was kept constant  at 25°C by a Haake temperature controller. The zeta 
potential was calculated from the electrophoretic mobility, µE, using the Henry correction to 
Smoluchowski’s equation. 
 
I.2.9.3. Trasmission electron microscopy (TEM): ‘negative contrast’ 
 
A drop (10 µL) of vesicle dispersion diluted 10-times was applied to a carbon film-covered 
copper grid. Most of the dispersion was blotted from the grid with filter paper to form a thin 
film speciment, which was stained with a phosphotungstic acid solution 1% w/v in sterile 
water. The samples were dried for 3 minutes and than they were examined under a JEOL 
1010 electron microscope and photographed at an accelerating voltage of 64 kV. 
 
I.2.9.4. Trasmission electron microscopy (TEM): ‘encapsulation method’ 
 
Liposomal dispersions were fixed with Karnovski’s solution overnight, washed with 
cacodylate solution buffer and then fixed with osmium tetroxide in sodium cacodylate 
buffer (1:1) for 1 h. Following post fixation, the samples were dehydrated in 30%, 50%, 
70%, 80%, 95% and 100% acetone solutions and embedded in epon-araldite resin. 
Ultra-thin sections of liposomal dispersions were obtained with a LKB NOVA 
ultramicrotome using a diamond knife and stained with an alcoholic solution of uranyl 
acetate, followed by a solution of concentrated bismuth subnitrate. These sections were 
examined under a JEOL 1010 electron microscope and photographed. 
 
I.2.9.5. Encapsulation efficacy (EE%) 
 
Free artemisinin was removed by means of  dialysis. Liposomal formulation was 
transferred in a dialysis bag. This dialysis bag was stirred in 800 mL of aqueous medium 
(used for rehydrating the lipid film) at room temperature for 2 hours. The aqueous medium 
was refreshed once. The content of the liposomes with the cleaned surface were 
quantified by HPLC/DAD/ESI MS analysis using artemisinin, rutin triidrate and curcumin  
as external standards for artemisinin, flavonoid and curcumin respectively. 
The artemisinin encapsulation yield is expressed as the so-called entrapment efficiency. 
The EE is defined as the percentual amount of artemisinin entrapped in the vesicles in 
relation to the total amount of artemisinin present during the vesicle formation and 
entrapment procedure. 
EE(%) = {(amount of artemisinin entrapped in the vesicles)/(total amount of artemisinin 
used)}×100. 
 
I.2.10.  In vivo experiment: pharmacokinetic study 
 
I.2.10.1. Mice 
 
Male CD1 mice (25-30 g) were used for the study of pharamacokinetic profile.  
The animal were placed in the experimental room 4 days before the test for 
acclimatization. The animals were fed a standard laboratory diet and tap water ad libitum 
and kept at 23±1°C with a 12-h light/dark cycle, light at 7 AM. All experiments were carried 
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out in accordance with the European Communities Council Directive of 24 November 1986 
(86/609/EEC) for experimental animal care. All efforts were made to minimize the number 
of animals used and their suffering. 
 
I.2.10.2. Pharmacokinetic study 
 
Sixty mice were randomly separated into three groups. One group of mice received 
artemisinin dissolved in DMSO 10% v/v at the dosage of 10 mg/kg i.p. and the other two 
groups were given artemisinin-loaded conventional and PEGylated liposomes dissolved in 
NaCl 0.9% v/v at the same dosage of artemisinin. From jugular vein, blood samples were 
collected into heparinized tubes (to prevent blood coagulation) at 0, 10, 30 min, 1, 2, 3, 4, 
6 and 24 hours after i.p. injection. Blood samples were centrifuged at 2000 rpm for 20 min 
at 17°C to separate plasma from other blood elements. The obtained plasma was stored at 
-20°C prior to analysis.  
 
I.2.10.3. Calibration curves 
 
The calibration curve was determined by constant volume of blank plasma with increasing 
concentration of artemisinin (0-100 µM, final concentration of artemisinin)  dissolved in 
methanol 0.3% v/v. My dilution scheme was: 
 
solution µM dilution 
a 100 - 
b 50 solution a/2 
c 10 solution b/5 
d 6 solution a/1.67 
e 5 solution c/2 
f 2 solution c/5 
g 1 solution f/2 
h 0.5 solution g/2 
i 0.2 solution g/5 
l 0.1 solution i/2 
m 0.05 solution l/2 
n 0 only plasma 
 
I.2.10.4. Sample pre-treatment 
 
Because of the complex nature of plasma, a pre-treatment procedure is often needed to 
remove protein and potential interferences prior to HPLC/MS/MS analysis. Protein 
precipitation is commonly used for fast sample clean-up and disrupting protein–drug 
binding. Each sample, including each point of the calibration curve, were diluted 7 times 
with acetonitrile in order to precipitate plasma proteins. Each sample was vortexed for 15 
seconds and centrifuged at 10000 rpm for 2.5 minutes. 200 µL of each sample were 
transferred in 96-well format plates, which resulted in shorter sample preparation time. 
 
I.2.10.5. Analytical HPLC/MS/MS characterization 
 
An Applied Biosystems-Sciex (Toronto, Canada) API 4000 bench-top Triple-Quad Mass 
Spectrometer equipped with the TurboIonSpray source was used. The TurboIonSpray 
source operated under positive ion mode at a voltage of 5000V and with a “turbo” gas flow 
of 10 L/min of air heated at 150°C. Collision activated dissociation (CAD) MS/MS was 
performed through the LINAC Q2 collision cell, operating with 10mT or pressure of 
nitrogen as collision gas.  
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Declustering Potential (DP), Collision Exit Potential (CXP) and Collision Energy (CE) were 
automatically optimized for Artemisinine by the "Quantitation Optimization" option. The 
resulting DP was +30 Volts. Optimal CE and CXP were found at 15 V and 12 V 
respectively. MS and MS/MS spectra were collected in continuous flowmode by 
connecting the Infusion pump directly to the TurboIonSpray source. The quantitation 
experiments were undertaken by using a Series 1100 Agilent Technologies (Waldbronn, 
Germany) CapPump coupled to an Agilent Micro ALS autosampler, both being fully 
controlled from the API 4000 data system. Liquid chromatography was performed using an 
Agilent Zorbax Eclipse XDB-C18 3.5µm, 3 × 150 mm HPLC column (Waldbronn, 
Germany). Column flow was 0.4 mL/min using an aqueous solution of 85% Acetonitrile 
containing 0.1% formic acid. The eluent from the column was directed to the 
TurboIonSpray probe without split ratio. The data were processed using the Analyst 1.4.1 
proprietary software. The molecular ion (283 m/Z) was selected in the first quadrupole and 
two fragments 151 m/Z (MRM 1 as quantifier transition) and 209 m/Z (MRM 2 as qualifier 
transition) were monitored in the third quadrupole. 
 
  
m/Z 
MRM 1  283→151  
MRM 2  283→209 
 
I.2.10.6. Data analysis 
 
Analysis of artemisinin concentrations in plasma was performed with a computerised 
program (Syphar, version 4.0; SIMED) using a two-compartment model on the basis of the 
extended least squares regression method with the Powell minimisation algorithm, and 
elimination from the central compartment. The AUC was determined by trapezoidal rule 
and was extrapolated to 24 h. AUC values were determined for the period 0–24 h. Cmax 
was the observed peak value. The elimination half-life (tβ1/2) was determined as 0.693/β 
(where β is the elimination rate constant, obtained by the equation dC/dt =−βC, where C is 
the concentration and t is time); CL was calculated by dividing the dose by the AUC0–24h 
(Gibaldi M, 1982).  
 
I.2.10.7. Statistics 
 
Statistical analysis was carried out using GraphPad Version 4. PK parameters were 
analysed with the two-way analysis of variance (ANOVA) test and Duncan’s post-hoc test. 
Data are reported as mean±S.D. unless otherwise stated. A P-value <0.05 was considered 
significant. 
 
I.2.11.  In vivo experiment: antiplasmodian activity 
 
I.2.11.1. Mice 
 
Female BALB/c mice (20-25 g) were used for the study of antimalarian activity.  
The animals were fed a standard laboratory diet and tap water ad libitum and kept at 
22±1°C with a 12 h light/dark cycle, and 60% humidity regulated environment. All 
experiments were carried out in accordance with the European Communities Council 
Directive of 24 November 1986 (86/609/EEC) for experimental animal care. All efforts 
were made to minimize the number of animals used and their suffering. 
 
I.2.11.2. Inoculation of parasites 
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A cryopreserved isolate of the virulent rodent malaria parasite strain Plasmodium berghei 
(NK 65), originally from the Istituto Superiore di Sanità (Rome, Italy) is a specific mouse 
malaria and does not infect man. Immediately after thawing, the isolate was injected i.p. in 
a mouse that later served as a donor. Then, parasite strain was maintained by weekly 
serial passage of blood from donor mouse to other mice. The parasitaemia was checked 
daily. A thin smear of peripheral blood from the tail vein was taken, Giemsa stained and 
observed under an immersion optical microscope (David AF, 2004). When the count of the 
infected red blood cells is 20-30%, blood was taken from venous ocular sinus and was 
diluted with isotonic saline solution. Each mouse was inoculated i.p. with 200 µL inoculum, 
which is constituted by 1x107 infected erythrocytes. 
 
I.2.11.3. In vivo antiplasmodial activity 
 
Antiplasmodial activity was evaluated using the 4-day suppressive test described by 
Peters and coworkers (Peters W, 1975; David AF, 2004; Fidock DA, 2004) employing P. 
berghei NK 65. 
Each Balb/c mouse was inoculated i.p. with 200 µL of inoculum, which is constituted by 
1x107 infected erythrocytes. Mice were divided in 4 groups, each group is constituted by 2 
animals: 
• negative control, mice were injected i.p. with 200 µL of bidistilled water 
• positive control, mice were injected i.p. with artesunate 50 mg/kg 
• conventional liposomes, mice were injected with artemisinin delivered at 10 mg/kg. 
Artesunate and the formulation were injected daily for one week, starting 24 hors after 
infection of mice with inoculum (1x107 red blood cells/mL infected with P. berghei). 
The parasitaemia was checked 3, 5 and 7 days after infection. A thin smear of peripheral 
blood from the tail vein was taken, coloured with Giemsa 10% and observed at the 
immersion optical microscope 100x. The level of parasitaemia was determined counting 
the number of infected red blood cells. The reduction of parasitaemia was calculated by 
the following formula  
100 (A−B/A) 
where A is the percentage of parasitaemia in the negative control group and B is the 
percentage of parasitaemia in the tested groups (Tona L, 1998). 
During the whole experiment, the survival of the animals was assessed. 
 
I.3.  Results and discussion 
 
I.3.1.  Content of artemisinin and flavonoids at various developmental stages 
of the plant 
 
Artemisinin and bioactive flavonoids were identified from aerial parts (inflorescences and 
leaves) of Artemisia annua plants and were quantified by HPLC/DAD/ESI MS analyses 
during different developmental stages: pre-flowering, full bloom and post-flowering. 
Artemisinin (qinghaosu), an endoperoxide sesquiterpene lactone, is considered the most 
important secondary metabolite and bioactive constituent (Klaiman DC, 1985; van Agtmael 
MA, 1999; Heppner DG, 1998). Its relativel low yields can vary considerably, depending on 
the plant material, growing conditions and seasonal and geographic variations: in the plant 
it is generally present in the shoots and seeds (Abdin MZ, 2003) with highest levels in field 
grown leaves and flowers (0.01-1.4% dry weight; van Agtmael MA, 1999) where 
artemisinin is sequestered in glandular trichomes (Duke MV, 1994).  
Although its total synthesis has been achieved (the total organic synthesis gives low yields 
and is uneconomical due to its complex structure), its extraction from the plant still 
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represents the only reliable resource (Klaiman DC, 1985; De Vries PJ, 1996; Van Geldre 
E, 1997) even if the required annual targets of 20-22 t/yr of artemisinin are not being 
achieved (RBM, 2005; WHO, 2005). At present, commercial artemisinin is mainly 
extracted from selected heedings (artemisinin high yelds, up to 2%), but they are still 
affected by pedoclimatic variations. 
Artemisinin concentration vary with genotype (Charles DJ, 1990; Jain DC, 1996), plant 
tissue and time of harvesting (Laughlin JC, 1993, 1995; Morales M, 1993; Ferreira JFS, 
1996), and is influenced by soil and climatological conditions (Van Geldre E, 1997; Vaz 
APA, 2006).  
In view of the scarcity of artemisinin and of its actual high demand in the world, it is 
important, therefore, to establish the conditions that favour the increase of these 
metabolites together with the content of artemisinin at various stages of the vegetative life 
of the plant.  
Artemisinin determination in Italian ecotypes of A. annua would provide information about 
its utilization for commercial production of this compound.  
Previous studies have pointed out that other secondary metabolites of plants, such as the 
polymethoxyflavonoids casticin and artemetin present in the phytocomplex can enhance 
the bioavailability or the activity of artemisinin against P. falciparum (Elford BC, 1987). In 
particular, casticin was found to be active in inhibiting some cytophysiological activities of 
the parasite (Yang SL, 1995).  
 
I.3.1.1. Analytical HPLC/DAD/ESI MS characterization 
 
In the chromatogram at 280 nm of the n-hexan extract of Artemisia annua L., four 
flavonoids were detected, namely eupatin, an unseparable mixture of chrysoplenetin and 
casticin, and artemetin, previously isolated and identified in the aerial parts of a selected 
breeding of Artemisia annua L. (Bilia AR, 2002).  
O
R3
R2
H3CO
H3CO
OH O
R1
 
 
flavonoid R1 R2 R3 
eupatin -OH -OCH3 -OH 
casticin -OCH3 -OCH3 -OH 
chrysoplenetin -OCH3 -OH -OCH3 
artemetin -OCH3 -OCH3 -OCH3 
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Identification of flavonoids was carried out by 
HPLC/DAD and HPLC/ESI MS analysis, UV-Vis 
and mass spectra of the peaks with those of 
authentic standards when possible, or isolated 
compounds and, and/or by comparison and 
combination of their retention times, or 
characterised extracts as well as based on 
literature data. The UV spectrum of 
polymethoxylated flavonoids is rapresented in 
figure 2. Polymethoxylated flavonoid were 
quantified at 280 nm using rutin trihydrate 
reference standard as external standard. 
  
 
Fig 2.  UV spectrum of flavonoids. 
 
 
 
Identification of artemisinin was carried out by 
HPLC/ESI MS analysis and mass spectra of the 
peaks with that of authentic standard. 
Artemisinin reference standard was also used 
for the calibration of artemisinin. Mass spectrum 
(fig 3) were optimized in scan modality, positive 
polarity and fragmentor of 120 V.  
 
 
 
 
 
 
 
 
 
Fig 3. Mass spectrum of artemisinin. 
 
I.3.1.2. Content of polymethoxylated flavonoids 
 
All the constituents were found in both leaves and inflorescences at all the developmental 
stages. Nevertheless, their distribution pattern vary with both plant component and 
developmental stage. Among flavonoids, the highest yields were obtained for an 
flavonoid  m/Z 
eupatin [M+H]+ 361 
casticin [M+H]+ 375 
chrysoplenetin [M+H]+ 375 
artemetin [M+H]+ 389 
  m/Z 
artemisinin [M+Na]+ 305 
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inseparable mixture of the two isomers casticin/chrysoplenetin followed by artemetin and 
eupatin.  
Eupatin (fig 4) was found in very low concentrations in all plant parts and during all the 
developmental stages. In leaves, eupatin level increased from 0.035 mg 100 g-1 dried 
herbal drug (DHD) at pre-flowering to 0.69 mg 100 g-1 DHD at post-flowering. The highest 
contents were measured in full bloom and post-flowering inflorescences (1.08 and 1.11 mg 
100 g-1 DHD, respectively).  
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Fig 4. Eupatin contents in the different developmental stages of A. annua. 
 
Casticin and chrysoplenetin (fig 5) reached similar highest contents during full bloom in 
both inflorescences and leaves (39.2 and 36.2 mg 100 g-1 DHD, respectively). Significantly 
lower levels were measured during pre- and post-flowering in both plant organs.  
 
0
5
10
15
20
25
30
35
40
45
incipient
flowering
blossom time post floweringca
st
ic
in
/c
hr
ys
o
pl
en
et
in
 
(m
g/
10
0g
 
dr
ie
d 
he
rb
al
 
dr
u
g)
inflorescences
leaves
 
Fig 5. Casticin/Chrisoplenetin contents in the different developmental stages of A. annua. 
 
The fourth flavonoid, artemetin (fig 6), had a different distribution pattern. The highest 
concentration was again found at blossom time and it was higher in leaves (14.2 mg 100 g-
1
 DHD) than in the inflorescences (11.1 mg 100 g-1 DHD). The latter content was not 
statistically different to those observed in the inflorescences during pre- and post-
flowering. On the contrary, during these stages, artemetin concentrations in the leaves 
significantly decreased compared to the level recorded at full bloom. 
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The total levels of flavonoids were thus higher at full bloom with similar values in both plant 
organs (about 50 mg 100 g-1 DHD). 
 
0
2
4
6
8
10
12
14
16
incipient
flowering
blossom time post floweringar
te
m
et
in
 
(m
g/
10
0g
 
dr
ie
d 
he
rb
al
 
dr
u
g)
inflorescences
leaves
 
Fig 6. Artemetin contents in the different developmental stages of A. annua. 
 
I.3.1.3. Content of artemisinin  
 
Concerning the distribution pattern of artemisinin (fig 7), the highest levels were reached in 
both leaves and inflorescences at full bloom (54.1 and 44.0 mg 100 g-1 DHD, respectively) 
with the former value significantly higher than the latter. In pre- and post-flowering, 
artemisinin levels reached lower concentration in analyzed plant organs. Significant 
differences were observed during pre-flowering with the highest level (25.2 mg 100 g-1 
DHD) in the inflorescences, almost two times more than the value obtained in the leaves. 
At post-flowering these plant organs contained only one-tenth of the content recorded 
during blossom time. No significant differences were observed in the leaves at pre- and 
post-flowering. 
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Fig 7. Artemisinin contents in the different developmental stages of A. annua. 
 
It is interesting to observe that both total flavonoids (eupatin, casticin, chrysoplenetin and 
eupatin) and artemisinin showed higher values in aerial parts at full bloom (fig 8), when the 
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total amount of the polyphenols was about twice the values observed during incipient and 
post-flowering stages. On the other hand, artemisinin content was only 40 and 20% at pre- 
and post-flowering, respectively, in comparison with the values measured at blooming. 
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Fig 8. Content of total flavonoids and artemisinin during the investigated developmental stages of A. 
annua. 
 
Several reports have shown that artemisinin concentration changes, not only during the 
vegetative growth, but it varies considerably also in the different plant components 
between strain origin (Laughlin JC, 2002). Furthermore, reports differ regarding the stage 
at which the highest content of artemisinin occurs during plant development: just before 
flowering (Acton N, 1985; ElSohly HN, 1990; Liersh R, 1986; Woerdenbag HJ, 1991; 
1993), or at the point of full blooming (Ferreira JFS, 1995; Morales M, 1993; Pras N, 1991; 
Singh A, 1988). Since these differences may be attributable to climatic conditions, 
ecotype, cultural practices or a combination of these factors, it is worthwhile to determine 
experimentally the time of peak artemisinin concentration for any area of production and 
for any ecotype rather than to rely only on published data. We demonstrated that the 
tested ecotype, yielded the maximum artemisinin content at full bloom in both leaves and 
inflorescences where, as proposed for other glanded biotypes (Duke MV, 1994; Ferreira 
JFS, 1995), this sesquiterpenoid compound accumulates almost exclusively in the 
subcuticular space of capitate glandular trichomes that are abundantly present on the 
surfaces of leaves and flower organs of these plants (Rotondi, personal communication). 
At this stage of development, the artemisinin concentration varied from 0.04 to 0.05% of 
plant dried weight, in the range of the relatively low average of artemisinin concentration in 
plants of European origin (0.03-0.22; Charles DJ, 1991; Trigg PI, 1990). 
Besides, in the fully bloomed plants flavonoids also accumulate more in both plant organs 
(0.05% dried weight), with foliage and inflorescences yielding about equal amounts. To our 
knowledge these are is the first results on flavonoid content in A. annua L., regarding plant 
phenological stages and, therefore for obtaining the highest yields of both artemisinin and 
polyphenol compounds. 
 
I.3.2.  Formulations of artemisinin 
 
I.3.2.1. Conventional liposomes 
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In all the experiments reported, mixtures of soy phosphatidylcholines (P90G) were used as 
the main vesicle forming amphiphile. The phosphatidylcholines are amphiphiles, all of 
which have the same zwitterionic head group (phosphocholine) linked to glycerol through 
the oxygen atom at sn-3 of glycerol. Each of the two hydroxyl groups at sn-1 and sn-2 is 
esterified with a fatty acid with the following percentage composition: 
 
fatty acid % 
linoleic acid 66.5 
palmitic acid 12.9 
oleic acid 10.5 
linolenic acid 5.7 
stearic acid 4.4 
 
P90G was used in combination with cholesterol, which alters the organization and 
mechanical properties of the lipid bilayers (McMullen TPW, 1995). 
In the table all the constituents of the bilayer of conventional liposomes were indicated with 
their molar ratio: 
 
molecule MW molar ratio mg/mL 
P90G 760 5 33 
cholesterol 386.66 0.6 2 
artemisinin 282 2 5 
 
It is well-known that dry lipid films form spontaneously large multilamellar vesicles upon 
addition of an aqueous phase. This is, however, erroneous. When dry lipid films are 
hydratated the lamellae swell and grow into thin lipid tubules. Additional energy has to be 
dissipated into the system in order to produce smaller and less lamellar liposomes (Lasch 
J, 2003). Liposomes were homogenized by high pressure emulsificator in order to make 
their sizes smaller and size distribution narrower. In addition, homogenization is useful in 
order to improve liposomal physical stability in terms of sedimentation or floating. Even if 
the vesicles are stearically stabilized, smaller size (70-200 nm) and good size 
homogeneity is of advantage for prolonged circulation (Liu D, 1992). So, different pressure 
for changeable time were applied to liposomal empty samples in order to find the best 
balance between size and polidispersity index. Results derived from DLS analysis: 
 
pressure  
(kPa) 
time            
(s) 
mean diameter    
(nm) PDI 
50 000 60 103.57 0.619 
75 000 20 127.48 0.921 
75 000 60 124.14 0.530 
75 000 100 165.58 0.821 
100 000 20 90.56 0.637 
100 000 60 128.30 0.456 
100 000 100 117.29 0.508 
125 000 20 119.02 0.008 
125 000 60 190.01 0.620 
125 000 100 65.58 0.911 
150 000 60 112.64 0.213  
 
The best results is obtained applying to the sample the pressure of 150 000 kPa for 60 
seconds. So, artemisinin-loaded liposomes were emulsified following these optimized 
parameters. Results derived from DLS: 
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aqueous 
medium 
artemisinin 
(mg/ml) 
Mean 
diameter 
(nm) 
PDI 
Zeta 
potential 
(mV) 
bidistilled 
water − 183.0±39.60 0.27±0.05 −17.5±1.20 
bidistilled 
water 5 180.1±1.74 0.31±0.06 −32.3±0.78 
NaCl 
0.9% 5 136.2±42.27 0.54±0.07 −17.7±1.74 
 
The sample rehydrated with physiological solution (NaCl 0.9% v/v) was polydispersed 
(PDI>0.4), but analyses were always repeatable.  
Different cholesterol/P90G ratio were tried in order to improve the encapsulation efficacy 
(EE%) of our formulations. As we expected, all the obtained EE, summarized in the 
following table, are low; this is attribuible to the hydrophobicity of the drug that the 
formulations delivered. Results derived from HPLC/DAD/ESI MS analysis: 
 
chol/P90G EE             (%) 
0.20 8.98 
0.33 2.93 
0.47 6.91 
0.60 12.54 
0.73 13.38 
0.87 13.82 
1.00 10.02 
 
When the ratio cholesterol/P90G is 0.20, the vesicles appeared sphere-shaped at the 
electron microscopy. When the ratio was increased, the encapsulation efficacy is better, 
but, this higher amount of cholesterol can be related with unusual tridimensional structure 
(detailed explanation will follow below, in the section related to transmission electron 
microscopy). 
 
I.3.2.2. Liposomes with superficial charge 
 
Negatively and positively charged vesicles were prepared by using either dicetylphosphate 
(dihexadecylphosphate, DP, 4.84 mg/ml final concentration) or stearylamine (SA, 2.38 
mg/ml final concentration), respectively, as a charge inducer. P90G was used in 
combination with dicetylphosphate or stearylamine, with the aim of preventing vesicle 
fusion (Sada E, 1988).  
In the table all the constituents of the bilayer of liposomes were indicated with their molar 
ratio: 
 
molecule MW molar ratio mg/mL 
P90G 760 5 33 
cholesterol 386.66 0.6 2 
SA 269.51 1 2.38 
DP 546.85 1 4.84 
artemisinin 282 2 5 
 
Results derived from DLS analysis: 
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artemisinin 
(mg/ml) 
P90G 
(mg/ml) 
Chol. 
(mg/ml) 
SA 
(mg/ml) 
DP 
(mg/ml) 
Mean 
diameter 
(nm) 
PDI 
 
Zeta 
potential 
(mV) 
− 33 2 − − 183.0±39.6 0.27±0.05 −17.5±1.2 
5 33 2 − − 180.1±1.74 0.31±0.06 −32.3±0.78 
5 33 2 2.38 − 191.8±37.5 0.42±0.03 −61.8±4.2 
5 33 2 − 4.84 135.6±28.1 0.45±0.04 −46.4±1.7 
 
These samples were polydispersed (PDI>0.4), but analyses were always repeatable. 
Moreover, the mean size of positively charged liposomes was large if compared with those 
containing dicetylphosphate; this is due to the presence in the bilayer, of the highly 
hydrophilic amphiphile stearylamine that increase the vesicle surface energy which causes 
vesicle enlargement (Fang JY, 2001). 
Results derived from HPLC/DAD/ESI MS analysis: 
 
SA  DP  EE (%) 
+ − 14.56±1.57 
− + 23.14±0.51 
 
As shown in the table, the formulations presented a high encapsulation efficiency (EE%). It 
is interesting to note that SA liposomes showed an encapsulation efficiency that was lower 
than that of the DP vesicles. This could be due to the higher energy required for 
artemisinin-incorporating vesicle formation when SA was present in the lipid phase. In fact, 
in the preparation of SA-containing liposomes, emulsification was less efficient in 
comparison with the preparation of negatively charged. 
 
I.3.2.3. Trasmission Electron Microscopy 
 
The homogeneity and morphology of liposomes can also be visualized by electron 
microscopy (Meyer HV, 1998; 1999; 2000; 2001; Ulrich AS, 1999). The spheroidal shape 
of lipid vesicles with their bimolecular arrangement of the amphiphiles is known since the 
pioneering work of Bangham et al. (Bangham  AD, 1964; 1965), who originally called these 
aggregates spherulites (Bangham  AD, 1964). These aggregates are also called 
phospholipids vesicles (Papahadjopoulos D, 1974) which has been simplified in the past to 
lipid vesicles (Szoka F Jr, 1980), artificial vesicles (Ingolia TD, 1978) or just vesicles 
(Fendler JH, 1982; Rosoff M, 1996). Vesicles is used as a general term and includes all 
types (often spherical) of single or multicompartment closed bilayer structures, regardless 
of their chemical composition (Fendler JH, 1982; Fuhrhop  JH, 1984).  
Two different techniques were used in order to visualize vesicles: the ‘negative contrast’ 
and the ‘encapsulation method’. The first is very quick and easy to perform, while the 
second one, typically used for observing skin samples, needs many days to prepare the 
slice of the sample. 
 
I.3.2.3.a. Trasmission Electron Microscopy: “negative contrast” 
 
The samples were diluted 10 times in order to photograph isolated vesicles and to 
measure their sizes. There is a perfect correlation between the dimension measured by 
Dynamic Light Scattering DLS (around 200 nm) and those visualized at the electron 
microscopy. Dimensions measured by DLS, data were presented as a mean of particle 
sizes, assuming that observed structure were sphere-shaped. Electron microscopy can 
confirm this.  
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Fig 9. LUV: large unilamellar vesicles.  
Mean diameter 100-500 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10. LUV: large unilamellar 
vesicles.  
Mean diameter 100-500 nm. 
 
 
 
 
 
 
 
 
 
I.3.2.3.b. Trasmission Electron Microscopy: “encapsulation method” 
 
Ultra-thin sections of liposomal dispersions were obtained with a ultramicrotome, 
examined under electron microscope and photographed. The slice of liposomal dispersion 
can show the lamellarity together with the dimensional analysis. Obviously, multilamellar 
(10 bilayers) and oligolamellar (2-5 bilayers) vesicles were bigger than UVs and 
sometimes they appeared coalesced. In order to overcome this problem of potential fusion 
of the vesicles, liposomes with superficial charge were prepared. 
 
 
 
Fig 11. OLV: oligolamellar 
vesicles.  
Mean diameter 0.1-10 µm, 
typically 1 µm. 
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Fig 12. MVV: multivesicular 
vesicles.  
Schematic representation 
and real electron 
micrograph. 
 
 
 
 
 
 
 
 
Fig 13. LUV: large unilamellar vesicles.  
Mean diameter 100-500 nm. 
 
 
 
 
 
 
 
 
 
Physical instabilities of lipid vesicle systems involve vesicle aggregation and fusion 
(possibly leading to vesicle precipitation and formation of flat bilayers) (Crommelin DJA, 
1994; Leung D, 1996). Lipid vesicles are generally not a thermodynamically stable state of 
amphiphiles and do not form ‘spontaneously’ (without input of external energy); they are 
only kinetically stable, kinetically trapped systems (Laughlin RG, 1997; Lasic DD, 1990; 
1999; Horbaschek K, 2000; Luisi PL, 2001).  
The mean size, the lamellarity and the physical stability of the vesicles not only depend on 
the chemical structure of the amphiphiles used, but also on the method of vesicle 
preparation. It must be generally noted that any hydrophobic drug is likely to affect the 
phase diagram of its liposomal carrier, hence  great care has to be taken to characterize 
the corresponding behaviour of the loaded  system (Peleg-Shulman T, 2001; Fatouros DG, 
2001; Stoye I, 1998; Fahr A, 2001; Ardhammar M, 1999). Summarizing the type of lipid 
used, the preparation method and the molecule loaded influenced the shape of the 
system. But there is something else. In addition, unexpected structures, different from 
vesicles, were appeared at the transmission electron microscopy, if the cholesterol is 
added to the P90G with a ratio of about 0.60 (fig 14). 
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Fig 14. Tridimensional unexpected structures obtained if the chol/P90G ratio is 0.6. 
 
 
 
 
 
 
 
 
Fig 15. Skeleton of the previous 
hexagonal structure. 
 
 
 
 
 
 
 
It can be related to the fact that also the amount of cholesterol affects the morphology of 
the tridimensional aggregates. An explanation may be derived from literature. 
 
a
b
c
 
Fig 16. Overview of lipid phase transitions and polymorphism. 
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Lipid polymorphism is described as an essential aspect to consider in the rational design 
of liposomes for drug delivery, and has been well reviewed (Gerasimov  OV, 1999; Maurer  
N, 1999;  Hafez  IM, 2001). Concerning the lamellar phase, the most common is that 
assumed by the vesicles (fig 16a), but other morphologies, such as the inverted hexagonal 
phase HII or various cubic phases Q can be observed, as  summarized in figure 16 (Ulrich 
AS, 2002). The hexagonal phase (fig 16b) consists of an array of cylindrical rods, wherein 
the lipids are oriented with their headgroups towards the aqueous core. Cubic phases (fig 
16c) are made up of bicontinuous surfaces, such that every point of the internal surface of 
this macroscopic assembly has access to the external aqueous space via aqueous 
channels, and any lipid molecule may exchange places with another in the same 
monolayer simply by diffusion (Shah JC, 2001).  
Surprising also in the case of samples obtained using mixtures of cholesterol/P90G it is 
possible to observe such aggregates. Thus, if the cholesterol is added to the P90G with a 
ratio of about 0.60, vesicles were present as aggregates related to inverted hexagonal 
phase as reported in figure 14. 
These unusual structures are now under further physical-chemical investigations in order 
to clarify their formation and stability. 
 
I.3.2.4. PEGylated liposomes  
 
When liposomes were proposed as vehicles for drug delivery, their major disadvantage 
was discover: typical liposome composition rapidly exited the bloodstream and 
accumulated in the Kupffer cells in the liver, as well as in spleen macrophages (Senior JH, 
1987). An excess of empty liposomes were administered in order to overcome this 
problem (Patel KR, 1983). However, blocking RES is not the most appropriate approach 
for human therapy. The real breakthrough was achieved with the discovery of  polymer-
modified long-circulating liposomes (Lasic DD, 1995). Coating uncharged colloidal 
particles with non-ionic hydrophilic polymers, such as PEG, renders them stable against 
non specific interactions and self-aggregation, because the hydration repulsion and the 
steric barrier prevent close approach (Ulrich AS, 2002; Allen C, 2002). Explanation of the 
phenomenon of PEGylated liposomes involve the formation of a ‘conformational cloud’ by 
flexible liposomes-grafted polymers over the liposomal surface (Torchilin VP, 1994) and 
the decreased rate of plasma protein adsorption  on the hydrophilic surface of PEGylated 
liposomes (Lasic DD, 1991). The incorporation of PEG into so-called ‘stealth’ liposomes 
establishes a steric barrier that delays their recognition by the mononuclear phagocyte 
system. As consequence, circulation times of conventional liposomes (typically several 
minutes) have been increased this way up to many hours (Ulrich AS, 2002). 
In the table all the constituents of the bilayer of PEGylated liposomes were indicated with 
their molar ratio: 
 
molecule MW molar ratio mg/mL 
P90G 760 5 33 
cholesterol 386.66 0.6 2 
18:0/18:0 PEG 2000 2805.497 0.25 6.2 
artemisinin 282 2 5 
 
Results derived from DLS analysis: 
 
NaCl 
0.9% 
artemisinin 
(mg/ml) 
P90G 
(mg/ml) 
Chol. 
(mg/ml) 
18:0/18:0 
PEG 
2000 
(mg/ml) 
Mean 
diameter 
(nm) 
PDI 
Zeta 
potential 
(mV) 
+ − 33 2 − 136.2±42.27 0.22±0.07 −17.7±1.74 
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+ 5 33 2 6.2 132.6±8.78 0.39±0.01 −17.5±1.85 
The mean size of PEGylated liposomes was similar to conventional liposomes but the 
polidyspersity index was higher, because of the presence of PEG in the bilayers. 
 
I.3.3.  In vivo experiment: pharmacokinetic study 
 
I.3.3.1. Calibration curves 
 
The calibration curve (R2=0.999) was determined by constant volume of blank plasma with 
increasing concentration of artemisinin (0-100 µM, final concentration of artemisinin)  
dissolved in methanol 0.3% v/v. 
 
theoretical µM real µM  accuracy 
50 42.4 84.9 
10 9.89 98.9 
6 6.05 101.0 
5 5.17 103.0 
2 1.96 97.9 
1 0.984 98.4 
0.5 0.476 95.1 
0.2 0.205 103.0 
0.1 0.086 86.0 
0.05 0.0452 90.3 
 
I.3.3.2. Pharmacokinetic study 
 
There are no clues in literature about the parenteral dosages of artemisinin and only a 
study on β-artemether-loaded liposomes is reported (Chimanuka B, 2002). This study 
showed the successful treatment of Plasmodium berghei infected mice at the dosage of β-
artemether of 4.8 mg/kg (Chimanuka B, 2002). In our preliminary studies a dosage of 
artemisinin of 10 mg/kg was tested to evaluate the pharmacokinetic performance of 
liposomes versus artemisinin solubilized in DMSO 10% v/v. 
In order to select the best way of parenteral administration, the properties of the carrier 
were considered. Regardless of the circulation time of an intravenously injected liposomal 
dose, however, the majority will eventually be taken up by the mononuclear phagocyte 
system (Ulrich AS, 2002). Subcutaneous injection has been the route of administration 
most extensively investigated for targeting to the lymphatic system (Oussoren C, 1998). 
When intramuscular injected, liposomes with the particle size above 100 nm remain at the 
injection site and act as sustained drug release system for manteining prolonged drug 
concentration in the blood compartment (Storm G, 2000). Intraperitoneally administration 
of liposomal drugs has been shown to reduce systemic toxicity (Alberts DS, 1996) and 
prolong the blood circulation of liposomes caused by slow absorption of the liposomes 
from the abdominal cavity (Sadzuka Y, 1997). The AUC of spleen and liver were lower 
after i.p. injection than after i.v. injection (Lin YY, 2009). I.p. administration was selected as 
the most suitable for our needs. 
 
Both artemisinin-loaded conventional and PEGylated liposomes increased the 
pharmacokinetic parameters of artemisinin such as Cmax, AUC0-24h and t1/2β. In addition, 
delivered artemisinin reduced CL compared to free artemisinin (control) as described in 
the following table and in fugures 17 and 18. 
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Cmax (µM±SD) 0.25±0.08 1.11±56.00 1.04±0.01 
AUC 0-24h (µM/h) 0.132 0.836 0.899 
t1/2β (h) 0.38 0.67 2.02 
CL (mL/h) 63.11 9.97 9.20 
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Fig 17. Pharmacokinetic profile of free artemisinin versus artemisinin-loaded liposomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 18. Pharmacokinetic profile. Zoom within 6 hours. 
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The plasma maximum concentration of free artemisinin was increased 4.4 and 4.2 folds 
more in conventional and stealth liposomes, respectively.  
AUC values, determined for the period 0–24 h, was increased  about 6 times more in both 
of the liposomal formulations in comparison with free artemisinin. 
t1/2β was 0.38 h for artemisinin. However, incorporation of artemisinin into liposomes 
prolonged t1/2β to 0.67 h and 2.02 h for conventional and stealth liposomes, respectively. 
Compared with the t1/2β of free artemisinin, the ones of artemisinin in conventional and 
stealth liposomes were much lengthened by 1.7 and 5.3 folds, respectively. The effect of 
formulation was much better in PEGylated liposomes because of steric stabilizing effect of 
PEG on liposome surface. An additional hydration layer on the surface of liposomes 
resulted that liposomes cannot be recognized by macrophages and RES as foreign 
particles, and are spared phagocytic clearance (Lian T, 2001). 
Free artemisinin was so rapidly cleared from plasma that the remained artemisinin was 
hardly detected in the plasma at 1 h after dosing. The clearance of artemisinin from blood 
plasma could be decreased by importing liposomes as drug carriers. Both liposomal 
formulations showed much longer blood circulation time than free artemisinin. It took about 
3 h to be cleared from plasma for conventional liposomes. In the case of PEGylated 
liposomes, artemisinin was still detectable after 24 hours. 
Concluding, the artemisinin-loaded liposomes have proper physical characteristics as drug 
carrier for parenteral administration in terms of particle size, polydispersity index and zeta 
potential. From in vivo studies, it could be concluded that encapsulation into liposomes is a 
reasonable method to prolong the circulating time of artemisinin in blood plasma. In 
addition, the effect of formulation on the half-life of artemisinin was enhanced by inclusion 
of PEG into liposomes. 
 
I.3.4.  In vivo experiment: antiplasmodial activity 
 
Artemisinin at the dosage of 10 mg/Kg was administred i.p. delivered in conventional 
liposomes to Plasmodium berghei infected mice. Artesunate (Sigma Aldrich) at the dosage 
of 50 mg/Kg was administred i.p. as well, as positive control. 
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Fig 19. Parasitaemia of Plasmodium berghei infected mice treated with conventional artemisinin-
loaded liposomes. Each group conteined two mice. 
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The parasitaemia in the mice was followed for 7 days. The results are presented in figure 
19 and take into account the pattern of the parasitaemia in each group. Each value of 
percentage of parasitaemia is a daily mean value of two mice per group. The reduction of 
the percentage of parasitaemia is monitored for verifying the antiplasmodial in vivo activity. 
At the beginning of the treatment there were no differences in parasitaemia in any of the 
groups.  
In the negative control group, the percentage of parasitaemia increase progressively so all 
the mice were infected in the right way; in the positive control group, antiplasmodial activity 
of artesunate was effective during the whole experiment so, the results will be reliable. 
On the fifth day of treatment, the parasitaemia reached around 17.4% in the negative 
control group, 5.3% in the positive control group and 6.0% in the conventional liposomes 
group, respectively. On the seventh day of treatment, the parasitaemia reached around 
76.7% in the negative control group, 7.0% in the positive control group and 5.0% in the 
conventional liposomes group, respectively. In the mice treated with artemisinin-loaded 
conventional liposomes, the percentage of parasitaemia had the same trend of the positive 
control group. 
 
I.3.5.  Artemisinin-curcumin loaded  liposomes   
 
Artemisinin-based combination therapy is now the first line policy in most malaria-endemic 
countries (Ioset JR, 2009; Eastman RT, 2009) in order to delay the development of 
resistance. Curcumin has been recently proposed as an attractive partner drug for 
artemisinins (Reddy RC, 2005; Nandakumar DN, 2006).  
So, liposomes delivering both of these antimalarian drugs were producted. Before 
preparing artemisinin-curcumin loaded  liposomes , a screening of curcumin-loaded 
liposomes was done. The lipidic film was rehydrated with buffer solution at different pH 
values, ranging from 5 to 7.4. The best results, in terms of size (<200 nm) and 
polidispersity index (about 0.20), were obtained using the highest tested value of pH. 
Then, liposomes delivering both of the two antimalarian drugs were prepared. Results 
derived from DLS analysis: 
 
artemisinin 
(mg/mL) 
curcumin 
(mg/mL) 
ratio 
chol/P90G 
mean 
diameter (nm) PDI 
Zeta 
potential 
(mV) 
- - 0.2 183.0±39.6 0.27±0.05 −17.5±1.20 
5 - 0.2 180.1±1.74 0.31±0.06 −32.3±0.78 
5 2 0.2 71.0±4.14 0.36±0.05 −21.2±2.95 
5 5 0.2 310.6±37.19 0.47±0.09 −18.8±0.25 
1 5 0.2 316.0±10.01 0.22±0.06 −21.6±0.78 
 
When curcumin had an initial concentration of 2 mg/mL, the size is very low and the 
system was quite homogeneous. When the concentration of curcumin is 5 mg/mL, 
artemisinin and curcumin loaded liposomes had size bigger than artemisinin or curcumin 
loaded liposomes. The emulsification of these formulations was more difficult, but the 
mean diameter is acceptable considering the intraperitoneally administration as 
perspective. Results derived from HPLC/DAD/ESI MS analysis: 
 
artemisinin curcumin 
mg/mL EE% mg/mL EE% 
5 22.87±0.28 2 54.78±0.13 
5 15.71±0.12 5 25.37±0.18 
1 12.55±0.99 5 25.62±0.18 
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The encapsulation efficacies were satisfactory for every combination of concentration of 
the two drugs. There was no competition between two hydrophilic molecules to enter into 
the vesicles. These formulations will be suitable for in vivo administering. 
 
I.4.  Future perspectives 
 
Physical-chemical investigations will be developed for understanding the potential use of 
the tridimensional structures that we had observed at the electron microscopy in order to 
finger out the role of the cholesterol in the lamellar phase and in the morphology. 
Improved pharmacokinetic parameters of PEGylated liposomes are encouraging and 
these carriers will be tested in Plasmodium berghei infected mice for testing their 
antiplasmodial activity and their enhancement in comparison with conventional liposomes. 
Artemisinin-curcumin loaded liposomes will be developed with the aim of producing an 
appropriate formulation to be suggested as an artemisinin-based combination therapy.  
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II.1.  Introduction 
 
II.1.1.  Hystory 
 
Verbascoside is a phenylpropanoid glycoside widely spread in nature (Scogin R, 1992). 
Because of their broad presence in the vegetal world, there was much confusion in the 
literature regarding the name and structures of phenylethanoid glycosides. In the 1963, 
verbascoside was isolated for the first time from Verbascum sinatum (Scrophulariaceae), 
but its structure was not determined at that time (Scarpati ML, 1963). Verbascoside was 
isolated again in 1966 from Syringa vulgaris (Oleaceae) and its structure determined to be 
β-(3,4-dihydroxyphenyl)ethyl-O-α-L-rhamnopyranosyl (1”→3”)-β-D-(4-O-
caffeoyl)glucopyranoside, but it was named as acteoside (Birkofer R, 1968). In 1982 
Andary et al. found that the structure of verbascoside and acteoside were identical (Andary 
C, 1982). A year later, kusaginin was isolated from Clerodendron tricholomum 
(Verbenaceae) and subsequently shown to be identical to verbascoside = acteoside 
(Sakurai A, 1983). 
 
II.1.2.  Source  
 
Verbascoside has been reported from 14 angiosperm families (44 genera, 71 species). 
This distribution of verbascoside contains many families traditionally clustered in a 
Scrophulariaceae-Lamiales complex (Scogin R, 1992). It is isolated from several medicinal 
plants of different families such as Verbenaceae, Oleaceae, Buddlejaceae, Lamiaceae, 
Scrophulariaceae (Küpeli E, 2007; Scogin R, 1992), including plants of the Traditional 
Chinese Medicine (Jiangshu Botanic Institute, 1991). 
Lemon verbena, Lippia citriodora H.B.K. is an aromatic shrub belonging to the 
Verbenaceae family, which is widely used all over South America and was introduced into 
Europe in the 17th century. It is cultivated mainly due the lemon-like aroma emitted from its 
leaves that are utilized for the preparation of herbal tea, which is reputed to have 
antispasmodic, antipyretic, sedative and digestive properties (Carnat P, 1999; Pascual CJ, 
2001; Santo-Gomes R, 2005; Valentao J, 1999). Lemon verbena has a long history of folk 
uses in treating asthma, spasms, cold, fever, flatulence, colic, diarrhoea, indigestion, 
insomnia and anxiety (Carnat P, 1999). 
 
II.1.3.  Chemical properties 
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Verbascoside is a diglycoside ester of the caffeic acid which, upon hydrolysis, yields 
caffeic acid, glucose, rhamnose and 3,4-dihydroxyphenylethanol (Scogin R, 1992). This 
molecule is very water soluble (up to 30 mg/mL) but it is unstable and it undergoes to 
degradation that depends upon its concentration (Sinico C, 2008). Degradation products 
were analyzed by mass spectrometry which pointed out that the main reaction involved in 
this process is the leakage of the caffeic acid moiety and the opening of the two emiacetal 
groups. 
 
II.1.4.  Analgesic activity 
 
Methanol or ethanol sequential extracts of Buddleja globosa leaves produce a dose-
dependent antinociceptive activity, as observed through different algesiometric tests. The 
major metabolites involved in sequential extracts antinociception mechanism are 
verbascoside and 7-O-luteolin glycoside (Backhouse N, 2008). Verbascoside showed 
topical and oral analgesic effects (Backhouse N, 2008).  
Verbascoside exhibit analgesia (writhing and tail pressure methods) and a weak sedation 
(prolongation of pentobarbital-induced anaesthesia and methamphetamine-enhanced 
locomotor activity) by the oral administration (Nakamura T, 1997). However, in a study 
about the anxiolytic and sedative properties of infusions of Aloysia triphylla in normal 
volunteers, no difference was observed between plant or placebo (Wannmacher L, 1990).  
A topical preparation of Verbena officinalis L. showed anti-inflammatory and analgesic 
activities (Calvo MI, 2006). 
Verbascoside has been reported for its antinociceptive and anti-inflammatory activity 
(Küpeli E, 2007), together with its ability for inhibiting the formation of PGE2, the tumor 
necrosis factor-α, nitric oxide, suppressing the inducible nitric oxide synthase, the 
enzymatic activity of cyclooxygenase and for exerting a protective action against oxygen 
free radical-induced peroxidative damage to biomembranes (Lee JL, 2005; Liu MJ, 2003).  
 
II.1.5.  Pharmacological effects 
 
The literature regarding the biological activities of this compound is significant: indeed 
concerning anti-inflammatory, anti-ulcerogenic and antispasmodic activity (Küpeli E, 2007; 
Korkina LG, 2007; Hausmann M, 2007; Fleer H, 2007; Penido C, 2006; Lau CW, 2004; 
Diaz AM, 2004), antiproliferative properties and inhibition of telomerase (Efferth T, 2007; 
Lee KW, 2007), immunomodulatory (Akbay P, 2002), antioxidant (Bilia AR, 2008; Lee JY, 
2005) and antibacterial activity (Didry N, 2002). 
Mostly of the plants containing verbascoside as a major constituent are traditionally used 
in the treatment of inflammatory diseases. This activity may be attributed, at least in part, 
to the selective 5-lipoxygenase inhibition and potent in vitro free radical scavenging action 
of verbascoside and some other phenylpropanoid derivatives (Deepak M, 1999). The high 
redox potential as electron donor of verbascoside, protects cells against glucose oxidase-
mediated cytotoxicity and apoptosis (Chiou WF, 2004), and a preventive potential may be 
attributed to the treatment of oxidative stress-mediated diseases (Kim SS, 2005). 
Verbascoside showed a stronger COX-2 inhibition activity (23.1±2.0% at a concentration 
of 10−4 M and IC50 = 0.69 mM) than towards COX-1. A structure–activity relationship 
suggests that the presence of more than one sugar unit increases the steric hindrance 
which prevents the molecule getting easily to the active site of the enzyme (Sahpaz S, 
2002). 
Verbascoside showed inhibitory effect on histamine and bradykinin-induced contractions 
and oral antiinflammatory activity (Schapova E, 1998). 
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Verbascoside impairs endothelial NO-mediated aortic relaxation partially through of 
agonist-induced endothelial Ca2+ mobilization and Ca2+-dependent NO production and 
subsequent suppression of cyclic GMP formation. This action, if occurring in small vessels 
in vivo, may contribute to the reported anti-inflammatory effect of verbascoside against 
NO-mediated vascular permeability-related acute oedema (Lau CW, 2004).  
Verbascoside showed a photoprotective effect against UV-B induced cellular death, 
evaluated by challenge experiments using E. coli (Avila Acevedo JG, 2005).  
An aqueous extract of Verbena officinalis had a neuroprotective effect against β-amyloid 
peptide, important cytotoxic factor in the Alzheimer’s disease; a pre-treatment with this 
extract attenuated the toxicity of Aβ in primary cultures of cortical neurons (Lai SW, 2006). 
 
II.2.  Materials and methods 
 
II.2.1.  Plant material  
 
Verbascoside was extracted with an hydroalcoholic solution  (EtOH 80%) of dried leaves 
of cultivated Lippia citriodora H.B.K. (Verbenaceae) harvested in 2004, a gift from Aboca 
(Pistrino di Citerna, PG, Italy), lot n. 4L0466. 
 
II.2.2.  Chemicals and standards 
  
Ethanol was analytical reagent grade from Riedel-de Haen (Seelze, Germany). All the 
solvents used for the extraction and HPLC analysis (MeOH, n-hexane, dichloromethane, 
and acetonitrile) were HPLC grade from Merck (Darmstadt, Germany); 85% formic acid 
was provided by Carlo Erba (Milan, Italy). Water was purified by a Milli-Qplus system from 
Millipore (Milford, MA). Solution NaCl 0.9%, Fresenius Kabi, Italy. Verbascoside was 
purchased from IRB Istituto di Ricerche Biotecnologiche of Altavilla Vicentina. Egg 
phosphatidylcholine (Phospholipon90G, P90G) were kindly obtained from Natterman 
Phospholipids, Gmb. Cholesterol was analytical grade and were purchased from Aldrich 
(Milan, Italy). Carboxymethylcellulose Sodium Salt (CMC), Fluka Chemie GmbH, 
Steinheim, Germany. Naloxone hydrochloride (> 99%), tramadol (> 99%), ketorolac (≥ 
99%), (Sigma, St. Louis, USA). Morphine hydrochloride (> 99%) was from S.A.L.A.R. 
Pregabalin (> 99%) was purchased from Chem Pacific, Baltimore. Size esclusion column 
chromatography was carried out on Sephadex LH-20 (Amersham Biosciences AB, 
Uppsala, Sweden). TLC (plates of silica gel 60 F254, Merck, Damrastatt Germany). β-CD 
(kleptose) was purchased from Rochette and D2O was purchased from Sigma Aldrich. 
Verbascoside reference standard (purity 98% by HPLC/DAD/ESI MS, GC, NMR) from IRB 
Istituto di Ricerche Biotecnologiche of Altavilla Vicentina. 
 
II.2.3.  Isolation of verbascoside 
 
500 g of herbal drug were exhaustively extracted with an hydroalcoholic solution (EtOH 
80%). This extract was concentrated to dryness in a rotavapor under reduce pressure and 
controlled temperature (30°C) and lyophilised. 34.75 g of dried extract was obtained (6.96 
% with respect to the HD). 5 g of the extract (about 12% of verbascoside by 
HPLC/DAD/ESI MS, fig 20) were dissolved in 5 mL EtOH 50% and purified with a 
Sephadex LH-20 column chromatography (length 50 cm, diameter 4 cm) using  EtOH 
50%. Fractions were analysed by TLC plates of silica gel 60 F254; solvent CHCl3/MeOH 
7:3) using vanilline 5% in MeOH and H2SO4 1%. Purity of isolated verbascoside (700 mg, 
81.2%) was assessed by HPLC/DAD/ESI MS analysis using verbascoside reference 
standard (purity 98% by HPLC/DAD/ESI MS, GC, NMR). Verbascoside was re-
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crystallised from MeOH to obtain pure compound (510 mg, purity > 98%). Purification of 
verbascoside from the extract was repeated 6 times. 
 
II.2.4.  Analytical HPLC/DAD characterization 
 
The HPLC system consisted of a HP 1100 L instrument with a Diode Array Detector and 
managed by a HP 9000 workstation (Agilent Technologies, Palo Alto, CA, USA). The 
column was a Varian Polaris TM C18-E (250 mm x 4.6 mm i.d., 5 (m) maintained at 26°C 
with a pre-column of the same phase. The eluents were H2O at pH 3.2 by formic acid and 
acetonitrile. The following multi-step linear gradient was applied:  
 
Time 
(min.) 
CH3CN 
(%) 
H2O/HCOOH 
pH=3.2 
(%) 
0.1 13 87 
10 15 85 
20 25 75 
23 25 75 
25 95 5 
28 95 5 
 
Total time of analysis was 28 min, equilibration time was 10 min, flow rate was 0.8 mL/min, 
injection volume was 10 µL and oven temperature 26°C. The UV-vis spectra were 
recorded between 220–500 nm and the chromatographic profiles were registered at 240, 
330 and 350 nm.  
 
II.2.5.  Analytical HPLC/ESI MS characterization 
 
The HPLC system described above was interfaced with a HP 1100 MSD API-electrospray 
(Agilent Technologies, Palo Alto, CA, USA). The interface geometry, with an orthogonal 
position of the nebulizer with respect to the capillary inlet, allowed use of analytical 
conditions similar to those used for HPLC/DAD analysis in order to achieve the maximum 
sensitivity of ESI values. The same column, time period and flow rate were used during the 
HPLC/ESI MS analyses. Mass spectrometry operating conditions were optimised in order 
to achieve maximum sensitivity values: negative and positive ionisation mode, scan 
spectra from m/Z 100 to 800, was used with a gas temperature of 350°C, nitrogen flow 
rate of 10 L min-1, nebulizer pressure 30 psi, Quadrupole temperature 30°C, Capillary 
voltage 3500V. The applied fragmentors were in the range 80–180 V. Identification of 
constituents was carried out by HPLC/DAD and HPLC/ESI MS analysis, and/or by 
comparison and combination of their retention times, UV-Vis and mass spectra of the 
peaks with those of authentic standards when possible, or isolated compounds or 
characterised extracts as well as based on literature data. 
 
II.2.6.  Formulations 
 
II.2.6.1. Production  of liposomes  
 
Multilamellar vesicles were prepared according to the film hydratation method (Bangham 
AD, 1965). P90G and cholesterol were dissolved in chloroform. The organic solvent were 
vacuum evaporated and the dry lipid film was hydratated by addition of a verbascoside 
aqueous solution or a verbascoside physiological solution (NaCl 0.9%). The dispersion 
was stirred with a mechanical stirrer for 30 minutes with a waterbath at the constant 
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temperature of 38°C. Glass beads were used to increase the contact surface between the 
lipidic film and the verbascoside solution. In order to reduce the dimensions of the vesicles 
from MLV to LUV, an high pressure homogenizer Emulsiflex C3® was used at the applied 
pressure of 150000 kPa for 30 seconds. Then the liposomes were characterized by 
different techniques. 
 
II.2.6.2. Production of ethosomes 
 
Multilamellar vesicles were prepared according to the film hydratation method (Bangham 
AD, 1965) as describe above for liposomes. In the case of ethosomes, the dry lipid film 
was hydrated by addition of a verbascoside hydroalcolic solution (EtOH 30%), stirring for 1 
hour. The size of ethosomes was reduced form MLV to LUV by sonicator. 
 
II.2.6.3. Inclusion complex preparation  
 
Co-freeze dried technique was used to prepare the inclusion complex of verbascoside and 
β-cyclodextrin. A mixture of verbascoside and β-cyclodextrin at different molar ratio was 
solubilized in water and this solution was stirred for 3 h in the dark. After equilibration the 
solution was frozen and freeze dried. 
 
II.2.7.  Characterization of formulations 
 
II.2.7.1. Characterization of liposomes and ethosomes 
 
II.2.7.1.a. Dynamic Light Scattering (DLS) 
 
Dynamic Light Scattering is an ALV CGS-3 system (Malvern Instruments, Malvern, UK) 
equipped with a JDS Uniphase 22 mW He–Ne laser operating at 632.8 nm, an optical 
fiber-based detector, a digital LV/LSE-5003 correlator and a temperature controller 
(Julabowater bath) set at 25 °C. Time correlation functions were analyzed to obtain the 
hydrodynamic diameter of the particles (Zh) and the particle size distribution (polydispersity 
index, PDI) using the ALV-60X0 software V.3.X provided by Malvern. Autocorrelation 
functions were analyzed by the cumulants method (fitting a single exponential to the 
correlation function to obtain the mean size (Zave) and polydispersity index (PDI)) and 
CONTIN (to fit a multiple exponential to the correlation function to obtain particle size 
distributions). The diffusion coefficients calculated from the measured autocorrelation 
functions were related to the hydrodynamic radius of the particles via the Stokes–Einstein 
equation 
     Zh = (kBTq2)/(3piηΓ) 
 
where Zh is the hydrodynamic radius of the particles,  
 kB is the Boltzmann constant,  
 T is the absolute temperature,  
 η is the solvent viscosity,  
 Γ is the decay rate,  
 q is the scattering vector  
     q = [4pinsin(Ф/2)]/λ 
 
in which  n is the refractive index of the solution,  
  Ф is the scattering angle,  
  λ is the wavelength of the incident laser light.  
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Scattering was measured in an optical quality 4 mL borosilicate cell at a 90° angle.  
 
II.2.7.1..b. Trasmission electron microscopy (TEM) 
 
A drop (10 µL) of vesicle dispersion diluted 10-times was applied to a carbon film-covered 
copper grid. Most of the dispersion was blotted from the grid with filter paper to form a thin 
film specimen, which was stained with a phosphotungstenic acid solution 1% w/v in sterile 
water. The samples were dried for 3 minutes and than examined and photographed with a 
Zeiss EM 109 transmission electron microscope at an accelerating voltage of 80 kV. 
 
II.2.7.1.c. Encapsulation efficacy (EE%) 
 
Verbascoside-incorporated vesicles were separated from the not encapsulated material by 
gel chromatography on Sephadex G-50. This method is satisfactory for solutes less than 7 
kDa (Zuidam NJ, 2003). 200 µL of liposomal dispersion were added on the top of a 
minicolumn containing a dry matrix (G-50 gel bed). The not entrapped material was 
removed by centrifugation at 1000 g for 3 minutes. Liposomes with the cleaned surface 
were collected as eluates and free-verbascoside remained inside the minicolumn. 
Verbascoside was quantified by HPLC/DAD analysis using pure verbascoside (purity 98% 
by HPLC/DAD/ESI MS, GC, NMR) as external standard. 
 
II.2.7.2. Inclusion complex characterization 
 
II.2.7.2.a. NMR analyses  
 
Proton  spectra and  2D-NMR  NOESY  and ROESY  experiments  were  carried  out  in  a  
Bruker DRX  600  MHz  and  Bruker  DRX  400  MHz.  
NOESY mixing  time was 900ms and ROESY spin-lock  time of 350ms.  
 
II.2.7.2.b. Job’s plot  
 
A solutions of verbascoside 10 mM was mixed in different ratios (ranging from 0.1 to 0.9) 
with solution of β-CD in D2O (10 mM) to obtain final solutions of 10 mM and ratios of 
guest/[β-CD +guest] ranging from 0.1 to 0.9. All samples were filtered before NMR 
analysis and were allowed to equilibrate at 298 K for at least 15 minutes prior to 
acquisition. Each spectrum was calibrated and the chemical shift displacements were 
recordered. The construction of the continuous variation plot required 2D COSY and 
ROESY experiments for most of the data points; they were useful to determine the 
chemical shift displacements where overlapping resonances (Zouvelekis D, 2002) and line 
broadering fenomena occurred. 
 
II.2.7.2.c. Diffusion Ordered SpectroscopY 
 
DOSY experiments  were  carried  out  in  a  Bruker DRX  600  MHz. DOSY was carried 
out using a spectrometer  equipped with  a  5 mm  triple  indirect detection  probe  capable  
of  providing  pulsed  field gradients of up to 60 G/cm. Between  8  and  25  
measurements,  each  of  4–64 transients,  of  diffusion-attenuated  stimulated  echo 
spectra  were  made  for  each  sample,  using  z  field gradient strengths between 3 and 
60 G/cm spaced at equal  intervals  of  gradient  squared.  The  data were then  processed  
using  least-squares  fitting  of  peak heights to derive estimated diffusion coefficients and 
standard  errors  from  the  attenuation  of  signal  as  a function of the square of field 
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gradient pulse area. The gradient strength was logarithmically incremented in 32 steps 
from 2% up to 95% of the maximum gradient strength. Diffusion times and gradient pulse 
durations were optimised for each experiment in order to achieve a 95% decrease in 
resonance intensity at the largest gradient amplitude; typically, diffusion times (D) between 
60 and 100 ms, gradient strength (δ * 0.5) between 2.5 and 3.6 ms and spoil gradient 
strength of 6 ms. Gradient strength, g in the z direction was calibrated by DH2O = 2.3 x 10-9 
m2/s)1 at 298 K using a 90% H2O/ 10% D2O mixture. After Fourier transformation and 
baseline correction, the diffusion dimension of the 2D DOSY spectra was processed by 
means of the Bruker Topspin software package. 
 
II.2.8.   Stability 
 
II.2.8.1. Stability test of verbascoside-loaded liposomes  
 
Liposomal formulation was kept at 4°C±1°C and its stability was studied over 6 months. At 
fixed time intervals (once a week for the first month and than once a month) liposomes 
were assayed for their drug content after disruption of purified vesicles with methanol. 
Verbascoside chemical stability was checked by HPLC/DAD analysis. Physical stability of 
vesicular dispersion was investigated by DLS measurements and by TEM visualization. 
 
II.2.8.2. Stability test of the inclusion complex 
 
The inclusion complex was kept at room temperature covered by sunlight and its stability 
was studied within 1 month. A water solution of β-cyclodextrin 15 mM (closed to 
saturation) was prepared and verbascoside was added at different concentration: 0.1, 2 
and 5 mg/mL. At fixed time intervals (every 5 days) an aliquote of these three solutions 
was collected in order to quantified the content of verbascoside still present in β-
cyclodextrin solution. Verbascoside chemical stability was checked by HPLC/DAD 
analysis.  
 
II.2.9.  In vitro experiment: skin permeation studies 
 
In vitro experiments were performed in triplicate (at least five times in order to achieve 
statistical significance) using skin fragments excised from new born pigs (Sinico C, 2006). 
The subcutaneous fat was carefully removed and the skin was cut into squares of 3 × 3 
cm2 and randomized. The skin, previously frozen at –18°C, was placed at +4°C 1 day 
before the experiments and, one hour before the start of the experiments, was pre-
equilibrated in 0.9% NaCl solution at +25°C. Circular pieces of this skin were fixed on 
vertical Franz diffusion cells (Franz TJ, 1975). The receiver compartment (volume 7 cm3; 
effective diffusion area 0.636 cm2) was filled with 0.9% NaCl solution, which was 
constantly stirred with a small magnetic bar and thermostated at 37°C throughout the 
experiments. A hydroxyethylcellulose gel containing verbascoside or verbascoside-loaded 
liposomes (200 µL) were applied to each of the skin pieces and the donor compartment 
was closed by means of a cork and sealed with parafilm in order to achieve occlusive 
conditions. At hourly intervals up to 24 h, the receiver solution was removed, the chamber 
was refilled with fresh pre-thermostated 0.9% NaCl solution, and the samples were 
analyzed by HPLC/DAD to determine the amount of permeated verbascoside. At the end 
of the experiment the skin surface was washed 3 times with 0.9% NaCl solution and then 
removed and dried with filter paper. The amount of drug accumulated into the skin was 
evaluated after dermis-epidermis separation. The stratum corneum was removed by 
stripping with tapes of Tesa® film. A piece of skin was separated into epidermis and 
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dermis by pressing the skin surface against a hot plate (60°C) and peeling off the 
epidermis. The layers were soaked separately and then exposed to four sonication cycles 
of 30 min each in an ultrasound bath. Finally, the obtained solutions were concentrated 
and the verbascoside content quantified by HPLC/DAD. 
 
II.2.10. In vivo experiment: antihyperalgesic activity 
 
II.2.10.1. Rats 
 
Male Sprague-Daloley albino rats (180-200 g) from Harlan (S. Piero al Natisone, Italy) 
were used. Four rats were housed per cage. The cages were placed in the experimental 
room 24 h before the test for acclimatization. The animals were fed a standard laboratory 
diet and tap water ad libitum and kept at 23±1°C with a 12-h light/dark cycle, light at 7 AM. 
All experiments were carried out in accordance with the European Communities Council 
Directive of 24 November 1986 (86/609/EEC) for experimental animal care. All efforts 
were made to minimize the number of animals used and their suffering. 
 
II.2.10.2. Administration of tested substances 
 
Drugs were dissolved in isotonic (NaCl 0.9%) saline solution or dispersed in 
carboxymethylcellulose sodium 1% solution immediately before use; it depends on the 
route of administration. Drug concentrations were prepared so that the necessary dose 
could be administered in a volume of 10 mL kg-1 by i.p. and p.o. injection. 
 
II.2.10..3. Animal models of neuropathic pain  
 
II.2.10.3.a. Chronic constriction injury (CCI) 
 
A peripheral mono neuropathy was produced in adult rats by placing loosely constrictive 
ligatures around the common sciatic nerve according to the method described by Bennett 
(Bennett GJ, 1988). Rats were anaesthetised with chloral hydrate. The common sciatic 
nerve was exposed at the level of the middle of the thigh by blunt dissection through 
biceps femoris. Proximal to sciatica’s trifurcation, about 1 cm of the nerve was freed of 
adhering tissue and four ligatures (3/0 silk tread) were tied loosely around it with about 1 
mm spacing. The length of the nerve thus affected was 4-5 mm long. Great care was 
taken to tie the ligatures such that the diameter of the nerve was seen to be just barely 
constricted when viewed with 40x magnification. In every animal, an identical dissection 
was performed on the opposite side except that the sciatic nerve was not submitted to 
constrictive ligature ligated. The left paw was untouched. 
 
II.2.10.3.b. Monoiodioacetate injection (MIA) 
 
Joint damage was induced by a single intra-articular injection of 2 mg of sodium 
monoiodioacetate into the left knee joint of anaesthetised rats in a total volume of 25 µL. 
The dose of monoiodoacetate was chosen based on previous literature (Guingamp C, 
1997) and in-house dose-response data using 0.5, 1 and 2 mg. 
 
II.2.10.4. In vivo tests 
 
II.2.10.4.a. Paw-pressure test 
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The pharmacological assay is carried out using the paw-pressure test (Leighton CE, 
1988), in the two animal models of neuropathic pain described above. The instrument 
exerts a force which is applied at a constant rate (32 g per second) with a cone-shaped 
pusher on the upper surface of the rat hind paw. The force is continuously monitored by a 
pointer moving along a linear scale. The pain threshold is given by the force which induces 
the first struggling from the rat. An arbitrary cut off value of 250 g was adopted. Those 
mice scoring less than 40 g or over 75 g in the pretest were rejected (25%). The pain 
threshold was measured before (pretest) and 15, 30 and 45 min after the beginning of the 
test. 
 
II.2.10.4.b. Rota-rod test 
 
The apparatus consisted of a base platform and a rotating rod with a diameter of 3 cm and 
a non slippery surface, The rod was placed at a height of 15 cm from the base. The rod, 
30 cm in length, was divided into five equal sections by six disks. Thus, up to five rats were 
tested simultaneously on the apparatus, with a rod-rotating speed of 16 rpm. The integrity 
of motor coordination was assessed on the basis of the number of falls from the rod in 30 
s. Those mice scoring less than three and more than six falls in the pretest were rejected 
(20%). The performance time was measured before (pretest) and 15, 30 and 45 min after 
the beginning of the test. A total of 4-5 rats per group were tested. 
 
II.2.10.4.c. Statistics 
 
All experimental results are given as the mean ± SEM. An analysis of variance ANOVA, 
followed by Fisher's Protected Least Significant Difference procedure for post-hoc 
comparison, were used to verify significance between two means. Data were analyzed 
with the StatView software for the Macintosh. P values of less than 0.05 were considered 
significant. 
 
II.3.  Results and discussion 
 
II.3.1.  Isolation of verbascoside 
 
Commercial dried plant material (Lippia citriodora H.B.K.) was exhaustively extracted with 
hydroalcoholic solution (EtOH 80%) as described in the experimental part. The macerates 
were filtered and evaporated under reduced pressure and lyophilized to obtain a dried 
extract which was analysed by HPLC/DAD/ESI MS. The presence of verbascoside in the 
extract was assessed by comparison of its tR with the authentic sample verbascoside 
international standard and it was confirmed by UV and NMR data. Verbascoside resulted 
about 12% of the dried extract calculated using international standard (fig 20).  
 
II.3.1.1. Analytical HPLC/DAD/ESI MS characterization 
 
Chromatograms were acquired at different wavelengths for monitoring the diverse classes 
of compounds that can be present in the extract of leaves of Lippia citriodora H.B.K. (fig 
20). The different registered wavelengths were: 240 nm for monitoring iridoids, 330 nm for 
monitoring phenylpropanoids and 350 nm for monitoring flavonoids. 
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Fig 20. Chromatographic profiles at 240, 330 and 350 nm of a representative sample of Lippia 
citriodora H.B.K. leaf extracts. I=iridoids; Ph=phenylpropanoids derrivatives; Fl=flavonoids 
derivatives.  
 
At the wavelenght of 240 nm, only one iridoid was identified as verbenalin (figure 21, I2 in 
fig 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 21. Chemical structure and UV spectrum of verbenalin. 
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At the wavelenght of 330 nm, many phenylpropanoids derivates were evidenced: β-OH-
isoverbascoside, verbascoside, isoverbascoside, eukovoside and its isomer (figure 22, 
Ph2,3,4,5,7 respectively in fig 20). 
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β-OH-isoverbascoside   R=H; R1= caffeic acid; R2=OH 
verbascoside    R= caffeic acid; R1=H; R2=H 
isoverbascoside   R=H; R1= caffeic acid; R2=H 
  
Fig 22. Chemical structure and UV spectrum of phenylpropanoids derivates. 
 
At the wavelenght of 350 nm, only one flavonoid derivates was identified as luteolin-7-O-
diglucuronide  (figure 23, Fl1 in fig 20). 
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  R=diglucuronyl 
 
Fig 23. Chemical structure and UV spectrum of as luteolin-7-O-diglucuronide. 
 
Than, pure verbascoside was obtained by size exclusion chromatography (Sephadex LH-
20) eluting with ethanol (50%) and by recrystallization with methanol. Its good separation 
with Sephadex LH-20 in one purification step could represent a method easily applied at 
the industrial scale. This method is proposed as a fast and efficient tool for the isolation 
and purification of verbascoside recovering more than 85% of the constituent present in 
the crude dried extract (purity > 98%, determined by HPLC/DAD/ESI MS and confirmed by 
NMR).  
The advantages of this method include high recovery of the target product, short and well 
defined separation times, narrow bands which lead to good sensitivity, freedom from 
sample loss because solutes do not interact with stationary phase and the possibility to 
use “ecologically friendly” solvents. 
 
II.3.2.  Formulations 
 
II.3.2.1. Production and characterization of liposomes and ethosomes 
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In the table all the constituents of the bilayer of conventional liposomes were indicated with 
their molar ratio: 
 
molecule MW molar ratio mg/mL 
P90G 760 2.5 23 
cholesterol 386.66 0.5 2.2 
verbascoside 624 2 15 
 
These ratios were optimized starting from values reported in a precedent paper of our 
group (Sinico C, 2008). In the case of verbascoside, it is a molecule very hydrophilic, so 
the lipidic films were rehydrated with a solution of this drug dissolved in water, in a 
physiological solution (NaCl 0.9% v/v) or, in the case of ethosomes, in EtOH 30% v/v. 
All the obtained dimensional analysis were summarized in the following tables.  
Results derived from DLS analysis for liposomes: 
 
NaCl 
0.9% 
Verbascoside 
(mg/ml) 
P90G 
(mg/ml) 
Chol. 
(mg/ml) 
Mean 
diameter 
(nm) 
PDI 
− − 23 2.2 177.8 0.15 
− 15 23 2.2 155.0 0.15 
+ − 23 2.2 98.2±4.1 0.13 
+ 15 23 2.2 120.1±14.8 0.16 
 
Results derived from DLS analysis for ethosomes: 
 
EtOH 
30% 
Verbascoside 
(mg/ml) 
P90G 
(mg/ml) 
Chol. 
(mg/ml) 
Mean 
diameter 
(nm) 
PDI 
Zeta 
potential 
(mV) 
+ 15 23 2.2 239.9±1.5 0.6±0.1 -39.6±0.3 
 
In the case of liposomes, all the prepared formulations had a size very low, suitable not 
only for a topical delivery system but also for a parenteral administration. The polidispersity 
indexes (PDI) were less than 0.2, that means that the system is quite monodisperse.  
Conversely, the size of ethosomes were still acceptable but their PDI were not. The 
addition of ethanol in this percentage (30% v/v) to the bilayer act as enhancer of skin 
penetration (Touitou E, 1997), but verbascoside is not stable in this hydroalcoholic 
solution: the formulation started to become brownish. The in vitro test (Franz’s cell), 
described below, will be deluding. Ethosomes will be not developed more. 
After minicolumn centrifugation on sephadex G-50, useful for cleaning the liposomal 
surfaces from unentrapped drug, the encapsulation efficacy was evaluated. Results 
derived from HPLC/DAD/ESI MS analysis for liposomes: 
 
NaCl 0.9% 
Emulsiflex 
150.000 KPa 
30 s 
Sephadex G-
50 
Mean 
diameter 
(nm) 
PDI EE              (%) 
+ + + 120.15±14.85 0.16 91.44±1.28 
 
As we expected, the encapsulation efficacy of an water-soluble drug was very high. 
Liposomal formulation seemed to be a potential delivery for carrying in vivo verbascoside. 
 
II.3.2.2. Production and characterization of the inclusion complex  
 
Cyclodextrins are cyclic oligosaccharides consisting of six to eight D-glucose units (α, β 
and γ-CD, respectively) linked at C1 and C4 carbons (Bakkour Y, 2006). Due to their 
particular structure characterised by a hydrophobic internal cavity and a hydrophilic 
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external surface, they are able to entrap a variety of organic compounds. Cyclodextrins are 
widely applied in pharmaceutical and food industry, as they enhance the aqueous solubility 
of poorly water-soluble substances and they modify the physico-chemical properties of 
drugs and protect labile substances from oxidations or thermal and chemical degradations 
(Szejtli J, 1988; Bakkour Y, 2006). This type of inclusion complexes are able to reduce the 
volatility of fragrances and perfumes (Bakkour Y, 2006), to give a greater stabilization, to 
control the release and other wanted properties of the included compounds (Szejtli J, 
1988). In food industry they are used as additives to improve the taste (Szejtli J, 2005) and 
to control the enzymatic browning of different foods (Astray G, 2009). 
 
II.3.2.2.a. NMR analyses  
 
Nuclear  magnetic  resonance  is  one  of  the  most powerful  and versatile methods  for  
the elucidation of molecular structure and dynamics. It is also very well suited  to study 
molecular complexes and  their properties (Fielding L, 2000).  Therefore  it  has  been  
widely  used for  studying  inclusion  complexes  formed  by cyclodextrins (Dodjiuk H, 
2004). The success of NMR spectroscopy  in  this  field  is  due  to  its  ability  to study  
complex  chemical  systems  and  to  determine stoichiometry,  association  constants,  
and conformations  of molecular  complexes, as well as to provide information on the  
symmetry  and dynamics. NMR provides a detailed picture of the inclusion complexes, at 
least through four different and independent pieces of information (Schneider  HJ, 1998). 
In the first place, one can simply measure complexation shifts, i.e. the difference between 
free and bound resonance frequency (in ppm) for the same nucleus; secondly, one can 
take advantage of through-space proximity of nuclei on the host and the guest molecule, 
by means of ROESY; third one can build a Job’s plot and finally one can measure a 
decreasing of the diffusion coefficient, due to the fact that when the verbascoside is 
included, it assumes the same (slower) dynamic behaviour of cyclodextrin (Brand T, 
2005). First of all, the difference between the chemical shifts of free and complexed 
verbascoside for the same nucleus were measured in order to understand which proton 
were mainly involved in the complexation. In figures 24 and 25, the 1H NMR spectra of 
verbascoside in D2O and verbascoside in a satured solution of β-CDs. 
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Fig 24. 1H NMR spectrum of verbascoside in D2O 
 
 
 
 
 
 
 
 
 
 
1.01.52.02.53.03.54.04.55.05.56.06.57.07.5 ppm
 
Fig 25. 1H NMR spectrum of verbascoside-βCDs complex in D2O. 
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Following table reports the complexation shifts ∆δ for verbascoside alone and in presence 
of β-cyclodextrin. This compound features a certain scatter in the complexation shifts. The 
assignment of the peaks was unambiguously made by 2D spectra like COSY. 
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δ (ppm) 
verbascoside 
δ (ppm) 
verbascoside- 
βCDs complex 
∆δ (ppm) No. H 
 
 
    
 
aglycon 
6.7919 *  1 d H-2 
6.7869 *  1 d H-5 
6.6902 6.6295 0.0607 1 dd H-6 
2.7647 2.7831 0.0184 2 dd H-7a,b 
4.0241 4.0180 0.0061 1 m H-8a 
3.7933 3.9056 0.1123 1 m H-8b 
     
glucose 
4.4466 4.4889 0.0423 1 d H-1’ 
3.3849 3.3885 0.0036 1 dd H-2’ 
3.8040 *  1 dd H-3’ 
4.8975 4.9707 −0.0732 1 dd H-4’ 
3.6438 *  1 m H-5’ 
3.4226 *  1 dt H-6’a 
3.5038 *  1 dd H-6’b 
     
rhamnose 
5.0322 5.0033 0.0289 1 d H-1’’ 
3.9266 3.9967 −0.0701 1 dd H-2’’ 
3.5773 3.6542 −0.0769 1 dd H-3’’ 
3.2499 3.2944 −0.0445 1 t H-4’’ 
3.6100 *  1 m H-5’’ 
0.9653 0.9661 −0.0008 3 d H-6’’ 
     
caffeoyl 
7.1349 6.9808 0.1541 1 d H-2’’’ 
6.8641 6.7981 0.0660 1 d H-5’’’ 
7.0709 6.8569 0.2140 1 dd H-6’’’ 
7.6299 7.5877 0.0422 1 d H-7’’’ 
6.3335 6.2645 0.0690 1 d H-8’’’ 
 
* Peaks were completely or partially submerged, so it was not possible to figer out the 
chemical shift, neither with the help of bidimensional spectra. 
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The complexation shifts ∆δ for verbascoside alone and in presence of β-cyclodextrin 
involved all the nuclei, so this is the a clue that an interaction between host and guest 
happened. The signals assigned to the protons H2’’’ and H6’’’ of the caffeoyl moiety were 
the most affected with or without the presence of β-CDs; in addition, the signals of these 
protons were isolated, not overlapped with peaks of the β-cyclodextrin, so can be 
monitored in order to understand the stoichiometry ratio of the complex by Job’s plot 
analysis. In the figure 26 an enlargement of the 1H spectrum shows the ∆δ in ppm in the 
aromatic region related to H2’’’ and H6’’’. 
 
 
Fig 26. Zoom of overlapped 1H NMR of verbascoside with (up) or without (down) the presence of β-
CDs. 
 
Starting from monodimensional NMR spectroscopy, protons H2’’’ and H6’’’ of the caffeic 
acid moiety of verbascoside were involved in the formation of the complex between 
verbascoside and β-CDs.  
Secondly, one can take advantage of through-space proximity of nuclei on the host and 
the guest molecule, by means of ROESY; the network of intermolecular contacts for 
verbascoside included in β-CDs is depicted in figures 27 and 28. The most relevant 
interactions are between the sugar proton H3’ and the protons H2’’’, H5’’’ and H6’’’ of the 
caffeic acid moiety of verbascoside: these data confirm a deep inclusion of drug with the 
aromatic tail in the hydrophobic pocket of β-CDs, oriented toward the primary hydroxyl rim.  
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Fig 27. 2D ROESY spectrum of verbascoside-βCDs complex in D2O. 
 
 
 
 
Fig 28. Partial 2D ROESY spectrum where cross peaks between H3’ of β-CDs and H2’’’ and H6’’’ were 
found out. 
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The absence of other intermolecular contacts is a first strong indication of the existence of 
one well-defined 1:1 complex only. Different adduct stoichiometries (for example, β-
CDs/guest 2:1) would necessarily lead to other contacts, e.g. involving the 
dihydroxyphenylethanol and β-CyD or two different β-CDs molecules. This conclusion is 
also confirmed by the Job’s plot analysis discussed below. Figure 29 shows a 
representation of the interaction of verbascoside with β-cyclodextrin. 
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Fig 29. Schematic representation of verbascoside and its interaction with β-CDs. 
 
In  the  case  of  verbascoside  induced  proton  shifts and  intermolecular  ROE  signals 
demonstrated  that  the  caffeoyl  moiety  is  deeply inserted in the cyclodextrin cavity.   
H2’’’ and H6’’’ were selected for monitoring ∆δobs during the continuous variation method 
because their shifts were more considerable and their peaks do not overlap with others. 
 
II.3.2.2.b. Job’s plot  
 
A molecule and β-CDs may be in fast, intermediate or slow exchange with the complex 
molecule-β-CDs on the 1H NMR time-scale (Connors KA, 1987). When a molecule and β-
CDs are in a slow exchange with their complex, two signals for one specific proton can be 
seen in the spectrum, corresponding to complexed and uncomplexed molecule. When 
they are in a fast exchange, only one signal for a specific proton is observed. In the case 
of verbascoside and β-CDs, they are in a fast exchange and the doubt about the 
stoichiometry can be ascertained by a Job’s plot. 
An important step of a molecular complex is to determine its stoichiometry. This is 
frequently obtained by applying the method of continuous variations (Job’s plot) (Connors 
KA, 1987; Job P, 1928; Bratu I, 2004; Zouvelekis D, 2002; Fielding L, 2000; Dodziuk H, 
2004). This method is often applied with various analytical techniques, such as 1H NMR, 
UV–vis spectroscopies or circular dichroism. In each case, the Job plot is based on the 
spectral change observed either for the host or the guest (Landy D, 2007). 
Values of the experimentally observed spectral parameter (usually chemical shifts that are 
sensitive to complex formation) are determined for varying host (H) to guest (G) mole 
ratios where the sum of their concentrations is kept constant (Ejchart A, 2006; Job, 1928). 
The data are plotted as the product of guest mole fraction and its complexation induced 
shift versus host mole fraction (fig 30). The ratio of mole fractions XG : XH at the position of 
the maximum indicates the complex stoichiometry (Ejchart A, 2006). 
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Fig 30. Job’s plot 
 
The Job’s plots confirmed the 1:1 inclusion complex. The complexation happened when 
the ratio of mole fractions XG : XH  is 0.5 : 0.5. 
 
II.3.2.2.c.  Diffusion Ordered SpectroscopY 
 
DOSY experiments were carried out in order to establish the inclusion of verbascoside in 
the β-CDs cavity. DOSY is based on diffusion coefficients which are different for free and 
complexed molecules and whose measurements make it possible to determine the binding 
constant between β-CDs and verbascoside. 
While the above data provide a complete picture of the complex structure, they do not lend 
themselves to speculations on the magnitude of the association constant. This is due to 
the fact that the system is in fast exchange (on the NMR timescale) and consequently one 
observes resonances falling at the weighted average between the positions of the free and 
bound form. Nowadays is very easily performed on NMR instruments equipped with z-
gradient coils (Johnson CS jr, 1999) in order to determinate the apparent binding constant 
by diffusion experiment. It is necessary to measure the diffusion coefficient of the guest 
alone DF, of the host alone DH, and of the mixture Dmix, in solution (Fielding L, 2000). Then, 
provided the host is large enough, one can approximate the diffusion coefficient of the 
bound complex to that of the host alone (DB ≈ DH), which amounts to saying that 
complexation is only a minor perturbation to the host. In such a case, the following 
equation holds: 
HF
mixF
BF
mixF
B DD
DD
DD
DD
x
−
−
≈
−
−
=  
where  xB is the mole fraction of the bound drug. 
The DOSY spectra in figure 31 clearly demonstrate that in the presence of β-CDs the 
translational diffusion of verbascoside is sizably slowed down with respect to the free drug, 
although it is not completely reduced to that of the macrocycle.  
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Fig 31. Overlapped DOSY of verbascoside with (up) or without (down) the presence of β-CDs. 
 
 
 
This confirms that we are indeed in the presence of a free/bound equilibrium, and by 
means of the previous equation: 
 
(2.45 − 2.06) x 10−10 0.39 0.75 
(2.45 − 1.93) x 10−10         0.52 
 
We can estimate the extent of inclusion to about xB ≈ 75% for verbascoside in D2O; owing 
to the approximations introduced above, no more accurate figures can be provided.  
Diffusion  ordered  spectroscopy  (DOSY),  a  high-resolution  NMR  technique  which  was 
used extensively  to  study  supramolecular  aggregates  and solubilisation  processes.   
Compared  to  other  techniques NMR  spectroscopy  provides  a  superior method  to  
study  complexation phenomena , because guest and host molecules are simultaneously 
observed at the atomic level.   
 
II.3.3.  Stability 
 
II.3.3.1. Stability test of verbascoside-loaded liposomes  
 
sample in D2O  diffusion diffusion rate (m/s2) 
verbascoside DF −9.611 2.45 x 10−10 
β-CDs DB ≈ DH −9.714 1.93 x 10−10 
verbascoside + β-CDs Dmix −9.685 2.06 x 10−10 
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The physical stability of a liposome formulation is determined by its colloidal behaviour and 
its ability to retain the cargo for long periods during storage. The liposomes should ideally 
remain intact upon dilution or changes in the ionic strength, as typically encountered 
during administration. From a thermodynamical point of view it is notable that plain 
liposomes are not at equilibrium but represent kinetically trapped systems. Hence, their 
structures are relatively stable upon dilution, whereas thermodynamically reversible 
systems such as micelles and microemulsions would immediately aggregate or 
disintegrate (Chung H, 2001 ). If the liposomal dispersion is physically stable, phenomena 
of aggregation, disaggregation or fusion of the vesicles will not occur. 
Chemical stability of the lipids during storage is another point of concern, especially 
against hydrolysis, and in the case of unsaturated lipid chains also against oxidation 
(Ulrich AS, 2002). If the liposomal dispersion is chemically stable, phenomena of leakage 
and chemical degradation of the delivered drug will not happen. 
Verbascoside-loaded liposomes were kept at 4°C±1°C for 3 months and their physical and 
chemical stability were assessed. 
 
day after 
preparation 
mean 
diameter (nm) 
retained 
verbascoside            
(%) 
1 120.15±14.85 100±0.2 
7 120.95±22.27 97±1.4 
30 125.97±19.09 97±1.2 
90 163.26±19.85 91±3.4 
180 - 83±2.7 
 
Stability studies (DLS measurements and TEM visualization) pointed out that vesicles 
were physically stable for 90 days and neither verbascoside leakage nor vesicle size 
alteration occurred during this period. Moreover, no verbascoside degradation occurs over 
the whole period. This results suggest that verbascoside concentration in the aqueous 
phase of the vesicles is always closed to saturation. 
 
II.3.3.2. Stability test of the inclusion complex 
 
The inclusion complex was kept at room temperature covered by sunlight and 
verbascoside chemical stability was checked within 1 month.  
 
verbascoside in beta-CDs 15 mM
0
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0 10 20 30 40
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%
verbascoside 0.1 mg/mL 
verbascoside 2 mg/mL
verbascoside 5 mg/mL
 
Fig 32. Stability in time of verbascoside-β-CDs inclusion complex. 
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The inclusion complexes containing verbascoside at concentrations of 2 and 5 mg/mL 
were stable for the whole tested period; verbascoside, cheched by HPLC/DAD analysis, is 
not degradated for more than 95%. 
 
II.3.4.  In vitro experiment: skin permeation studies 
 
A Franz diffusion cell methodology has been performed with the aim to understand if 
carriers like liposomes or ethosomes will be able to delivery verbascoside, once topically 
applied, to deeper subcutaneous regions. 
Results of in vitro permeation study of different formulations through pig skin were 
summarized in the following table (SC strato corneum; E epidermis; D derma). 
 
Accumulated drug (µg x cm2) formulation Permeated drug (µg x cm2) SC E D 
verbascoside ‒ ‒ ‒ ‒ 
 verbascoside-loaded liposomes ‒ 430±75 75±18 ‒ 
 verbascoside-loaded ethosomes ‒ 17.72±1.5 0.90±0.01 ‒ 
 
Results reported in table show that verbascoside-loaded liposomes promoted drug 
accumulation into the stratum corneum, but they did not give rise to any significant 
transdermal verbascoside delivery. Verbascoside crossed the skin layers to the epidermis 
only with a low amount. Ethosomes were really deluding and it make no sense to develop 
this kind of formulation with additional studies or in vivo experiments. 
 
II.3.5.  In vivo experiment: antihyperalgesic activity  
 
The antihyperalgesic activity of pure verbascoside was investigated in two animal models 
of neuropathic pain: CCI and MIA. In the MIA model, the intra-articular injection of sodium 
monoiodioacetate produce an inflammation; so drugs able to revert this hyperalgesia will 
be active against chronic inflammation. On the other hand, in the case of CCI model, a 
peripheral mono neuropathy was produced in rats thank to the constriction of sciatic nerve; 
so drugs able to revert this hyperalgesia will be active against neuropathic pain. To the 
best of our knowledge no study has been reported on the activity of verbascoside on 
neuropathic pain, a widespread disorder induced by autoimmune diseases, drug or toxin 
exposure, infections, metabolic insults or trauma. As a consequence, nerve damage may 
cause muscle weakness, altered functionalities and sensitivity, and a chronic pain 
syndrome characterized by allodynia (pain elicited by a nonnoxious stimulus) and 
hyperalgesia (increased pain response to a noxious stimulus) which can persist long after 
the initial injury is resolved (Woolf CJ, 1999). The underlying molecular mechanisms are 
still not completely understood, and as a consequence, treatment is unsatisfactory in many 
cases (Syndrup SH, 1999). Therefore, there is an urgent need to develop novel 
therapeutics for an effective treatment of neuropathic pain. 
In the Paw pressure test, paw withdrawal threshold was measured exerting a force that 
increases at constant rate (32 g/s). Stimulus at which rats withdrew the paw was recorded 
before treatment and after drug administration at different times (15, 30, 45 and 60 min). 
The results represent means ± SEM of the mechanical threshold expressed as grams.  
Figure 33 shows the positive controls used as reference compounds in both of the two 
models of neuropathic pain in the rat paw-pressure test. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 33. Positive controls used as reference compounds in a chronic constriction injury of the sciatic 
nerve (a) and in an intra-articular injection of sodium monoiodoacetate (b) in the rat paw-pressure 
test. 
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II.3.5.1. In vivo antihyperalgesic activity: comparison of the behaviour of verbascoside 
and verbascoside-loaded liposomes administered intraperitoneally 
 
Verbascoside was unable to increase the pain threshold in naïve animals, showing the 
lack of any analgesic activity at the dosages of 50 and 100 mg/kg i.p. (fig 34). We can, 
therefore, exclude that the antihyperalgesic activity of verbascoside was a consequence of 
its analgesic properties.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
Fig 34. At the dosages of  50 and 100 mg/kg i.p. verbascoside shows the lack of any analgesic 
activity, in the rat paw-pressure test. 
 
The antihyperalgesic effect of verbascoside was not prevented by pre-treatment with the 
opioid antagonist naloxone, suggesting that verbascoside does not require the activation 
of the opioid system to reverse hyperalgesia (data not shown).  
First of all, there were no suggestions about the active dosage (if existing) of verbascoside 
i.p. in these animal models. So, several dosage of pure verbascoside, dissolved in 
physiological solution, were administered in order to find the active and the lowest dosage. 
Verbascoside, when administered intraperitoneally at the dose of 100 mg/kg reverted the 
mechanical hyperalgesia, evaluated in the paw pressure test in CCI treated rats (fig 35A). 
The antihyperalgesic effect started 15 min after administration and persisted up to 30-45 
min. By contrast in the controlateral paw the pain perception remained unchanged. 
In the case of MIA treated rats (fig 35B) verbascoside was active 15 min after 
administration and persisted up to 30-45 min, when administered intraperitoneally (i.p.) at 
the same dosage of 100 mg/kg. 
 
A liposome formulation containing verbascoside 100 mg/kg administered i.p. showed a 
longer lasting antihyperalgesic effect in comparison with a 100 mg/kg verbascoside saline 
solution. The effect appeared 15 min after administration and persisted up to 60 min in 
both models investigated (fig 35A,B). The intensity of the effect of the liposome 
formulation was comparable to that showed by the verbascoside saline solution (fig 
35A,B). 
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Effect of verbascoside and of verbascoside-loaded liposomes in a chronic constriction injury of the sciatic nerve (CCI) evaluated in the Paw-pressure 
test. 
*P<0.05 in comparison with pretest dx (antihyperalgesic effect). 
 
 
 
 
Effect of verbascoside and of verbascoside-loaded liposomes in an intra-articular injection of sodium monoiodoacetate (MIA) evaluated in the Paw-
pressure test. 
 
Paw pressure test in rats (g) 
after treatment before treatment 15 min. 30 min. 45 min. 60 min. 75 min. 
treatment 
100 mg/kg 
i.p. sn dx sn dx sn dx sn dx sn dx sn dx 
verbascoside 
50 mg/kg 60.9±1.2 31.7±2.1 53.0±3.7 39.6±2.3* 52.0±1.2 31.7±1.0 53.0±1.2 30.0±1.6     
verbascoside 
100 mg/kg 55.9±1.2 32.3±3.1 56.6±1.7 42.0±2.5* 64.0±2.1 44.6±1.0* 56.1±1.5 36.8±1.1* 51.0±0.7 31.3±1.3   
verbascoside-
loaded 
liposomes 
100 mg/kg 
54.9±1.2 32.3±0.7 55.3±1.4 39.3±0.7* 58.7±1.6 43.0±0.8* 59.9±2.0 45.7±0.7* 56.4±2.0 38.7±1.0* 50.1±1.4 34.3±0.4 
*P<0.05 in comparison with pretest dx (antihyperalgesic effect). 
Paw pressure test in rats (g) 
after treatment before treatment 15 min. 30 min. 45 min. 60 min. 75 min. treatment  i.p. 
sn dx sn dx sn dx sn dx sn dx sn dx 
verbascoside 
50 mg/kg 61.9±1.2 30.0±1.2 53.0±3.7 35.6±2.4 55.0±1.2 24.4±2.4 55.0±1.2 22.2±1.2     
verbascoside 
100 mg/kg 55.9±1.2 29.6±1.2 57.6±1.7 38.9±1.0* 63.0±2.1 42.0±1.2* 56.3±1.5 37.6±1.1* 53.0±0.7 32.2±0.9   
verbascoside-
loaded 
liposomes 
100 mg/kg 
55.9±1.2 30.0±0.8 55.2±1.4 37.2±1.1* 58.5±1.6 42.8±1.5* 60.9±2.0 45.9±1.2* 56.1±2.0 38.7±1.6* 51.1±1.4 33.1±0.9 
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Fig 35. Effect of verbascoside and of verbascoside-loaded liposomes in a chronic constriction injury 
of the sciatic nerve (A) and in an intra-articular injection of sodium monoiodoacetate (B) evaluated in 
the Paw-pressure test.  
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II.3.5.2. In vivo antihyperalgesic activity: comparison of the behaviour of verbascoside 
and verbascoside-βCDs inclusion complex administered orally 
 
Verbascoside was also effective against mechanical hyperalgesia when orally 
administered. At the doses of 300 and 600 mg/kg p.o. (fig 36) as well as 50 and 100 mg/kg 
i.p. (fig 34), verbascoside was unable to increase the pain threshold in naïve animals, 
showing the lack of any analgesic activity. 
 
Fig 36. At the dosages of 300 and 600 mg/kg p.o., verbascoside shows the lack of any analgesic 
activity, in the rat paw-pressure test. 
 
At the dosages of 300 and 600 mg/kg p.o. it reverted the hyperalgesia induced by both 
CCI (fig 37A) and MIA injection with a long lasting effect (fig 37B): the antihyperalgesic 
effect started 15 after administration and was still significant at 45 min.  
 
Conversely by the liposomal formulation, a β-cyclodextrin formulation containing 
verbascoside 300 mg/kg showed the same antihyperalgesic profile of 300 mg/kg 
verbascoside saline solution when orally administered in both CCI (fig 37A) and MIA 
injected (fig 37B) rats. 
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Effect of verbascoside and of verbascoside-β-CDs complex in a chronic constriction injury of the sciatic nerve (CCI) evaluated in the Paw-pressure 
test. 
 
Paw pressure test in rats (g) 
after treatment before treatment 15 min. 30 min. 45 min. 60 min. 75 min. treatment  p.o. 
sn dx sn dx sn dx sn dx sn dx sn dx 
verbascoside 
300 mg/kg 56.7±1.4 34.6±0.8 60.8±4.2 47.5±0.8* 66.6±3.0 52.4±0.8* 57.5±0.8 45.0±1.7* 52.5±0.8 38.3±1.0   
verbascoside-
β-CDs 
complex 
300 mg/kg 
55.0±3.5 34.2±1.6 58.3±4.4 45.8±1.6* 64.1±2.1 51.7±2.1* 55.8±1.6 42.5±0.8* 55.8±1.6 36.7±1.4   
verbascoside 
600 mg/kg 57.5±3.7 33.3±2.9 
73.3±2.0
^ 
50.0±4.0* 73.3±5.0^ 60.8±5.1* 68.3±4.3
^ 
58.3±7.2* 60.8±4.7 45.0±4.3* 48.3±5.2 36.7±2.9 
*P<0.05 in comparison with pretest dx (antihyperalgesic effect). 
  
 
Effect of verbascoside and of verbascoside-β-CDs complex in an intra-articular injection of sodium monoiodoacetate (MIA) evaluated in the Paw-
pressure test. 
 
Paw pressure test in rats (g) 
after treatment before treatment 15 min. 30 min. 45 min. 60 min. 75 min. 
treatment 
300 mg/kg 
p.o. sn dx sn dx sn dx sn dx sn dx sn dx 
verbascoside 
300 mg/kg 56.8±1.4 31.7±0.6 56.7±1.4 38.5±0.6* 55.7±1.4 43.9±1.0* 54.7±1.4 38.9±0.7* 58.7±1.4 30.7±1.0   
verbascoside-
β-CDs 
complex 
300 mg/kg 
54.0±3.5 31.7±0.6 55.1±3.5 37.5±0.4* 55.3±3.5 45.0±1.0* 53.0±3.5 39.2±0.4* 55.3±3.5 35.0±0.7   
verbascoside 
600 mg/kg 56.5±3.7 30.0±2.4 55.5±3.7 44.2±3.4* 58.5±3.7 50.0±3.0* 57.4±3.7 41.7±1.7* 57.8±3.7 35.0±1.0   
*P<0.05 in comparison with pretest dx (antihyperalgesic effect). 
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Fig 37. Effect of verbascoside and of verbascoside-βCDs complex in a chronic constriction injury of 
the sciatic nerve (A) and in an intra-articular injection of sodium monoiodoacetate (B) evaluated in 
the Paw-pressure test.  
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II.3.5.3. Rota rod test 
 
The safety of verbascoside was also demonstrated. Verbascoside did not modify animals’ 
gross behaviour at the highest effective doses. The Rota-rod test was also employed to 
unmask any alterations of the  motor coordination induced by the compound investigated. 
The number of falls from the rotating rod showed the lack of any impairment in the motor 
coordination of animals treated with verbascoside in comparison with the control group, 
ruling out that the results obtained were due to animals’ altered viability. During each 
session the number of falls of mice with unaltered locomotor activity decreases since 
animals learn how to balance on the rotating rod. The results were summarized in the 
following table. 
 
after treatment treatment dose (mg/kg) p.o. 
before 
treatment 15 min. 30 min. 45 min. 
CMC 
 3.6 ± 0.3 2.2 ± 0.4 1.9 ± 0.3 1.2 ± 0.3 
verbascoside 1000 3.9 ± 0.4 2.5 ± 0.3 2.1 ± 0.3 0.7 ± 0.2 
 
Each value represents the mean of 5 mice. 
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III.  trans-Resveratrol 
 
 
 
 
 
 
 
 
 
 
 
 
III.1.  Introduction 
The non-flavonoid phytoalexin trans-resveratrol (trans-3,5,4′-trihydroxystilbene) and its 
various derivatives are widely distributed in Gymnosperms and Dicotyledons (Gorham J, 
1980; Ingham JL, 1976). trans-Resveratrol was discovered in 1976 in the grape vine, Vitis 
vinifera L., and was observed to occur there as a response to fungal infection or injury 
(Langcake P, 1976) is produced by plants in response to infection by the pathogen Botrytis 
cinerea (Delmas D, 2006). It is also induced in response to a variety of stress conditions, 
such as pedoclimatic conditions, exposure to ozone, sunlight and heavy metals 
(Bavaresco L, 2003).Later studies revealed trans-resveratrol in grape skins (Creasy LL, 
1988; Jeandet P, 1991, 1995; Roggero JP, 1995) and more recently in wines (Goldberg 
DM, 1994, 1995; Vrhovsek U, 1995). trans-Resveratrol has been suggested as a cause for 
reduced CHD mortality in wine drinkers and numerous studies describe potential 
mechanisms by which trans-resveratrol could reduce heart disease (Trela BC, 1996). The 
roots of P. cuspidatum are traditionally used as a remedy or prevention for allergic 
inflammatory diseases, hyperlipidemia and cancer (Kimura Y, 2001). Resveratrol is known 
to have potent anti-inflammatory and antioxidant effects (Fremont L, 1999; Lee SK, 1998; 
Athar M, 2007). 
III.1.1.  Chemical properties 
 
Resveratrol is a molecule with low solubility in aqueous media, poor bioavailability, and it 
has propensity to oxidize (Walle T, 2004; Trela BC, 1996; Wenzel E, 2005). Regarding its 
solubility, trans-resveratrol is soluble in ethanol, DMSO, and other organic solvents, 
whereas different authors have put its solubility in water at 1 mg/mL, limiting its use in the 
food industry (Lopez-Nicolas JM, 2008; Caddeo C, 2008). 
It exists as two geometric isomes: cis- (Z) and trans- (E). Cis- isomer is unactive, it has 
biological activity unuseful for our needs. The trans- form can undergo isomerisation to the 
cis- form when exposed to ultraviolet irradiation (Prokop J, 2006). Unfortunately, the use of 
trans-resveratrol in pharmaceutical and cosmetic field is problematic owing to its fast 
degradation mainly linked to the isomerization from the active trans form to the inactive cis 
one (Wang Y, 2002).  
A knowledge of the protonation state of resveratrol is important to understand its biological 
activity. pka1 = 8.8 (H-4’, essential for cytogenetic, radical scavenging, antioxidant and 
antiproliferative activities), pka2 = 9.8 (H-3 or H-5), pka3 = 11.4 (H-5 or H-3) calculated on 
the basis of the variation on the fluorescence of emission signal (Lopez-Nicolas JM, 2008). 
HO
HO
OH
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When the pH of the medium is higher than the first pka, the biological activity of resveratrol 
will be strongly reduced (Lopez-Nicolas JM, 2008). 
The logarithm of octanol–water partition coefficient (log P) is used as a measure of the 
hydrophobicity of compounds and it is assumed to represent the general tendency of a 
chemical to partition between an aqueous and an organic phase. The value of log P for the 
resveratrol is 1.87 (Fabris S, 2008). 
 
III.1.2.  Pharmacological effects 
 
The preventive anti-carcinogenic effects of resveratrol appear to be closely associated with 
its antioxidant activity. RSV, and it has been shown to inhibit hydroperoxidase, protein 
kinase C, Bcl-2 phosphorylation, Akt, focal adhesion kinase, NF-κB, matrix 
metalloprotease-9, and cell cycle regulators (Athar M, 2007). 
Resveratrol has been shown to modulate lipoprotein metabolism (Frankel EN, 1993; 
Belguendouz L, 1998), eicosanoid synthesis (Kimura Y, 1985; Pace-Asciak CR, 1995; 
Rotondo S, 1998) and lipid oxidation (Belguendouz L, 1997). It inhibits the oxidation of 
low-density lipoproteins and platelet aggregation (Kimura Y, 1985; Frankel EN, 1993; 
Pace-Asciak CR, 1995; Bertelli AA, 1996; Belguendouz L, 1997; Rotondo S, 1998; Wang 
Z, 2002; Athar M, 2007). 
 
III.1.2.1. In vitro anti-inflammatory activity 
 
Resveratrol has a strong anti-inflammatory property acting through the inhibition of cyclo-
oxygenases, thereby amongst others the arachidonic acid metabolism is disrupted (Pace-
Asciak CR, 1995; Jang M, 1997). Resveratrol also suppresses the induction of nitric oxide 
synthase and disrupts arachidonic acid metabolism by inhibiting cyclooxygenase-2 (Chan 
MY, 2000; Moreno JJ, 2000; Athar M, 2007). 
Kimura et al. reported that resveratrol strongly inhibited the formation of 5-lipoxygenase 
products, 5-hydroxy-6,8,11,14-eicosatetraenoic acid, leukotrienes B4 and C4, and the 
cyclooxygenase product thromboxane B2 from arachidonic acid (Kimura Y, 1985a; 1985b; 
1995). 
Resveratrol significantly reduces both acute and chronic chemically induced oedema 
(Jang M, 1997; Bohm M, 2004; Chen G, 2005), lipopolysaccharide-induced airway 
inflammation (Birrell MA, 2005) and osteoarthritis (Elmali N, 2005) and helps to prevent 
allograft rejection (Wu SL, 2005). 
Resveratrol exerts powerful antiinflammatory effects in the setting of ischemia/riperfusion, 
actions that may explain in part the cardioprotective effects associated with regular 
consumption of this type of alcoholic beverage. (Shigematsu S, 2003).  
Resveratrol has been reported as a powerful antioxidant for the therapy of AD (Jang JH, 
2003; Russo A, 2003; Sharma M, 2002).  
In vitro studies on PC12 cells, human umbilical vein endothelial cells (HUVECs), SHSY5Y 
neuroblastoma cells and hippocampal neuronal cell cultures, had found that resveratrol 
protected cells from oxidative stress and apoptosis induced by Aβ (Jang JH, 2003; Russo 
A, 2003; Sharma M, 2002; Savaskan E, 2003; Han YS, 2004). 
12-hr pre-incubation of resveratrol-loaded nanoparticles protected PC12 cells from Aβ-
induced damage in a dose dependent manner (1-10µM) by attenuating intracellular 
oxidative stress and caspase-3 activity (Lu X, 2009). 
 
III.1.2.2. In vivo anti-inflammatory activity 
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Although resveratrol behaves as a poor in vitro scavenger of ROS (Leonard S, 2003), it 
acts as a potent antioxidant in vivo. The in vivo antioxidant property of resveratrol probably 
arises from its ability to increase nitric oxide synthesis, which in turn functions as an in vivo 
antioxidant, scavenging superoxide radicals (Das DK, 2006). 
It is becoming increasingly clear that resveratrol has two faces. On one hand, it protects 
cells by potentiating a survival signal. On the other hand, it selectively kills cancer cells. It 
behaves as an antioxidant, yet it can induce redox signalling or it behaves as a pro-
oxidant, it is an antiproliferative agent for cancer (Das DK, 2006; Alarcón C, 2007). It 
induces apoptosis in tumor cells and sensitizes cancer cells by inhibiting cell survival 
signal transduction and antiapoptotic pathways (Das DK, 2006). Administration of high 
doses of resveratrol to rats promotes death signals (Jocelyn D, 2008). The potential 
beneficial effects of natural antioxidants cannot justify the risk of severe side effects 
(Mancuso C, 2007). 
Resveratrol possesses anti-inflammatory properties: it exhibits toxicity towards RAW 264.7 
mouse macrophages with a IC50≤ 25 µM. This toxicity most probably arises from its 4’- 
hydroxyl group found on phenyl ring B ( Billack B, 2008). 
Resveratrol has been reported to protect several types of cells against β-Amyloid peptide 
(Aβ) toxicity by scavenging Reactive Oxygen Species (ROS) and inactivating caspase-3 at 
the concentrations of 5, 10 µM (Lu X, 2009).  
 
III.1.2.3. In vitro chemopreventive activity  
 
The cancer chemopreventive potential of resveratrol has been demonstrated in the models 
of carcinogenesis in vivo and in cells in vitro (Sale S, 2004).  
Cancer chemopreventive activity of resveratrol was investigated in a mouse mammary 
gland culture model of carcinogenesis (Moon RC, 1990). Resveratrol inhibited, in a dose-
dependent manner, the development of DMBA-induced preneoplastic lesions (ED50 = 3.1 
µM). No signs of toxicity were observed, as judged by morphological examination of the 
glands (Jang M, 1997). 
 
III.1.2.4. In vivo chemopreventive activity  
 
Resveratrol inhibits tumor growth and causes apoptosis as a cancer chemopreventive 
mechanism (Jang M, 1997; Ciolino HP, 1998; Ragione FD, 1998; Fontecave M, 1998; 
Subbaranmaiah K, 1998; Sun NJ, 1998; Clèment MV, 1998; Carbò N, 1999). 
Epidemiological evidence shows that long-term inhibition of cyclooxygenase significantly 
reduces the risk of developing many cancers and deletion of the gene that encodes 
cyclooxygenase 2 is protective in a mouse model of colorectal cancer (Oshima M, 1996).  
In several studies, small doses (0.02-8 mg/kg) of resveratrol, given prophylactically, 
reduced or prevented the development of intestinal and colon tumors in rats given different 
carcinogens (Athar M, 2007).  
Administration of 1–5 mg/kg daily of resveratrol failed to affect the growth or metastasis of 
breast cancer in mice, despite promising in vitro results (Bove K, 2002). 
Resveratrol treatment appeared to prevent the development of mammary tumors in animal 
models; however, it had no effect on the growth of existing tumors. Paradoxically, 
treatment of pre-pubertal mice with high doses of resveratrol enhanced formation of 
tumors. Injected in high doses (40 mg/Kg) into mice, resveratrol slowed the growth of 
neuroblastomas (Chen G, 2004).  
Topical application of resveratrol reduced the number of skin tumors per mouse by up to 
98%  (Jang M, 1997). 
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The in vivo studies appear to show that resveratrol is not an effective chemotherapeutic 
agent in inhibiting melanoma growth in animals, although more pre-clinical studies would 
be needed for confirmation (Athar M, 2007).  
Topical application of resveratrol in mice, both before and after the UVB exposure, 
inhibited the skin damage and decreased skin cancer incidence (Athar M, 2007).  
 
III.1.2.5. In vitro anticancer activity 
 
Resveratrol’s potential chemopreventive and chemotherapeutic activities have been 
demonstrated in all three stages of carcinogenesis (initiation, promotion, and progression) 
(Jang M, 1997; Athar M, 2007).  
It was found to act as an antioxidant and antimutagen and to induce phase II drug-
metabolizing enzymes (anti-initiation activity) (Jang M, 1997). Resveratrol was also found 
to inhibit events associated with tumor initiation: for example, it inhibited, in a dose-
dependent manner, free-radical formation (ED50 = 27 µM) when human promyelocytic 
leukemia (HL-60) cells were treated with 12-O-tetradecanoylphorbol-13-acetate (Sharma 
S, 1994). 
It mediated anti-inflammatory effects and inhibited cyclooxygenase COX-1 (median 
effective dose ED50 = 15  µM) and hydroperoxidase functions (anti-promotion activity) 
(Jang M, 1997). 
In addition, it induced human promyelocytic leukemia cell differentiation (anti-progression 
activity) (Jang M, 1997). Suh et al. tested the ability of resveratrol to inhibit the progression 
stage of carcino-genesis by treating cultured HL-60 cells with resveratrol (Suh N, 1995). 
Treatment of LLC cells in vitro with resveratrol significantly increased apoptotic cells. It 
induced cleavage of caspase-9 and caspase-3 (it was involved in in vivo apoptosis) (Lee 
EO, 2006). 
Angiogenesis is required to support the growth of most solid tumors beyond a diameter of 
2–3 mm. When delivered systemically at a dose of 2.5–100 mg/kg, resveratrol inhibits 
tumor-induced neovascularization (Kimura Y, 2001; Tseng SH, 2004) and wound healing 
(Brakenhielm E, 2001).  
Murias et al. found that the catechol group formed by hydroxyl groups at the 3’- and 4’- 
positions of phenyl ring B increases the cytotoxic potential of stilbenes (Murias M, 2005). 
 
III.1.2.6. In vivo anticancer activity 
 
In contrast to a large number of studies demonstrating the antiproliferative effects of 
resveratrol on several tumor cell lines in vitro, very little is known about the antitumor 
activity of resveratrol in vivo. A few studies in which the antitumor effect of resveratrol on 
tumor growth in vivo was investigated, employed solid tumors only (Goldberg DM, 1995a; 
Langcake P, 1976). In our case that is good because only solid tumors display the EPR 
effect, i.e. passive targeting with nanoparticulate systems. For blood cancers, the evidence 
is equivocal, even if massive doses of resveratrol are used (Athar M, 2007).  
Resveratrol suppressed solid hepatoma growth and metastasis in rats, which harboured 
s.c. implanted hepatoma cells (Miura D, 2003). 
Gao et al. demonstrated that despite strong antiproliferative and apoptotic effects of 
resveratrol on 32Dp210 leukemia cells in vitro, resveratrol has only a weak if any 
antileukemic activity in vivo when  administered orally at a dose of 8 mg/kg once a day, 5 d 
per week (Gao X, 2002).  
Kimura et al. found that resveratrol, at doses of 2.5 and 10 mg/kg i.p., significantly reduced 
the tumor volume (42%), tumor weight (44%) and metastasis to the lung (56%) in mice 
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bearing highly metastatic Lewis lung carcinoma (LLC) tumors, but not at a dose of 0.6 
mg/kg (Kimura Y, 2001).  
In addition it reduced the number of tumor cell colonies that metastasized to the lung 
compared with the LLC-bearing mice and it inhibited tumor-induced neovascularization  
(Kimura Y, 2001).  
Resveratrol partially inhibited the tumor growth and metastasis of Lewis lung carcinoma 
and T241 fibrosarcoma in mice (Kimura Y, 2001; Brakenhielm E, 2001).  
Resveratrol prevented or delayed the development of esophageal (Li ZG, 2002) and 
mammary malignancies (Banerjee S, 2002; Bhat KPL, 2001) and intestinal adenomas in 
the ApcMin mouse model (Schneider Y, 2001), although the latter effect was subsequently 
shown to be very weak (Sale S, 2005; Ziegler CC, 2004).  
Resveratrol possesses antiangiogenic properties (Cao Y, 2005; Tseng SH, 2004); it 
inhibits vascularization in the corneal micropocket assay in mice at a dose of only 48 µg/kg 
when administered daily (Brakenhielm E, 2001).  
Resveratrol (25 mg/kg, for 3 weeks) decreased angiogenesis and increased apoptotic 
index in Erα- Erβ+ MDA-MB-231 tumors in resveratrol-treated nude mice compared with 
controls (Garvin S, 2006). 
So far, no results of human clinical trials for cancer have been reported (Athar M, 2007). 
 
III.1.4.  Toxicity 
 
The maximum tolerated dose of resveratrol has not been thoroughly determined, but 300 
mg/kg showed no detrimental effects in rats (Crowell JA, 2004) and doses up to 100 mg/kg 
p.o. have been used routinely in studies on rodents (Baur JA, 2006). 
No patients experienced any toxicities while enrolled on the clinical trial, orally administred. 
Specifically, there were no reported changes in bowel habits (diarrhea or constipation), no 
abdominal bloating, no nausea or vomiting, and no gastrointestinal bleeding (Nguyen AV, 
2009). 
 
III.2.  Materials and methods 
 
III.2.1.  Chemicals  
 
Acetonitrile and methanol were HPLC grade and were purchased from Biosolve Ltd. 
(Valkenswaard, The Netherlands); ethanol absolute was provided by Merck (Darmstadt, 
Germany). Acetic acid was a product of Amersham (Roosendaal, The Netherlands). 
Phosphate buffered saline was purchased from B-Braun, Melsungen, Germany. All buffers 
and reversed osmosis water were filtered through 0.2 mm filters (Schleicher & Schuell 
MicroScience GmbH, Dassel, Germany) prior to use. NaCl was purchased from Sigma-
Aldrich, Buchs SG, Switzerland. Resveratrol (purity by HPLC >98%) was provided by 
Chengdu Biopurify Phytochemicals Ltd. DPPC was purchased from Natterman Phospholipids, 
Gmb. Cholesterol was analytical grade and was purchased from Aldrich (Milan, Italy). Lipoid 
PE 18:0/18:0 PEG 2000 was purchased by Lipoid, art.no. 882. Triton X-100 was purchased 
from Sigma-Aldrich, Buchs SG, Switzerland. Bovine serum albumin and Albumin bovine 
cross-linked 4% beaded agarose (bead diameter: 45-165 microns) were purchased from 
Sigma-Aldrich, Buchs SG, Switzerland. FluoSpheres Size Kit #2, carboxylate-modified 
microspheres of 0.02–0.1–0.2–0.5–1.0–2.0 µm, yellow-green fluorescent (505/515), was 
purchased from Molecular Probes, Invitrogen, Breda, The Netherlands. LabelIT Fluorescein 
Nucleic Acid Labeling Kits were purchased from Mirus Bio, Madison, WI, USA.  
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III.2.2.  Production  of liposomes 
 
Samples of liposomes were prepared with a phospholipid concentration of ca. 100 µmol 
PL/mL and with a varying amount of resveratrol.  
Multilamellar vesicles were prepared according to the film hydratation method (Bangham 
AD, 1965). 5-10 ml of ethanol absolute were added in order to dissolve the lipids by 
heating at 50 ºC in a waterbath. The organic phase was evaporated using a rotavapor till a 
dry lipid film develops; the lipid film further was dried by flushing with nitrogen for 10 
minutes. 5 ml of PBS were added to the lipid film and rotate the flask for 5-10 minutes at 
50 ºC in the waterbath of the rotavapor without the vacuum. If the lipid film sticks to the 
glass wall, glass beads were used. Then the dimensions were reduced by extrusion 
technique. The liposomes were extruded twice through 2 polycarbonate filters with pore 
size 600 nm, putting the filters on top of each other, than twice through 2 polycarbonate 
filters with pore size 600 nm and 200 nm and, at last they were extruded 8 times through 2 
filters with pore size 100 nm. 
 
III.2.2.1. Production of fluorescent liposomes 
 
Fluorescent liposomes were prepared with 3 different fluorescent labels: 
• DiD 
• NBD-PE 
• calcein 
 
III.2.2.1.a. Production of liposomes with the fluorescent label DiD 
 
Fluorescent liposomes had a total lipid concentration of 16.436 mM.  
The liposomes contained 0.1% mol of the fluorescence label DiD. DiD’s bleuish stock 
solution has a concentration of 200 µg/mL in EtOH and it could be saved in freezer. 
 
III.2.2.1.b. Production of liposomes with the fluorescent label NBD-PE 
 
Fluorescent liposomes had a total lipid concentration of 16.436 mM.  
The liposomes contained 1% mol of the fluorescence label NBD-PE (N-(7-nitrobenz-2-oxa-
1,3-diazol-4-yl)-1,2-dihexadecanoyl-snglycero-3-phosphoethanolamine, triethylammonium 
salt). NBD-PE’s yellowish stock solution has a concentration of 1 mg/mL in CHCl3 and it 
could be saved in freezer.  
 
III.2.2.1.c. Preparation of calcein solution 
 
A solution of calcein at the concentration of 100 mg/mL in RO-water (161 mM) was 
prepared. One pellet of NaOH was added in order to dissolve the calcein and the pH of the  
solution of calcein was adjust with a 4 M NaOH solution to pH 7.5. The osmolality of the 
calcein solution was checked and it was diluted with RO-water until it was iso-osmotic 
(between 280-300 mOsmol/kg) using the Osmomat 030.  
 
III.2.2.1.d. Production of liposomes with calcein 
 
Liposomes with calcein had a total lipid concentration of 16.436 mM.  
Multilamellar vesicles were prepared according to the film hydratation method (Bangham 
AD, 1965), as described above. 5 ml of calcein solution were added to the lipid film and 
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rotate the flask for 5-10 minutes at 50 ºC in the waterbath of the rotavapor without the 
vacuum. Then the dimensions were reduced by extrusion technique. The liposomes were 
extruded twice through 2 polycarbonate filters with pore size 600 nm, putting the filters on 
top of each other, than twice through 2 polycarbonate filters with pore size 600 nm and 
200 nm and, at last they were extruded 8 times through 2 filters with pore size 100 nm. 
 
III.2.3.  Characterization of liposomes 
 
III.2.3.1. Dynamic Light Scattering (DLS) 
 
Dynamic Light Scattering is an ALV CGS-3 system (Malvern Instruments, Malvern, UK) 
equipped with a JDS Uniphase 22 mW He–Ne laser operating at 632.8 nm, an optical 
fiber-based detector, a digital LV/LSE-5003 correlator and a temperature controller 
(Julabowater bath) set at 25 °C. Time correlation functions were analyzed to obtain the 
hydrodynamic diameter of the particles (Zh) and the particle size distribution (polydispersity 
index, PDI) using the ALV-60X0 software V.3.X provided by Malvern. Autocorrelation 
functions were analyzed by the cumulants method (fitting a single exponential to the 
correlation function to obtain the mean size (Zave) and polydispersity index (PDI)) and 
CONTIN (to fit a multiple exponential to the correlation function to obtain particle size 
distributions). The diffusion coefficients calculated from the measured autocorrelation 
functions were related to the hydrodynamic radius of the particles via the Stokes–Einstein 
equation 
     Zh = (kBTq2)/(3piηΓ) 
 
where Zh is the hydrodynamic radius of the particles,  
 kB is the Boltzmann constant,  
 T is the absolute temperature,  
 η is the solvent viscosity,  
 Γ is the decay rate,  
 q is the scattering vector  
     q = [4pinsin(Ф/2)]/λ 
 
in which  n is the refractive index of the solution,  
  Ф is the scattering angle,  
  λ is the wavelength of the incident laser light.  
Scattering was measured in an optical quality 4 mL borosilicate cell at a 90° angle.  
 
III.2.3.2. Disruption of liposomes by Triton X-100 
 
After the purification of the surface of the liposomes, they were disrupted by 0.025% non 
ionic Triton X-100 in order to calculate the encapsulation efficacy. In order to prepare a 
0.025% Triton X-100 solution, 25 mg  of Triton X-100 were dissolved in 100 mL bidistilled 
water and heated until 70°C. 500µL of 0.025% Triton X-100 were added to liposomal 
dispersions and they were heated for 20 minutes at 70°C in a water bath. Allow the 
samples to cool at room temperature. 
The same was done also with a know amount of resveratrol in order to calibrate the 
disruption method: resveratrol (100 µg/mL in EtOH) was added to a dispersion of empty 
liposomes. Empty liposomes have the same concentrations of the constituents of 
resveratrol-loaded liposomes. After 5 minutes of vortex, 0.025% Triton-100 was added to 
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this mixture. The concentration of resveratrol of the liposomes was determined by 
HPLC/PDA analysis. 
 
III.2.3.3. Encapsulation efficacy (EE%) 
 
Free resveratrol was removed by means of  dialysis. The liposomes were transferred into 
a Slide-A-Lyzer cassette (cut off= 3000 kDa). This dialysis cassette was stirred in 1 liter 
PBS at 4-8 ºC for 24 hours; the PBS were refreshed four times within these 24 hours 
(equilibrium is obtained after ca. 4 hours) in order to remove all free resveratrol.  
During dialysis, samples of the liposomes (50 µL each one) and samples of the medium (1 
mL), were taken before refreshing the PBS in order to optimize the conditions of dialysis. 
These samples were collected and diluted with eluent. The concentration of resveratrol 
was determined by HPLC analysis, in order to check that all the free resveratrol is 
removed. The addition of the amount of resveratrol found in the liposomes with the amount 
found in the medium has to be ~100% for each sample. 
In the case of the production of liposomes with calcein, the dialysis cassette was stirred in 
1 liter PBS at 4-8 ºC for 48 hours; the PBS were refreshed eight times within these 48 
hours in order to remove not only all free resveratrol but also free calcein. 
 
III.2.3.4. HPLC/PDA analysis 
 
An HPLC/PDA Waters System (Waters Associates Inc., Milford, MA) with a differential 
refractometer model 410 was used for analising the content of resevratrol inside the 
vesicles. Peak areas were determined with Empower Software Version 2 build 1154 
(Waters Associates Inc). Resveratrol is determined by HPLC/PDA on column X-Terra RP-
18 (5 µm, 4.6 x 25 mm, Waters), using an isocratic method and a gradient method already 
present in literature (Caddeo C, 2008; Juan ME, 2009) but modified. Resveratrol was 
detected at 306 and 288 nm (absorption of cis-resveratrol). 
  
III.2.3.5. Recovery  
 
A known amount of resveratrol (100 µg/mL in EtOH) was added to a dispersion of empty 
liposomes in order to check the percentage of recovery. This mixture was stirred for 5 
minutes with vortex after both of the additions.  
 
µL of empty 
liposomes 
µL of RSV 
(100 µg/mL) µL of eluent 
dilution of conc. 
of RSV (times) 
conc. of RSV 
(µg/mL) 
100 - 9900 - - 
100 50 9850 200 0.5 
100 100 9800 100 1 
100 150 9750 66.7 1.5 
 
III.2.4.  Stability 
 
III.2.4.1. Stability test of free resveratrol in solution 
 
Two concentrations of resveratrol (1-10 mg/mL in eluent) were prepared in glass vials. 
These vials were kept under sunlight, in absence of light (covered with an alluminium 
sheet) and under UV lamp (60%, 5982 mW/cm2, 717840 mJ/cm2) in order to test the 
stability of resveratrol in solution in different conditions. These solutions were divided in six 
parts: 3 conditions, each one in duplo. 
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A sample of the solutions kept under sunlight and kept in absence of light was taken after 
3, 7 hours and 1, 2, 3 and 4 days. These solutions were kept under UV lamp 1, 2, 4, 6, 8 
and 16 minutes. 
Every samples were collected and the samples with an initial concentration of resveratrol 
in solution of 1 mg/mL were diluted 100-times and the samples with an initial concentration 
of resveratrol in solution of 10 mg/mL were diluted 1000-times. They were transferred into 
some vials and were kept in freezer until HPLC/PDA analysis.  
 
III.2.4.2. Stability test of resveratrol-loaded LC liposomes at different temperatures 
 
Resveratrol-loaded long circulating liposomes with different initial concentrations of 
resveratrol were been prepared and they were kept at different temperatures in order to 
understand their stability in time and the future right way of stocking. 
Resveratrol-loaded long circulating liposomes were been prepared as described before 
with different initial concentrations of resveratrol: 0.1, 0.2, 0.3, 0.5, 1 and 1.5 mg/mL. 
Each liposomal dispersion was divided in 4 parts and was kept at diffent temperature 
values: 
• room temperature (RT, about +20°C) covered by light with an alluminum sheet 
• room temperature (RT, about +20°C) under the sunlight  
• fridge (+4°C)  
• oven at the body temperature (+37°C). 
Samples were diluted 100-times with eluent in order to analyze them by HPLC/PDA and to 
quantified the chemical degradation of resveratrol in time. 
Samples were diluted with PBS in order to analyze them by DLS for monitoring size and 
PD in time. The samples were taken after 0, 1, 3, 7, 24 hours and every week. 
 
III.2.4.3. Photostability 
 
A solution of resveratrol 1 mg/mL in eluent, a solution of resveratrol 10 mg/mL in eluent    
and resveratrol-loaded long circulating liposomes with the same initial concentration of 
resveratrol 1 mg/mL were irradiated in a dark cabinet (60%, 5982 mW/cm2, 717840 
mJ/cm2). The distance from the light source to the test sample was 6.5 cm. At different 
times: after 10 sec., 30 sec, 1 minutes, 2, 4, 6, 8 and 16 minutes 3 samples (10 µL) of 
each solution were collected. 
Samples were diluted 100-times with eluent in order to analyze them by HPLC/PDA and to 
quantified the chemical degradation of resveratrol in time. 
Samples were diluted with PBS in order to analyze them by DLS for monitoring size and 
PDI in time. 
 
III.2.5.  Stability in presence of blood protein 
 
The stability of the liposomal formulations in presence of blood protein (albumin at 
physiological concentration) was evaluated: size change in time by FACS analysis 
(Vorauer-Uhl K, 2000) and by fluorimeter analysis, leakage and extraction of drug from the 
formulation by incubation with albumine coated beads and than HPLC/PDA analysis. 
 
III.2.5.1. Fluorescent Activated Cell Sorting (FACS) 
 
Flow cytometry was performed using a FACSCalibur (Becton and Dickinson, Mountain 
View, CA, USA) benchtop flow cytometer equipped with an air-cooled Argon-ion laser at 
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488 nm and various flow speed controls or a FACSCanto II or FACSAria Cell Sorter 
(Becton and Dickinson, Mountain View, CA, USA) equipped with three air-cooled lasers at 
488, 633 and 405 nm. Side scatter outcome was set to logarithmic and detected at a 
scattering angle of 90° with a threshold set on FL-1 (set to logarithmic amplification) to 
exclude side scatter values from non-fluorescent particulate matter. Flow rates and/or 
dilutions were chosen such that less than 2000 events/s were recorded to prevent 
coincidence. For each measurement a total number of 10000 events were recorded. 
FACS parameters: 
 
sample flow rate 0.5 µL/s 
sample volume 5-20 µL 
mixing volume 50 µL 
mixing speed 100 µL/s 
number of mixes 2 
wash volume 400 µL 
 
III.2.5.1.a. FACS data processing 
 
FACSCalibur data were processed with Summit® software (Dako-Cytomation, Fort Collins, 
CO, USA) and FACSCanto II and FACSAria data with FACSDiva software (Becton and 
Dickinson, Mountain View, CA, USA) or FCS Express (http://www.denovosoftware.com). 
For calibration, histograms of SSC values were plotted and the geometric means of each 
peak corresponding to a bead size were derived. Bead sizes (y) and geometric means of 
SSC values (x) were then plotted in Graphpad Prism and fitted with non linear regression 
using      y=a+bxc 
as described previously (Vorauer-Uhl K, 2000). 
For size analysis of samples, raw data were converted to ASCI using the program MFI and 
FCSExtract for data obtained with the FACSCalibur data and FACSAria, respectively. Data 
were converted from 10-bit (1024 channels) to log4-scale using 
      y=10(x/256) 
Data from channel 0 were excluded from the analysis. The resulting log4-scale values 
were then converted to sizes by applying y=a+bxc. 
 
III.2.5.1.b. Incubation with albumin and FACS analysis 
 
Empty liposomes and liposomes with initial concentrations of resveratrol of 1 mg/mL were 
incubated with a solution of albumin (40 mg/mL in PBS) at the body temperature in a 
shaking waterbath to mimic the in vivo condition.  
They were labelled with NBD-PE 1% mol (N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-
dihexadecanoyl-snglycero-3-phosphoethanolamine, triethylammonium salt; λex= 463 nm: 
λem= 536 nm), and analysed by FACS experiment. 
200 µL of fluorescent liposomes were exposed to 2.2 mL of albumin solution (40 mg/mL). 
This volume of albumin was choosen because for in vivo mouse studies, the total blood 
volume of a mouse of approx. 25 grams is 2 mL, which equals approx 1.1 ml of serum 
(55% of 2 mL) and the maximum injection volume of 100 µL is used. 
Fluorescent liposomes were sampled (150 µL) at 20, 40, 60, 90 and 120 minutes.  
RSV-loaded liposomes and RSV-loaded liposomes after incubation with albumin were 
diluted 4 x 10 3-times in PBS and 4 x 102-times in PBS, respectively. They were 
subsequently analyzed by FACS for particle size. The experiment and the measurements 
were repeated in triplo. 
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III.2.5.1.c. Calibration curve by labeled beads 
 
The size distribution of the liposomes was determined by correlating the side scattered 
signals of the vesicles and the side scattered signals of the calibration beads. Diameters of 
the fluorescent beads were confirmed by Dynamic Light Scattering  (100, 210 and 500 nm 
bead). DLS was calibrated with 200 nm polystyrene latex standard beads (Duke Scientific, 
Leusden, The Netherlands). 
The standard beads were analized by FACS and a calibration curve based on 
measurements of the labelled beads was calculated. 
III.2.5.2. Fluorimeter analysis 
 
The FLUOstar OPTIMA is a fully automated microplate based multi-detection reader for 
measuring the fluorescence Intensity. By integrating a high intensity xenon flash lamp and 
liquid light guide technology, the FLUOstar OPTIMA can cover the wavelength range from 
240 to 740 nm. The FLUOstar OPTIMA can read all plate formats from 6- up to 384-well 
plates. The versatile optical system allows instant switching from top to bottom reading. 
Further, the instrument has a build-in incubator (from +8°C to +45°C) and is equipped with 
one reagent injector.  
 
III.2.5.2.a. Incubation with albumin and fluorimeter analysis 
 
Empty liposomes and liposomes with initial concentrations of resveratrol of 1 mg/mL were 
incubated with a solution of albumin (40 mg/mL in PBS, physiological concentration) at the 
body temperature in a shaking waterbath to mimic the in vivo condition.  
Liposomes were labelled with calcein, a small hydrophilic fluorofore (λex= 485 nm: λem= 
512 nm), and analysed by the Fluorometer. 
200 µL of fluorescent liposomes were exposed to 2.2 mL of albumin solution (40 mg/mL). 
This volume of albumin was choosen because for in vivo mouse studies, the total blood 
volume of a mouse of approx. 25 grams is 2 mL, which equals approx 1.1 ml of serum 
(55% of 2 mL) and the maximum injection volume of 100 µL is used. 
Fluorescent liposomes were sampled (150 µL) at 20, 40, 60, 90 and 120 minutes. The 
samples were put directly in a well-plate and analyzed by fluorimeter. The experiment and 
the measurements were repeated in triplo.  
The fluorescence of PBS, albumin, RSV-loaded liposomes and empty liposomes was 
measured as controls.  
 
III.2.5.2.b. Calibration curve by disrupted liposomes 
 
In order to quantified the amount of fluorescence, a calibration curve was prepared using 
increasing amount of disrupted liposomes. 2.2 mL of albumin (40 mg/mL) was added to 
200 µL of liposomes: albumin was added in order to measure some potencial interferences 
in the fluorescence because of its presence. 200 µL of Triton X-100 (10% aqueous 
solution) was added to this mixture in order to disrup the vesicles. These solutions were 
heated at 70°C for 20 minutes and than they were allowed to cool at room temperature. 
Different volumes of disrupted liposomes were diluted with PBS in order to obtain a 
calibration curves. 
III.2.5.3. Incubation with albumin coated beads 
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Liposomes with the initial concentrations of resveratrol of 1 mg/mL (%EE=42%, RSV final 
concentration 0.42 mg/mL) were incubated with a solution of albumin coated beads/PBS 
50% v/v at the body temperature in a shaking waterbath to mimic the in vivo condition. The 
molar ratio between RSV and albumin were 1:1, 1:1.5 and 1:2. As controls, the same 
liposomes were incubated also with PBS only and resveratrol at the concentration of 0.42 
mg/mL in EtOH was incubated with a solution of albumin coated beads/PBS 50% v/v. 
Each experiment was repeated in duplo. 
 
Molar ratio 
RSV:albumin 
50% (v/v) 
Albumin gel in 
PBS 
(µmol) 
µL of 
RSV-
loaded 
liposomes 
µL of a 50% 
(v/v) Albumin 
gel in PBS or 
PBS 
(reference) 
1:1 0.184 100 2125 
1:1.5 0.276 100 3188 
1:2 0.368 100 4252 
 
Some samples (250 µL per time point) were collected after 20, 40 minutes, after 1, 2, 4, 6, 
24, 48 hours and 6 days. Each sample was centrifuge at 10.000 g for 6 minutes. 
The supernatant was collected and diluted 100-times with eluent. 
The concentration of resveratrol was determined by HPLC/PDA analysis. 
 
III.2.6.  In vivo activity: tumor growth 
 
III.2.6.1. Cell lines 
 
The Human Head and Neck Squamous Cell Carcinoma cell line, UM-SCC-14C, developed 
by Dr. T.E. Carey (Carey TE, 1990), Ann Arbor, MI, was kindly provided by Dr. G.A.M.S. 
van Dongen, Department of Otolaryngology/Head and Neck Surgery, VU University 
Medical Center, Amsterdam, The Netherlands. 
 
III.2.6.2. Solutions for cell colture 
 
Completed DMEM medium: Plain DMEM (Dulbecco's modification of Eagle's medium, with 
3.7 g/l sodium bicarbonate, 4.5 g/l l-glucose, and L-glutamine (Cat. No: E15-810; PAA), 
completed with 5.7 ml antibiotics/antimycotics and 28 ml Foetal Bovine Serum (FBS) (final 
concentration 5%) stored as aliquots located in the freezer in the cell culture.  
PBS: Phosphate buffered saline, containing 10 mM phosphate buffer (pH 7.2) and 145 mM 
NaCl. Trypsin/EDTA solution. 
 
III.2.6.3. Materials for cell colture 
 
Culture flasks with vented cap (depending on the number of cells: 182 or 75 cm2, Greiner-
Bio-one, cat. no. 661175/658175). 5, 10 and 25 ml pipettes (Greiner-Bio-one, cat. no. 
606180, 607180, 760180). Biohazard safety cabinet (HB 2472, Holten B.V.) equipped with 
burner and aspiration device. CO2-incubator 37°C (Heraeus). Ethanol 70% in sprayer. 
 
III.2.6.4. Preparation of cell culture 
 
The Biohazard was switched 30 minutes beforehand and the working surface was cleaned 
with 70% ethanol. PBS and completed DMEM medium were warmed in water bath to 37°C 
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for 15 minutes. The medium were aspirated from the cells by suction and they were 
washed with PBS (about 15 ml, 10 ml or 3 ml to 175 cm2, 75 cm2 or 25 cm2 flasks, 
respectively) and than PBS was aspirated from the cells by suction. 
Trypsin/EDTA solution was added (about 6 ml, 3 ml or 1 ml to 175 cm2, 75 cm2 or 25 cm2 
flasks, respectively). The cells were incubated with trypsin for no longer than 15 minutes. 
Completed DMEM medium was added (about 3-4 times the trypsin/EDTA solution’s 
volume added before). Trypsin is inactivated by serum present in the medium. Gently cells 
were suspended again in the medium to obtain a homogeneous cell suspension without 
the presence of air bubbles. Cells were bringed in one or more (175 cm2, 75 or 25 cm2) 
culture flasks. In general 1:3 to 1:5 part of the last passage is transferred to a new flask. 
Complete medium was bringed in culture flask and add a certain volume of cell 
suspension, to an end volume of 35 ml, 15 ml or 5 ml, according to the flask (175 cm2, 75 
or 25 cm2, respectively). For maintaining this cell line 1:5 is satisfactory; if soon large 
numbers of cells are needed, less diluted passages (1:3) can be used. Place the culture 
flasks in the CO2-incubator at 37°C and 5% CO2. This procedure was repeated after a 
confluent monolayer has formed (twice a week). 
 
III.2.6.5. Mice 
 
Developed through crosses and back-crosses between BALB/cABom-nu and 
BALB/cAnNCrj-nu at Charles River Laboratories Japan (CRLJ). This mouse is inbred, and 
genetic monitoring results confirm it to be a BALB/c nude. The homozygous animals lack a 
thymus, so they are unable to produce T-cells and therefore they are immunodefficient. 
The coat colour is albino and they are hairless. 
 
III.2.6.6. In vivo experiment: tumor growth 
 
Balb/c nude female mice were housed in groups of 4–8 animals and had free access to 
water and food. All animal studies were performed in compliance with guidelines set by 
national regulations and were approved by the local animal experiments ethical committee. 
The head and neck squamous-cell carcinoma line 14C was introduced in the flank of the 
mice by inoculation (subcutaneous injection above the right hind leg) with 1 x 106 14C-
tumor cells. Palpable subcutaneous tumors had developed over a period of 2-3 weeks. 
The tumor was measured with a digital caliper in order to calculate the tumor volume. 
When the tumor measured 4x4 mm, that means 30 mm3, mice were treated with 
resveratrol-loaded long circulating liposomes intravenously (200 µL, via the tail vein of the 
mice) of the maximum concentration. During the whole experiment the tumor size was 
measured twice weekly. Tumor size was measured and volume calculated according to 
the formula 0,5 * a * b2 where a = the largest superficial diameter and b = the smallest. 
When the tumors reached the humane endpoint (1000 mm3) the mice were sacrificed one 
by one. After sacrificing, blood, tumor and organs were taken. 
 
III.2.7.  In vivo activity: biodistribution profile 
 
III.2.7.1. Recovery of trans-resveratrol from plasma 
 
Plasma was obtained by centrifugation at 1500 g for 15 minutes. 10 µL of a solution of 
resveratrol at the concentration of 40 µg/mL in eluent (0.4 µg of RSV) were added to 200 
µL of blank plasma. In the literature two factors were described as useful to precipitate the 
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blood proteins: the cold temperature and the increasing of acidity (Derakhshanded K, 
2005; Mathies JC, 1980). So, 500 µL of CH3CN kept in freezer (-20°C) and 100 µL of 
ChCl3, kept in freezer as well, were added to plasma. Also, 170 mg of finely powdered 
mixture of Na.bisulfate.monohydrate/NaCl in ratio 1/4 were added to plasma. As control, 
500 µL of CH3CN kept at room temperature and 100 µL of ChCl3 at room temperature as 
well were added to plasma. Plasma samples were vortexed for 30 seconds and they were 
centrifuged until they were dried at 40°C for 1 hour under a nitrogen flow. After adding 125 
µL of mobile phase, the samples were analysed by HPLC/PDA. 
 
III.2.7.2. Recovery of trans-resveratrol from tissues 
 
1 g  of  tissue  was  finely  minced  with  scissors,  and  placed  in  a homogenizer vessel. 
Methanol 80% (4 mL) v/v acidified with acetic acid 2.5% v/v and 10  µL  ascorbic  acid  
(15%, w/v) as  antioxidant were added. The samples were homogenized by Ultra-Turrax 
until they were homogeneous. The homogenizer was cleaned twice with 1 mL of acidified 
methanol, which were added to the 4 mL making a final volume of 8 mL. The recoveries of 
RSV from tissue were determined by spiking each tissues with the final concentration of 10 
µmol/g tissues. 625 µL of RSV 1 mM were added to 500 µL of each homogenized 
samples.        
 
III.2.7.2.a. Brain, testis, liver and lungs 
The samples were vortexed for 5 minutes and were centrifuged at 3000 g for 30 min at 
4°C. The residue was extracted two  more  times with 500 µL of  acidified  methanol by 
vigorous  agitation in  the  vortex  for  5  min,  followed  by centrifugation at 3000 g for 30 
min at 4°C. The samples were diluted 50-times with eluent (isocratic method) or with EtOH 
20% v/v (gradient method) and analysed by HPLC/PDA. 
  
III.2.7.2.b. Kidney 
 
500 µL  of acidified methanol were added to 500 µL  of homogenized tissue. Each sample 
was incubated at 60°C (oil bath with electrical thermometer connected to the hot plate) 
with constant stirring for 30 minutes. The samples were centrifuged at 3000 g for 30 min at 
4°C. The residue was extracted one more  time with 500 µL of  acidified  methanol by 
vigorous  agitation in  the  vortex  for  5  min,  followed  by centrifugation at 3000 g for 30 
min at 4°C. The samples were diluted 50-times with eluent (isoratic method) or with EtOH 
20% v/v (gradient method) and analysed by HPLC/PDA. 
 
III.3.  Results and discussion 
 
Starting from literature data, we found an article where resveratrol-loaded liposomes were 
prepared and characterized; they had final resveratrol concentration of 1.3 mM, 70% of 
resveratrol incorporation efficacy and they were stable over 60-days period at 4°C 
(Caddeo C, 2008). 
One of the aims of this project is to prepare resveratrol-loaded long-circulating liposomes 
with an improved final absolute concentration of resveratrol, with an optimized 
encapsulation efficacy and with the same stability in time at least. 
Resveratrol-loaded long-circulating liposomes were prepared in order to find the best 
balance between final absolute concentration and encapsulation efficacy of resveratrol 
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inside the vesicles and also in order to understand the trend of the incapsulation efficacy 
towards initial concentrations of resveratrol.  
 
III.3.1.  Production and characterization of liposomes 
 
In the table all the constituents of the bilayer of PEGylated liposomes were indicated with 
their molar ratio: 
 
molecule MW molar ratio mg/mL 
DPPC 734 2 75.00 
18:0/18:0 PEG 2000 2805.497 0.1 22.33 
cholesterol 386.66 1 20.92 
Twelve different initial resveratrol concentrations were used (0.1, 0.2, 0.3, 0.5, 1, 1.5, 2, 
2.5, 2.75, 3, 3.5 and 4 mg/mL) to prepare liposomes in order to find the optimal balance 
between final absolute concentration and EE of resveratrol.  
 
initial RSV 
conc.  
(mg/mL) 
molar 
ratio      
(%) 
mean 
diameter 
(nm) 
polydispersity 
index (PDI) 
final RSV 
conc. 
(mg/mL) 
EE (%) 
- - 125.0±3.97 0.07±0.04 - - 
0.1 0.3 126.6 0.08 0.08±0.01 77.45±4.73 
0.2 0.5 139.9 0.11 0.12±0.01 60.12±1.94 
0.3 0.8 133.4 0.02 0.17±0.01 55.95±2.66 
0.5 1.3 130.9±1.25 0.08±0.01 0.33±0.13 65.63±27.21 
1 2.7 134.0±10.39 0.09±0.03 0.51±0.09 50.58±8.85 
1.5 4.0 145.9±16.24 0.08±0.03 0.39±0.11 25.89±7.37 
2 5.3 117.9 0.09 0.27 13.31 
2.5 6.7 135.8 0.05 0.54±0.02 21.74±0.67 
2.75 7.3 124.0 0.09 0.47±0.01 17.05±0.02 
3 8.0 119.6 0.10 0.25±0.02 8.38±0.59 
3.5 9.3 142.8 0.14 0.56±0.04 16.00±1.24 
4 10.7 482.1 0.12 1.25 31.27 
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Fig 38. Resveratrol’s initial concentration plotted versus encapsulation efficacy. 
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Fig 39. Molar ratio plotted versus encapsulation efficacy. 
 
 
III.3.1.1. Optimization of method of disruption 
 
The reproducibility of resveratrol quantification with or without the addition of Triton X-100 
will be examined.  
After the purification of the liposomes by dialisys, they were disrupted with Triton X-100 in 
different molar ratio or they were diluted 100-fold with eluent (MeOH/CH3CN/water 
acidified with CH3COOH 75:22.5:2.4:0.1 v/v). 
 
initial RSV 
conc.  
(mg/mL) 
molar 
ratio      
(%) 
mean 
diameter 
(nm) 
polydispersity 
index (PDI) 
final RSV 
conc. 
(mg/mL) 
EE (%) 
2 5.3 117.9 0.09 0.27 13.31 
2.5 6.7 135.8 0.05 0.54±0.02 21.74±0.67 
3.5 9.3 142.8 0.14 0.56±0.04 16.00±1.24 
4 10.7 482.1 0.12 1.25 31.27 
 
 
samples Triton X-100: RSV-LCL 
initial 
RSV 
conc. 
(mg/mL) 
final RSV 
conc. 
(mg/mL) 
final RSV 
conc.   (mM) EE (%) 
Caddeo, 
2008* 
not explained 
the ratio ~ 0.4 0.30 1.3 ~70 
RSV-LCL - 2 0.27 1.17 13.31 
RSV-LCL 1:1 2 0.26 1.12 12.83 
RSV-LCL - 2.5 0.54±0.02 2.38±0.0736 21.74±0.67 
RSV-LCL 3:1 2.5 0.57±0.03 2.48±0.1554 22.68±1.42 
RSV-LCL 2:1 2.5 0.64 2.81 25.62 
RSV-LCL 1:1 2.5 0.56 2.44 22.26 
RSV-LCL - 3.5 0.56±0.04 2.45±0.1906 16.00±1.24 
RSV-LCL 3:1 3.5 0.60±0.02 2.61±0.1119 17.05±0.73 
RSV-LCL 2:1 3.5 0.57 2.49 16.24 
RSV-LCL 1:1 3.5 0.56 2.48 16.15 
RSV-LCL - 4 1.25 5.48 31.27 
RSV-LCL 1:1 4 0.40 1.74 9.95 
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*Caddeo C., Teskac K., Sinico C., Kristl J., 2008. Effect of resveratrol incorporated in liposomes on 
proliferation and UV-B protection of cells. International Journal of Pharmaceutics 36, 183-19. 
 
In every case the addition of Triton X-100 did not change the detected value. The eluent is 
probably already sufficient to disrupt the vesicles because of its high percentage of organic 
solvents. The only exeption is for the liposomes with a resveratrol’s initial concentration of 
4 mg/mL; in this case different results were obtained upon addition of Triton X-100. 
However, the dispersion was not homogeneous and so this discrepancy is presumably 
due to sample heterogeneity. This formulation probably had a too much high initial content 
of resveratrol, in fact it was not possible to extrude this dispersion through 2 filters with 
pore size of 600 and 200 nm. The size of liposomes was consequently not within the 
dimensional range wanted (70-130 nm).  
 
III.3.1.2. HPLC/PDA analysis 
 
III.3.1.2.a. Isocratic method 
 
Resveratrol is determined by HPLC/PDA on column X-Terra RP-18 (5 µm, 4.6 x 25 mm, 
Waters), using a mixture of  MeOH/CH3CN/water and CH3COOH (75:22.5:2.4:0.1 v/v) as 
mobile phase.  
Flow rate:  0.8 mL/min. 
Detection:  λ=306 nm 
   λ=288 nm (absorption of cis-resveratrol) 
Injection volume: 50 µL 
Run time:  8 minutes 
Temperature: 25°C 
A calibration curve was prepared at concentration of 1 mg/mL in eluent as external 
standard (solution a) in order to quantify the amount of resveratrol present in the samples 
in a higher range of concentration. The range of this calibration curve is: 2 - 25 µg/mL. My 
dilution scheme was: 
 
 
µg/mL µM 
µL 
of solution a 
µL 
of eluent 
 
dilution 
2 8.762 2 998 a/500 
4 17.525 4 996 a/250 
6 26.287 6 994 a/166.6 
8 35.049 8 992 a/125 
10 43.812 10 990 a/100 
14 61.336 14 986 a/71.4 
16 70.098 16 984 a/62.5 
20 87.623 20 980 a/50 
25 109.529 25 975 a/40 
 
Prepare a calibration curve using resveratrol at concentration of 1 µg/mL in eluent as 
external standard (solution a/1000) in order to quantify the amount of resveratrol present in 
the samples in a lower range of concentration.  
The range of this calibration curve is: 1 µg/mL - 5 ng/mL. My dilution scheme was: 
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III.3.1.2.b. Gradient method 
 
Resveratrol is determined by HPLC/PDA on column X-Terra RP-18 (5 µm, 4.6 x 25 mm, 
Waters), using a gradient eluent constituted by two mobile phases: 
Phase A:   CH3CN/Phase B 80/20 v/v 
Phase B:  CH3COOH 3% v/v. 
The following multi-step linear gradient was applied: 
 
time (minutes) Phase B (%) Phase A (%) 
0 78 22 
2 78 22 
6 70 30 
14 50 50 
18 40 60 
25 0 100 
28 78 22 
 
Flow rate:  1.5 mL/min. 
Detection:  λ=306 nm 
   λ=288 nm (absorption of cis-resveratrol) 
Injection volume: 100 µL 
Run time:  8 minutes 
Temperature: 40°C 
A calibration curve was prepared at concentration of 1 mg/mL in eluent as external 
standard (solution a) in order to quantify the amount of resveratrol present in the samples 
in a higher range of concentration. The range of this calibration curve is: 2 - 25 µg/mL. My 
dilution scheme was: 
 
µg/mL µL of RSV 1 mM µL of EtOH 20% v/v dilution (times) 
22.825 100 900 10 
18.26 80 920 12.5 
14.836 65 935 15.38 
11.4125 50 950 20 
7.9887 35 965 28.57 
4.565 20 980 50 
2.2825 10 990 100 
0.913 4 996 250 
0.4565 4 1996 500 
0.22825 1000 c 1000 c/2 
0.114125 1000 d 1000 d/2 
0.02282 1000 e 4000 e/5 
sol. µg/mL nM µL of 
solution 
µL 
of 
eluent 
dilution 
b 1 4381.161 a 10 9990 a/1000 
c 0.5 2190.580 b 1000 1000 b/2 
d 0.25 1095.290 c 1000 1000 c/2 
e 0.125 547.645 d 1000 1000 d/2 
f 0.025 109.529 e 1000 4000 e/5 
g 0.0125 54.764 f 1000 1000 f/2 
h 0.005 21.906 f 1000 4000 f/5 
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0.0114125 1000 f 1000 f/2 
0.004565 1000 f 4000 f/5 
 
III.3.1.2.c. Recovery 
 
Known amounts of resveratrol will be added to empty liposomes in order to check the 
percentage of recovery. 
 
expected conc. of RSV 
(µg/mL) 
found conc. of 
RSV (µg/mL) Recovery (%) 
- - - 
0.5 0.40±0.01 79.20±1.70 
1 0.92±0.01 92.45±1.34 
1.5 1.27±0.03 84.90±2.30 
 
The percentage of recovery with the isocratic method  was satisfied, so it seems not 
necessary to perform the gradient elution. It could be used in perspective, during the in 
vivo experiments. In fact, resveratrol and its metabolites will be monitored in plasma and 
tissues samples where could be useful an gradient eluent whit a more efficient capacity of 
separation. For the in vitro characterization fo the optimized formulation, the isocratic 
method will be used because it is easier and faster than the other. 
 
III.3.1.3. Optimization of method of dialysis 
 
In order to be sure that all the free resveratrol was removed from the liposomal dispersion, 
the conditions of dialysis was optimized.  
So, during the dialysis, samples of liposomes and of the medium will be collected before 
every refreshment. The concentration of resveratrol was determined by HPLC/PDA 
analysis. The addition of the amount of resveratrol found in the liposomes with the amount 
found in the medium has to be ~100% for each sample. 
 
initial RSV 
conc.  
(mg/mL) 
molar 
ratio      
(%) 
mean 
diameter 
(nm) 
polydispersity 
index (PDI) 
final RSV 
conc. 
(mg/mL) 
EE (%) 
2.75 7.3 124.0 0.09 0.47±0.01 17.05±0.02 
3 8.0 119.6 0.10 0.25±0.02 8.38±0.59 
 
 
Liposomes 
with an 
initial conc. 
of RSV 
(mg/mL) 
hours 
of 
dialysis 
final 
absolute 
conc. of RSV 
in liposomes 
(mg/mL) 
EE (%) 
final 
absolute 
conc. of 
RSV in the 
medium 
(µg/mL) 
Conc. of 
RSV 
liposome 
+ medium 
(%) 
2.75 0 0.41±0.01 15.07±0.06 0.000±0.00 14.9 
2.75 3 0.53±0.01 19.19±0.08 0.018±0.01 19.3 
2.75 6 0.47±0.02 17.04±0.93 0.010±0.01 17.1 
2.75 9 0.47±0.01 17.05±0.02 0.007±0.01 17.1 
2.75 24 0.34±0.03 12.23±1.17 0.007±0.01 12.4 
2.75 27 0.36±0.01 13.22±0.01 0.011±0.01 13.1 
2.75 30 0.35±0.01 12.93±0.02 0.009±0.01 12.7 
2.75 33 0.34±0.01 12.36±0.01 0.010±0.01 12.4 
3 0 0.16±0.01 5.32±0.36 0.000±0.00 5.3 
3 3 0.29±0.02 9.62±0.60 0.009±0.00 9.7 
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3 6 0.29±0.01 9.58±0.07 0.007±0.01 9.7 
3 9 0.25±0.02 8.38±0.59 0.008±0.01 8.3 
3 24 0.15±0.01 5.16±0.10 0.006±0.01 5.0 
3 27 0.18±0.01 5.98±0.37 0.010±0.01 6.0 
3 30 0.19±0.02 6.32±0.57 0.012±0.01 6.3 
3 33 0.16±0.01 5.35±0.01 0.011±0.01 5.3 
 
The final absolute concentrations of resveratrol and EE are lower than expected values. 
Each sample of liposomes was diluted with eluent 20-times instead of 100-times; probably 
this dilution is not sufficient to disrupt the vesicles completely. So the samples may be not 
homogeneous and it may explain also the increase of the concentration of  resveratrol 
after 3 hours of dialysis in both of the samples. 
The concentrations of resveratrol in the medium are quite constant in time; it means that 
presumably an equilibrium is reached after 3 hours, before every refreshment.  
The final concentrations of resveratrol in the medium are lower than the value of its 
solubility in water that it is < 0.001 mol/mL = 228.25 µg/mL (Caddeo C, 2008); probably 
mostly of the uncapsulated resveratrol remain at the bottom of the beaker because of its 
poor solubility in the medium.  
Dialysis could be stopped after 24 hours and every refreshment could be done every 3 
hours. 
 
III.3.2.  Stability 
 
III.3.2.1. Stability test of free resveratrol in solution 
To our best knowledge no more studies have been  reported on the  stability of resveratrol 
in solution. Some authors had tested solid trans-resveratrol under accelerated stability 
conditions (75% humidity and 40°C) for up to 4 years and under ambient conditions (60% 
humidity and 25°C) in a mixture with other grape polyphenols for 2 years. No significant 
decay in the content of resveratrol was observed in the presence of atmospheric oxygen 
and humidity. In addition, no by-products attributable to the stilbenoid degradation, neither 
trans–cis isomerism or oxidation, were detected (Bertelli AA, 1998; Prokop J, 2006). 
Resveratrol content also stayed stable in the skins of grapes and pomace taken after 
fermentation and stored for a long period (Roy H, 2005).  
100 µM aqueous solution of trans-resveratrol was stable for at least 8 h at room 
temperature when protected from light (resveratrol oxidation products were absent) 
(Camonta L, 2009). Trans-resveratrol in hydro-alcoholic solutions has been reported to be 
stable in the dark (Trela BC, 1996; Camonta L, 2009). The stability of trans-resveratrol is 
valuated in absence and in presence of sunlight.  
The solubility of resveratrol is very low (< 0.001 mol/mL = 228.25 µg/mL by Caddeo C, 
2008) so the stability in solution was evaluated for 2 concentrations (1 and 10 mg/mL) in 
the mobile phase of the HPLC/PDA isoctratic method. 
Initial concentration of resveratrol in eluent was 1 mg/mL: 
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Condition Time 
Found 
concentration 
of resveratrol 
in eluent 
(mg/mL) 
Amount of 
resveratrol 
(%) 
darkness 0 0.94±0.02 100 
darkness 3 hours 0.93±0.02 99.1 
darkness 7 hours 0.92±0.01 97.4 
darkness 1 day 0.90±0.03 95.4 
darkness 2 days 0.90±0.02 96.2 
darkness 3 days 0.91±0.03 97.1 
darkness 4 days 0.90±0.01 95.5 
darkness 9 days 0.89±0.18 94.2 
darkness 10 days 0.83±0.01 88.3 
darkness 14 days 0.85±0.10 90.9 
darkness 16 days 0.87±0.01 92.7 
darkness 18 days 0.74±0.09 78.6 
darkness 21 days 0.73±0.00 77.8 
sunlight 0 0.83±0.01 100 
sunlight 3 hours 0.82±0.04 98.7 
sunlight 7 hours 0.78±0.01 93.9 
sunlight 1 day 0.77±0.01 91.9 
sunlight 2 days 0.70±0.03 84.0 
sunlight 3 days 0.60±0.05 72.5 
sunlight 4 days 0.59±0.01 70.8 
sunlight 9 days 0.60±0.07 72.5 
sunlight 10 days 0.61±0.03 73.2 
sunlight 14 days 0.55±0.03 66.0 
sunlight 16 days 0.56±0.06 66.8 
sunlight 18 days 0.50±0.02 59.8 
sunlight 21 days 0.44±0.01 53.2 
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Fig 40. Stability in time of RSV 1 mg/mL in eluent. 
 
Initial concentration of resveratrol in eluent was 10 mg/mL: 
 
 90 
Condition Time 
Found 
concentration 
of resveratrol 
in eluent 
(mg/mL) 
Amount of 
resveratrol 
(%) 
darkness 0 8.88±0.04 100.0 
darkness 3 hours 8.45±0.08 95.2 
darkness 7 hours 8.53±0.01 96.0 
darkness 1 day 8.62±0.09 97.8 
darkness 2 days 8.33±0.01 93.8 
darkness 3 days 8.04±0.02 90.5 
darkness 4 days 7.88±0.01 88.7 
darkness 9 days 7.98±1.74 89.9 
darkness 10 days 7.72±0.14 87.0 
darkness 14 days 8.04±0.55 90.5 
darkness 16 days 7.58±0.73 85.4 
darkness 18 days 7.24±1.07 81.6 
darkness 21 days 6.37±0.01 71.7 
sunlight 0 9.76±0.04 100 
sunlight 3 hours 9.33±0.01 95.6 
sunlight 7 hours 9.63±0.02 98.7 
sunlight 1 day 8.36±0.03 85.6 
sunlight 2 days 7.36±0.09 75.4 
sunlight 3 days 7.90±0.13 80.9 
sunlight 4 days 7.65±0.01 78.3 
sunlight 9 days 6.99±0.30 71.6 
sunlight 10 days 7.24±0.18 74.1 
sunlight 14 days 5.98±0.43 61.2 
sunlight 16 days 6.22±0.20 63.7 
sunlight 18 days 5.66±0.49 58.0 
sunlight 21 days 4.79±0.01 49.1 
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Fig 41. Stability in time of RSV 10 mg/mL in eluent. 
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The amount of resveratrol with the initial concentration of 1 mg/mL after 16 days is 
reduced to 92.7% keeping it covered by light and to 66.8% keeping it under the sunlight. 
The amount of resveratrol with the initial concentration of 10 mg/mL after 14 days is 
reduced to 90.5% keeping it covered by light and to 61.2% keeping it under the sunlight. 
So, resveratrol is stable in solution within 21 days if it is kept in the dark. 
 
III.3.2.2. Stability test of resveratrol-loaded LC liposomes at different temperatures 
 
The stability of long circulating liposomes formulation was evaluated keeping a batch of 
empty liposomes in fridge (+4°C) in order to evaluated their stability during time. 
 
empty liposomes 
diameter 
(nm) PDI 
Time 
(days) 
127.8 0.10 0 
138.5 0.04 1 
135.4 0.06 9 
135.5 0.09 13 
133.9 0.07 15 
132.5 0.09 17 
126.4 0.06 20 
 
The formulation without the drug was stable after 20 days, kept at 4 °C. 
Resveratrol-loaded long circulating liposomes with different initial concentrations of 
resveratrol (0.1, 0.2 and 0.3 mg/mL) have been prepared. They were kept at different 
temperatures in order to understand their stability in time, resveratrol’s chemical 
degradation profile and their future right way of stocking. At scheduled intervals, aliquots of 
liposomes were removed and the size in time and the content of resveratrol were 
determined.                           
Conditions: 
• RTD room temperature (+20°C) and darkness 
• RTS room temperature (+20°C) under the sunlight  
• fridge (+4°C)  
• oven (+37°C) at the body temperature. 
Physical stability of vesicular dispersion was investigated by DLS measurements. 
Chemical stability that means resveratrol stability was checked by HPLC/PDA analysis. 
 
Results derived from DLS analysis: 
 
RSV 0.1 mg/mL 
loaded liposomes 
RSV 0.2 mg/mL 
loaded liposomes 
RSV 0.3 mg/mL 
loaded liposomes 
diameter 
(nm) PDI 
diameter 
(nm) PDI 
diameter 
(nm) PDI 
Time condition 
126.6 0.08 139.9 0.11 133.4 0.02 0 RTD 
132.8 0.08 137.8 0.07 134.9 0.01 1 hour RTD 
131.6 0.02 136.1 0.10 132.6 0.06 3 hours RTD 
128.8 0.07 134.9 0.08 133.1 0.07 7 hours RTD 
131.2 0.05 138.1 0.07 133.1 0.08 1 day RTD 
129.9 0.04 135.1 0.09 133.5 0.07 4 days RTD 
126.6 0.08 139.9 0.11 133.4 0.02 0 RTS 
132.5 0.08 138.6 0.07 136.8 0.04 1 hour RTS 
133.6 0.06 138.2 0.10 139.4 0.08 3 hours RTS 
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134.0 0.07 136.5 0.05 133.3 0.08 7 hours RTS 
130.5 0.03 139.3 0.07 136.3 0.06 1 day RTS 
124.1 0.11 126.7 0.10 129.0 0.09 4 days RTS 
126.6 0.08 139.9 0.11 133.4 0.02 0 +4°C 
133.0 0.08 134.0 0.08 135.9 0.04 1 hour +4°C 
131.3 0.03 137.8 0.06 135.8 0.09 3 hours +4°C 
130.0 0.07 136.1 0.09 132.1 0.04 7 hours +4°C 
134.1 0.02 138.1 0.07 132.7 0.09 1 day +4°C 
125.7 0.08 132.3 0.10 129.8 0.12 4 days +4°C 
126.6 0.08 139.9 0.11 133.4 0.02 0 +37°C 
136.9 0.23 137.1 0.07 135.0 0.07 1 hour +37°C 
128.2 0.07 136.5 0.09 135.2 0.09 3 hours +37°C 
131.1 0.07 136.5 0.04 134.5 0.09 7 hours +37°C 
131.5 0.08 138.6 0.06 136.9 0.08 1 day +37°C 
128.9 0.08 137.9 0.31 133.8 0.10 4 days +37°C 
 
There were no differences between the formulations kept at different temperature 
regarding the physical stability in time. 
 
 Results derived from HPLC/PDA analysis: 
 
initial conc. of RSV 
(mg/mL) 
final absolute conc. 
of RSV (mg/mL) 
final absolute conc. 
of RSV (mM) EE (%) 
0.1 0.077±0.01 0.339±0.02 77.45±4.73 
0.2 0.120±0.01 0.527±0.02 60.12±1.94 
0.3 0.168±0.01 0.735±0.03 55.95±2.66 
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RSV 0.1 mg/mL 
loaded liposomes 
RSV 0.2 mg/mL 
loaded liposomes 
RSV 0.3 mg/mL 
loaded liposomes 
EE 
(%) 
RSV % 
of initial 
content 
EE 
(%) 
RSV % of 
initial 
content 
EE 
(%) 
RSV % of 
initial 
content 
Time Condi tion 
77.45±4.73 100 60.12±1.94 100 55.95±2.66 100 0 RTD 
77.45±4.73 100 60.12±1.94 100 45.00±1.51 80.43±2.70 10 min. RTD 
73.85±1.34 95.35±1.74 58.25±1.13 96.88±1.88 45.52±1.06 81.36±1.89 30 min. RTD 
75.75±1.63 97.80±2.10 59.45±1.41 98.87±2.35 47.20±0.47 84.36±1.83 1 hour RTD 
74.45±3.04 96.12±3.92 58.85±2.05 97.88±3.41 54.33±1.36 97.11±2.44 3 hours RTD 
77.95±5.87 100.64±7.57 57.37±4.56 95.42±7.59 54.11±0.26 96.72±0.47 7 hours RTD 
61.40 79.28 42.45 70.60 48.30 86.33 1 day RTD 
48.30 62.36 31.75 52.81 42.63 62.36 4 days RTD 
77.45±4.73 100 60.12±1.94 100 55.95±2.66 100 0 RTS 
71.50±0.57 92.31±0.73 54.17±1.24 90.10±2.06 50.75±2.33 90.70±4.16 10 min. RTS 
68.30±0.61 88.18±0.91 51.15±1.62 85.08±2.69 47.53±2.88 84.96±5.15 30 min. RTS 
63.60±3.82 82.11±4.93 49.27±2.79 81.95±4.65 42.45±1.24 75.87±2.22 1 hour RTS 
48.10±0.42 62.10±0.54 36.70±1.98 61.04±3.29 32.11±0.26 57.40±0.47 3 hours RTS 
47.30±0.85 61.07±1.10 32.02±0.11 53.26±0.18 29.60±1.41 52.90±2.52 7 hours RTS 
41.00 52.94 27.50 45.74 27.70 49.51 1 day RTS 
35.30 45.58 23.85 39.67 21.23 37.94 4 days RTS 
77.45±4.73 100 60.12±1.94 100 55.95±2.66 100 0 +4°C 
73.85±1.20 95.35±1.56 57.00±0.71 94.80±1.17 55.95±2.69 100 10 min. +4°C 
79.75±5.59 102.97±7.21 56.30±2.76 93.63±4.59 47.51±0.54 84.92±0.97 30 min. +4°C 
74.50±2.69 96.19±3.46 54.65±1.91 90.89±3.17 46.13±0.61 82.45±1.10 1 hour +4°C 
75.35±1.06 97.29±1.37 55.87±2.16 92.93±3.59 52.43±4.15 93.71±7.42 3 hours +4°C 
79.25±2.90 102.34±3.76 57.15±1.06 95.05±1.77 48.56±0.80 86.80±1.43 7 hours +4°C 
76.50 98.77 50.55 84.07 50.33 89.95 1 day +4°C 
69.80 90.12 50.05 83.24 48.10 85.97 4 days +4°C 
77.45±4.73 100 60.12±1.94 100 55.95±2.66 100 0 +37°C 
78.15±2.62 100.90±3.39 54.35±4.10 90.39±6.82 51.93±6.55 92.82±11.72 10 min. +37°C 
76.35±2.05 98.58±2.64 53.32±3.08 88.69±5.12 49.68±2.67 88.95±4.55 30 min. +37°C 
77.90±1.41 100.58±1.82 54.75±4.18 91.06±6.94 50.93±4.19 92.58±5.31 1 hour +37°C 
77.20±2.69 99.67±3.47 54.10±2.47 89.98±4.11 51.43±2.45 91.93±4.38 3 hours +37°C 
75.00±1.27 96.83±1.65 53.85±1.98 89.56±3.29 47.83±2.47 85.48±5.31 7 hours +37°C 
75.5 96.19 51.75 86.07 49.43 88.35 1 day +37°C 
71.3 92.06 41.35 68.77 38.87 69.47 4 days +37°C 
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Fig 42. Stability in time of RSV-loaded LCL at different temperatures with initial concentrations of 
resveratrol of 0.1 mg/mL (up), 0.2 mg/mL (middle) and 0.3 mg/mL (down). 
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All the three tested formulations were stable at 4°C between the 83-90%. The best way of 
stocking is keeping them in the fridge before using.  
The solar radiations were responsible of the chemical degradation of resveratrol, indeed in 
the formulation with initial concentration of the drug of 0.1, 0.2 and 0.3 mg/mL, the 
percentage of non-degradated resveratrol was 45.58, 39.67 and 37.94% respectively. 
At the wavelength of 208 nm cis-resveratrol was not found, so other oxidated or 
degradated products were occurred during the storage of the formulations at room 
temperature under sunlight.  
At the body temperature, in the formulation with initial concentration of the drug of 0.1, 0.2 
and 0.3 mg/mL, the percentage of non-degradated resveratrol was 92.06, 68.77 and 
69.47% respectively. The formulation with the lower initial concentration of resveratrol 
(0.1<0.2<0.3 mg/mL) but with the higher encapsulation efficacy than the others 
(77.45<60.12<55.95 %EE) was more stable. That means that the free resveratrol was 
more suscettible to degradation; if it was inside the vesicles it was more protected. 
 
initial RSV 
conc.  
(mg/mL) 
molar 
ratio      
(%) 
mean 
diameter 
(nm) 
polydispersity 
index (PDI) 
final RSV 
conc. 
(mg/mL) 
EE (%) 
0.1 0.3 126.6 0.08 0.08±0.01 77.45±4.73 
0.2 0.5 139.9 0.11 0.12±0.01 60.12±1.94 
0.3 0.8 133.4 0.02 0.17±0.01 55.95±2.66 
 
Initial concentration of resveratrol was increased in order to find the best balance between 
final absolute concentration and encapsulation efficacy of resveratrol inside the vesicles. 
So, resveratrol-loaded long circulating liposomes with different initial concentrations of 
resveratrol (0.5, 1 and 1.5 mg/mL) were been prepared and they were kept in the fridge 
(+4°C) and at scheduled intervals, aliquots of liposomes were removed and the size in 
time and the chemical degradation profile was determined.                           
Conditions:  
• fridge (+4°C)  
• oven (+37°C) at the body temperature. 
Physical stability of vesicular dispersion was investigated by DLS measurements. 
Chemical stability that means resveratrol stability was checked by HPLC/PDA analysis. 
 
Results derived from DLS analysis: 
 
RSV 0.5 mg/mL 
loaded liposomes 
RSV 1 mg/mL 
loaded liposomes 
RSV 1.5 mg/mL 
loaded liposomes 
diameter 
(nm) PDI 
diameter 
(nm) PDI 
diameter 
(nm) PDI 
Time condition 
130.5 0.08 132.0 0.11 150.0 0.09 0 
134.0 0.04 132.1 0.07 150.6 0.07 10 min. 
131.9 0.09 132.2 0.06 150.7 0.06 30 min. 
132.3 0.11 133.2 0.07 152.1 0.08 1 h 
136.9 0.11 129.7 0.11 146.2 0.07 3 h 
135.8 0.07 132.8 0.08 152.7 0.05 7 h 
136.2 0.11 133.3 0.10 150.3 0.10 1 day 
134.0 0.10 135.3 0.09 151.7 0.06 4 days 
134.2 0.11 133.6 0.03 153.6 0.12 6 days 
142.3 0.11 140.6 0.12 160.4 0.11 16 days 
137.1 0.07 132.1 0.10 152.6 0.10 21 days 
153.9 0.03 164.9 0.11 159.5 0.07 28 days 
+4°C 
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130.5 0.08 132.0 0.11 150.0 0.09 0 
133.0 0.07 130.8 0.09 152.5 0.04 10 min. 
130.7 0.10 131.4 0.09 150.9 0.11 30 min. 
133.0 0.07 132.8 0.10 148.2 0.09 1 h 
133.9 0.07 134.0 0.10 148.2 0.09 3 h 
133.6 0.09 131.1 0.07 152.1 0.06 7 h 
138.0 0.10 132.5 0.07 152.8 0.10 1 day 
137.5 0.07 136.1 0.05 151.2 0.07 4 days 
133.2 0.09 135.9 0.05 155.6 0.07 6 days 
142.9 0.08 144.6 0.09 173.2 0.07 16 days 
141.3 0.04 139.9 0.11 162.5 0.08 21 days 
165.2 0.06 161.4 0.08 179.8 0.05 28 days 
+37°C 
 
All the three tested formulations were stable within 21 days. After 28 days, the index of 
polidispersity were acceptable but the mean diameters were >140 nm. 
The liposomes with the initial concentration of resveratrol of 1.5 mg/mL had a size >145 
nm at time zero and a lower encapsulation efficacy (21.34%, table below), so the other two 
formulations seem more suitable. 
 
Results derived from HPLC/PDA analysis: 
 
Initial RSV 
concentration 
(mg/mL) 
Final RSV 
concentration 
(mg/mL) 
Final RSV 
concentration 
(mM) 
EE (%) 
0.5 0.34±0.04 1.48±0.19 67.79±8.50 
1 0.49±0.07 2.15±0.30 49.02±6.60 
1.5 0.32±0.01 1.40±0.05 21.34±0.72 
  
 
RSV 0.5 mg/mL 
loaded liposomes 
RSV 1 mg/mL 
loaded liposomes 
RSV 1.5 mg/mL 
loaded liposomes 
EE 
(%) 
RSV %  
of initial 
content 
EE 
(%) 
RSV % of 
initial 
content 
EE 
(%) 
RSV % of 
initial 
content 
Time Condi tion 
67.79±8.50 100 49.02±6.60 100 21.34±0.72 100 0 
60.03±2.45 88.55±3.61 45.78±0.33 93.39±0.68 20.66±0.24 96.81±1.12 10 min. 
59.15±0.35 87.25±0.52 46.14±2.42 94.12±4.95 20.00±0.13 93.72±0.59 30 min. 
60.60±0.20 89.39±0.29 44.65±0.20 91.08±0.42 22.67±1.81 106.23±8.48 1 h 
68.99±6.89 101.74±10.12 45.36±0.60 92.53±1.22 21.23±1.07 99.48±5.04 3 h 
60.81±0.18 89.7±0.27 40.55±1.17 82.72±2.38 20.19±1.98 94.61±9.28 7 h 
66.70±0.45 98.39±0.66 39.25±0.57 80.06±1.16 20.72±0.49 97.09±2.32 1 day 
62.28±1.47 91.87±2.17 42.09±1.77 85.85±3.61 21.61±1.10 101.26±5.17 4 days 
69.48±8.23 102.49±12.14 42.43±1.00 86.54±2.04 21.77±1.10 102.04±5.13 6 days 
67.07±7.17 98.93±10.58 44.43±0.64 90.17±0.65 23.24±1.70 108.90±7.95 16 days 
63.02±0.40 92.96±0.59 34.08±3.94 69.52±8.04 20.69±1.81 96.95±8.48 21 days 
67.34±4.89 98.80±6.47 42.60±2.77 86.89±5.65 20.59±1.52 96.51±7.13 28 days 
+4°C 
67.79±8.50 100 49.02±6.60 100 21.34±0.72 100 0 
60.17±0.10 88.76±0.14 45.90±3.21 93.62±6.55 19.34±0.18 90.63±0.86 10 min. 
60.43±0.83 89.14±1.23 47.27±6.28 96.42±12.81 19.54±0.98 91.58±4.60 30 min. 
63.87±1.03 94.21±1.52 47.38±3.00 96.65±6.13 19.92±0.61 93.34±2.85 1 h 
66.39±3.27 97.93±4.81 48.60±2.86 99.13±5.82 20.62±0.95 96.63±4.44 3 h 
68.35±8.39 101.12±11.95 47.14±2.89 96.16±5.90 19.83±1.87 92.92±8.75 7 h 
62.46±1.92 92.13±2.83 45.52±1.77 92.85±3.61 20.61±0.03 96.57±0.13 1 day 
61.79±1.74 91.14±2.57 46.06±2.11 93.96±4.31 21.37±0.71 100.14±3.31 4 days 
60.23±1.09 88.84±1.60 46.63±2.04 95.11±4.15 21.92±0.71 102.74±3.35 6 days 
63.49±2.11 93.65±3.10 53.31±0.90 109.39±0.93 20.09±1.88 94.14±8.81 16 days 
+37°C 
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57.83±0.49 85.30±1.02 44.75±0.21 91.28±0.44 16.75±0.99 78.49±4.64 21 days 
64.65±8.36 95.37±12.33 46.66±1.27 95.18±2.58 20.06±3.05 94.02±14.28 28 days 
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Fig 43. Stability in time of RSV-loaded LCL at different temperatures with initial concentrations of 
resveratrol of 0.5, 1 and 1.5 mg/mL. 
 
At 4°C, in the formulation with initial concentration of the drug of 0.5, 1 and 1.5 mg/mL, the 
percentage of non-degradated resveratrol was 98.80, 86.89 and 96.51% respectively.  
At the body temperature, in the formulation with initial concentration of the drug of 0.5, 1 
and 1.5 mg/mL, the percentage of non-degradated resveratrol was 95.37, 95.18 and 
94.02% respectively.  
DLS measurements had pointed out that vesicles with the initial concentration of 1.5 
mg/mL was not within the optimized dimensional range.  
Within 21 days, both at 4°C and 37°C, neither resveratrol chemical degradation, nor 
vesicles size alteration occurred for the formulations with the initial resveratrol 
concentration of 0.5 and 1 mg/mL. 
As you can see in the table below, the encapsulation efficacy of the formulation with an 
initial concentration of resveratrol of 0.5 mg/mL is higher than the formulation with an initial 
concentration of resveratrol of 1 mg/mL (65.63>50.58 %EE) but the final concentration of 
resveratrol encapsulated into the vesicles is higher in the formulation with an initial 
concentration of resveratrol of 1 mg/mL (0.51>0.33 mg/mL). 
 
initial RSV 
conc.  
(mg/mL) 
molar 
ratio      
(%) 
mean 
diameter 
(nm) 
polydispersity 
index (PDI) 
final RSV 
conc. 
(mg/mL) 
EE (%) 
0.5 1.3 130.9±1.25 0.08±0.01 0.33±0.13 65.63±27.21 
1 2.7 134.0±10.39 0.09±0.03 0.51±0.09 50.58±8.85 
1.5 4.0 145.9±16.24 0.08±0.03 0.39±0.11 25.89±7.37 
 
So, the formulation with an initial concentration of resveratrol of 1 mg/mL was investigated 
more with the perspective of in vivo experiments. 
 
III.3.2.3. Photostability 
Unfortunately, the use of trans-resveratrol in pharmaceutical and cosmetic field is 
problematic owing to its fast degradation mainly linked to the isomerization from the active 
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trans form to the inactive cis one (Wang Y, 2002). Cis- isomer is unactive, it has biological 
activity unuseful for our aims.  
However, in the solid state, whether exposed to light or not, cis-resveratrol readily reverts 
to the  trans- isomer, the thermodynamically more stable isomer (Trela BC, 1996). Thus, 
as a solid, resveratrol and its analogs exist predominantly as trans- isomers (Prokop J, 
2006). trans-Resveratrolosides could convert to their  cis- isomeric form and/or be oxidized 
in solution (Prokop J, 2006). Trans-resveratrol in hydro-alcoholic solutions has been 
reported to be stable in the dark, with a tendency to isomerise to cis-resveratrol when 
exposed to UV light or sunlight (Trela BC, 1996; Camonta L, 2009). 100 µM aqueous 
solution of trans-resveratrol was stable for at least 8 h at room temperature when 
protected from light (resveratrol oxidation products were absent) (Camonta L, 2009). Trela 
and Waterhouse (Trela BC, 1996) reported that the isomerisation yield was highly variable, 
and depended on the UV wavelength (10% vs 90% after 1 h irradiation at 254 and 366 nm, 
respectively). The use of natural UV from sunlight for isomerisation is probably less 
efficient than exposure to an UV lamp and the exact equilibrium mixture may depend on 
the specific spectrum of light reaching the sample (Camonta L, 2009). 
So, the stability of resveratrol in solution will be tested under UV lamp at different 
concentrations: 1 and 10 mg/mL in eluent. 
Initial concentration of resveratrol in eluent was 1 mg/mL: 
time 
found concentration of 
RSV in eluent 
(mg/mL) 
amount of 
RSV  
(%) 
0 0.94±0.02 100 
10 seconds 0.69±0.02 73.4 
30 seconds 0.55±0.01 58.4 
1 minute 0.40±0.01 42.6 
2 minutes 0.32±0.01 33.8 
4 minutes 0.27±0.01 28.7 
6 minutes 0.23±0.02 24.1 
8 minutes 0.18±0.01 19.0 
16 minutes 0.10±0.01 11.1 
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Fig 44. Photostability of RSV 1 mg/mL in eluent under UV lamp. 
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 Initial concentration of resveratrol in eluent was 10 mg/mL: 
 
time 
found concentration 
of RSV in eluent 
(mg/mL) 
amount of 
RSV  
(%) 
0 9.76±0.04 100 
10 seconds 8.32±0.00 85.3 
30 seconds 6.57±0.48 67.3 
1 minute 5.61±0.02 57.4 
2 minutes 4.25±0.18 43.5 
4 minutes 3.62±0.07 37.1 
6 minutes 3.63±0.05 37.2 
8 minutes 3.51±0.18 36.0 
16 minutes 3.23±0.12 33.1 
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Fig 45. Photostability of RSV 10 mg/mL in eluent under UV lamp. 
 
Under UV lamp (60%, 5982 mW/cm2, 717840 mJ/cm2), the amount of resveratrol with the 
initial concentration of 1 mg/mL after 1 minute is reduced to 42.6%. The amount of 
resveratrol with the initial concentration of 10 mg/mL after 1 minute is reduced to 57.4%. 
A resveratrol-loaded long circulating liposomes with the same initial concentration of 
resveratrol 1 mg/mL of a solution of resveratrol in eluent was prepared to understand if 
vesicles can protect resveratrol from the photosensibilization that can provoke the 
trans/cis-isomeritation. Photostability of resveratrol-loaded long circulating liposomal 
formulations in comparison with resveratrol solution was measured. 
 
Initial RSV 
concentration 
(mg/mL) 
RSV 
concentration 
before dialysis 
(mg/mL) 
RSV 
concentration 
after dialysis 
(mg/mL) 
Final RSV 
concentration 
(mM) 
EE (%) 
1 0.64±0.06 0.49±0.05 2.13±0.20 48.6±4.66 
 
Results derived from DLS analysis: 
 
RSV 1 mg/mL 
loaded liposomes Time 
 100 
diameter 
(nm) PDI 
177.7±0.01 0.11±0.01 0 
174.6±0.02 0.07±0.01 10 sec. 
176.1±0.03 0.05±0.01 30 sec 
173.8±2.76 0.04±0.01 1 min. 
168.1±0.28 0.07±0.01 2 min. 
162.6±0.35 0.09±0.04 4 min. 
162.7±3.96 0.08±0.01 6 min. 
167.3±2.54 0.07±0.04 8 min. 
164.3±1.77 0.06±0.01 16 min. 
 
Results derived from HPLC/PDA analysis: 
 
RSV 1 mg/mL 
Found 
concentration of 
RSV (mg/mL) 
Amount of 
RSV 
(%) 
Time 
in eluent 0.94±0.02 100 0 
in eluent 0.69±0.02 72.6±2.55 10 sec. 
in eluent 0.55±0.01 57.8±0.21 30 sec 
in eluent 0.40±0.01 42.1±0.23 1 min. 
in eluent 0.32±0.01 33.4±1.22 2 min. 
in eluent 0.27±0.01 28.4±1.13 4 min. 
in eluent 0.23±0.02 23.8±1.72 6 min. 
in eluent 0.18±0.01 18.8±0.81 8 min. 
in eluent 0.10±0.01 11.0±0.99 16 min. 
loaded 
liposomes 0.64±0.06 100 0 
loaded liposomes 0.60±0.01 94.3±0.01 10 sec. 
loaded liposomes 0.60±0.01 93.8±0.20 30 sec 
loaded liposomes 0.54±0.06 84.5±10.24 1 min. 
loaded liposomes 0.47±0.02 73.8±2.76 2 min. 
loaded liposomes 0.40±0.05 62.7±8.05 4 min. 
loaded liposomes 0.49±0.23 69.3±5.40 6 min. 
loaded liposomes 0.42±0.09 65.7±4.16 8 min. 
loaded liposomes 0.43±0.15 67.4±4.40 16 min. 
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Fig 46. Photostability of RSV-loaded LCL with initial concentration of 1 mg/mL under UV lamp. 
 
Under UV lamp the amount of resveratrol with the initial concentration of 1 mg/mL after 1 
minute is reduced to 42.1%; if the same content of resveratrol was encapsulated in 
liposomes, it was reduced to 84.5%. It is clear that the vehicle is able to protect resveratrol 
from chemical degradation and photodegradation. Vesicles can protect resveratrol from 
the photosensibilization that can provoke the trans/cis-isomeritation. 
 
III.3.3.  Stability in presence of blood protein 
 
To further advance biomedical application, it is important to characterize the interactions 
between liposomes and blood components, particularly with serum proteins that play an 
important role in the stability and properties of liposomes in blood e.g. in their circulation 
lifetimes (Panagi Z, 1999; Chonn A, 1992). The amount of serum proteins associated on 
the liposomes used was inversely related to their circulation half-lives (Chonn A, 1992). 
The serum proteins associated onto the surface of liposomes systematically administered 
have been suggested to be one of the most important factors to determine their in vivo fate 
(Drummond DC, 1999; Luigi C, 2003). The  amount of blood protein associated with 
liposomes  in  the circulation dramatically affects liposome clearance behaviour in vivo 
(Chonn A, 1992). Specific bounded proteins can have a direct effect on particle 
internalization and biodistribution. Certain proteins allow macrophages of the 
reticuloendothelial system (RES) to more easily recognize nanoparticles (Owens  DE, 
2006). On  the other hand, dysopsonins such as albumin are said to promote prolonged 
circulation times in the blood (Goppert  TM, 2005; Moghimi SM, 1993; Ogawara K, 2004). 
It has been found that proteins partially penetrate (Sweet C, 1969; Law SL, 1986, 1988; 
Juliano, 1971; Sabin J, 2009) and modify the lipid bilayer (Lis LJ, 1967; Hoekstra H, 1979) 
when they are in contact with the membrane surface. This protein penetration into the 
liposomal membrane can change the properties of the bilayer with drastic consequences 
in their use as drug delivery systems (Sabin J, 2009).  
Increase  in  the  rate  of  efflux  of  different  liposomal contents in contact with serum 
albumin has been reported (Sweet C, 1969 1970; Zborowski J, 1977), but the role of 
albumin in phospholipid  transfer, leading to loss of bilayer integrity and release of 
liposomal contents, is controversial.  
 102 
Near-physiological  concentration (30 mg/mL) of albumin dissolved more then 50%  of 
liposomes (Michnik A, 1997).  
The addition of PEG can add protein/opsonization resistance properties by preventing 
interactions between the particle surface and the plasma proteins (Owens  DE, 2006; Jeon 
SI, 1991). Often water-soluble polymers like polyethylene glycol (PEG) are attached to the 
surface of long-circulating liposomes to reduce adhesion of opsonic plasma proteins that 
would otherwise induce recognition and rapid removal from the circulation by 
macrophages in the liver and spleen (Woodle MC, 1992; 1994; Oku N, 1994; Aggarwal P, 
2009, figure 47). Using this approach, PEG-coated long-circulating liposomes can remain 
in the circulation with a half-life as long as 50 hours (Gabizon  A, 1994; Hong  RL, 2001).  
 
 
Fig 47. Biodistribution of nanoparticles with varying coatings and bound proteins. 
Uncoated particles bind proteins and are taken up by the RES into the liver and spleen. PEGylated 
particles bind very fewproteins, avoid uptake by the RES, and are longer circulating in the blood 
(Aggarwal P, 2009). 
 
Application  of liposomes  as drug  carriers  is  associated with  their  stability  in  the  
bloodstream.  
Stability test of resveratrol-loaded and empty long-circulating fluorescent liposomes in 
presence of blood protein like albumin was performed in order to assess the capacity of 
albumin to extract the constituents of the bilayer and modified or disrupt the vesicles (size 
changes) and to assess the capacity of albumin to extract resveratrol from the formulation 
(drug content changes). 
 
III.3.3.1. Fluorescent Activated Cell Sorting (FACS) 
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Measure particle size do not allow reliable measurements in the presence of small 
particulate contaminations present in biological fluids as serum (Hsu CY, 2008). Serum is 
a complex fluid containing (amongst other) serum albumin, lipoproteins, immuno-, γ- and 
macrogobulins, and oleic acid (van Gaal E, 2009). This heterogeneous nature can give 
rise to significant background signals, whereas sizing techniques based on conventional 
light scattering require minimum levels of background noise for generation of accurate 
results. With imaging techniques such as electron microscopy individual particles can be 
studied, however, these techniques are laborious and have poor statistical power. Imaging 
is particularly valuable to obtain information regarding particle morphology, but when 
deriving sizes from images one should be aware of the risk for artefacts (Vorauer-Uhl K, 
2000; van Gaal E, 2009). 
Flow cytometry is a well established technique that integrates light scattering and 
fluorescence measurements to gather information regarding size, shape, morphology of 
cells and presence and intensity of diverse fluorescent signals. Flow cytometry was 
originally developed as a tool to study cells, which have typical sizes of 2–120 µm (with a 
majority being 10–20 µm), and attempts to apply this method to submicron particles are 
scarce. Recently this technique was exploited to study submicron matter, including 
unilamellar synthetic vesicles (Fuller LL, 1996), liposomes (Vorauer-Uhl K, 2000) and viral 
particles (Hercher M, 1979; Steen HB, 2004).  
Each single particle is measured in a continuous flow system, which is in contrast to the 
well-established light scattering systems, where a suspension is measured in a closed 
containment. By FACS, the detection of particles may be performed at an angle of 10° 
forward scatter and at 90° side scatter (Vorauer-Uhl K, 2000). As with cells (Salgado FJ, 
2003; 2005), the diffraction of the laser beam (forward scatter, FSC) is proportional to the 
liposome size while refraction plus reflection of the beam (side scatter, SSC) is 
proportional to the complexity of the liposome.  
For a representative measurement, 10000 particles per sample were analyzed (Vorauer-
Uhl K, 2000). 
 
III.3.3.1.a. Incubation with albumin and FACS analysis 
 
Empty liposomes and liposomes with initial concentrations of resveratrol of 1 mg/mL were 
incubated with a solution of albumin (40 mg/mL in PBS) at the body temperature in a 
shaking waterbath to mimic the in vivo condition.  
They were labelled with NBD-PE 1% mol and analysed by FACS experiment. 
 
constituent mg/mL MW µmol 
DPPC 7.5 734 51.090 
18:0/18:0 PEG 2000 2.233 2750 4.060 
cholesterol 2.092 387 27.030 
DiD 0.0172 1052.1 0.082 
NBD-PE 0.1572 956.24 0.822 
 
 
initial RSV 
conc. (mg/mL) 
diameter 
(nm) 
polydispersity 
index (PDI) 
final RSV 
conc. 
(mg/mL) 
EE (%) 
- 121.4 0.05 - - 
1 124.7 0.05 0.38±0.01 37.9±0.42 
 
III.3.3.1.b. Calibration curve by by labeled beads 
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The size distribution of the liposomes was determined by correlating the side scattered 
signals of the vesicles and the side scattered signals of the calibration beads. The 
standard beads were analized by FACS and a calibration curve based on measurements 
of the labelled beads was calculated. 
 
 
Fig 48. Calibration curve. 
 
 
The correlation between the mean diameter of the latex beads and their side scatter 
signals was determined according to equation 
      y = a + bxc 
where a = 18.39, b = 52.36 and c = 0.4482 (figure 48). 
Based on this equation, the side scatter signals of different samples may be classified in 
several size ranges. The following table showa the classification ranges based on latex 
beads values. 
 
size classes size range (nm) 
P1 4-178 
P2 330-930 
P3 3500-6500 
P10 24000-36000 
P11 90000-115000 
 
RSV-loaded liposomes and RSV-loaded liposomes after incubation with albumin (40 
mg/mL in PBS) were diluted 4 x 10 3-times in PBS and 4 x 102-times in PBS, respectively. 
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Fig 49. RSV-loaded liposomes diluted 4 x 10 3-times in PBS 
 
 
Fig 50. RSV-loaded liposomes after 2 hours of incubation with albumin (40 mg/mL in PBS) diluted 4 x 
102-times in PBS 
 
The dot plots represent the SCC-A (indicative of size) against FITC-A (fluorescence 
intensity of the particles).  
The size of empty and RSV-loaded liposomes are around 100 nm, according with the DLS 
measurements.  
Size is not affected by albumin. The vesicles that remain are stable and intact. 
 
The incubation with albumin was monitored at different time points. 
Liposomes were labelled with NBD-PE 1% mol, and this kind of fluorescent label is 
lipophilic and it forms the bilayer together with the other lipid. So, we expected a 
decreasing of fluorescent events in 10 second if the vesicles were disrupted because of 
the interaction with albumin. 
 
The experiment was repeated in triplo and each plate was measured 3 times. 
Count: 
 
Sample Events measured in 10 seconds 
RSV-loaded LCL 4919.4±1104.2 
RSV-loaded LCL + albumin after 20 minutes 1553.8±267.1 
RSV-loaded LCL + albumin after 40 minutes 1583.6±500.2 
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RSV-loaded LCL + albumin after 1 hour 1856.1±296.7 
RSV-loaded LCL + albumin after 1 hour and 30 
min. 2196.7±298.6 
RSV-loaded LCL + albumin after 2 hours 2592.1±218.4 
empty LCL 6924.2±1866.3 
empty LCL + albumin after 20 minutes 782.7±144.9 
empty LCL + albumin after 40 minutes 859.2±186.8 
empty LCL + albumin after 1 hour 598.7±187.2 
empty LCL + albumin after 1 hour and 30 min. 952.4±242.8 
empty LCL + albumin after 2 hours 752.3±106.6 
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Fig 51. RSV-loaded liposomes after 2 hours of incubation with albumin. 
 
The fluorescent signal decreases after only 20 minutes. It means that some vesicles are 
lost after incubation with albumin.  
A decreasing of fluorescence should be measured also if NBD-PE might form a shell 
around the vesicles, but, in this case, the fluorescent signal should be shifted and it is not. 
It seems that empty vesicles are less stable than RSV-loaded vesicles in presence of 
albumin. Probably the presence of encapsulated resveratrol may stabilize them. 
Concluding, it is necessary an independent method to measure the interaction between 
vesicles and albumin in order to cross the informations. 
 
III.3.3.2. Fluorimeter analysis 
 
Leakage of water-soluble molecules from liposomes can be measured using fluorescent 
markers. For this purpose the fluorophore calcein can be used.  Calcein is a small (620 
g/mol), hydrophilic fluorophore, which shows self-quenching properties at high 
concentrations. When the concentration of calcein is higher than 40 mM, the self-
quenching efficiency is about 90%. A concentration of 75-100 mM ensures an efficient 
self-quenching even when a considerable fraction of the encapsulated calcein has been 
release. Calcein can be encapsulated into the liposomes in a quenched concentration and 
when the liposomal membrane is destabilized, the encapsulated calcein will be released 
and diluted in the surrounding buffer. Upon dilution, the quenching effect is reduced and 
fluorescent signal increases. 
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III.3.3.2.a. Incubation with albumin and fluorimeter analysis 
 
Empty liposomes and liposomes with initial concentrations of resveratrol of 1 mg/mL were 
incubated with a solution of albumin (40 mg/mL in PBS, physiological concentration) at the 
body temperature in a shaking waterbath to mimic the in vivo condition.  
 
constituent mg/mL MW µmol 
DPPC 7.5 734 51.090 
18:0/18:0 PEG 2000 2.233 2750 4.060 
cholesterol 2.092 387 27.030 
 
 
initial RSV 
conc. (mg/mL) 
mean 
diameter by 
DLS (nm) 
polydispersity 
index (PDI) 
- 128.8 0.02 
1 126.9 0.09 
 
Liposomes were labelled with calcein, a small hydrophilic fluorofore (λex= 485 nm: λem= 
512 nm), and analysed by the Fluorometer. 
 
III.3.3.2.b. Calibration curve by disrupted liposomes 
 
In order to quantified the amount of fluorescence, a calibration curve was prepared using 
increasing amount of disrupted liposomes. Different volumes of disrupted liposomes were 
diluted with PBS in order to obtain the following calibration curves (figure 52). 
µL of liposomes 
disrupted by Triton 
X-100 (+ albumin) 
µL of PBS 
% of 
disrupted 
liposomes 
fluorescence 
0 150 0 2994.5 
30 120 20 16922.5 
45 105 30 22195.0 
60 90 40 26675.0 
75 75 50 31167.0 
90 60 60 37734.0 
105 45 70 41810.0 
120 30 80 46814.0 
135 15 90 51834.0 
150 0 100 59562.5 
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Fig 52. Calibration curve. 
 
The incubation with albumin was monitored at different time points.  
Each sample had the same dilution of the calibration curve. 
Liposomes were labelled with calcein, and this kind of fluorescent label is hydrophilic and it 
naturally remains inside the vesicle, in the internal core. So, we expected an increasing of 
fluorescence if the vesicles were disrupted because of the interaction with albumin. 
In the table below, the results obtained for empty liposomes were summarized: 
 
time (min) fluorescence disrupted              
empty liposomes 
% of disrupted               
empty liposomes 
0 50780.7±461.5 129.05±1.29 86.0±0.82 
20 41708.7±7258.9 103.65±20.32 65.0±6.73 
40 48144.3±3595.6 121.67±10.07 81.1±6.06 
60 49101.7±10193.0 124.35±28.54 89.9±18.7 
90 44376.0±2543.7 111.12±7.12 74.1±4.25 
120 51833.7±4631.7 132.00±12.97 88.0±7.86 
 
In the table below, the results obtained for RSV-loaded liposomes were summarized: 
 
time (min) fluorescence disrupted                   RSV-loaded liposomes 
% disrupted                
RSV-loaded liposomes 
0 50521.5±441.9 127.49±1.24 85.0±0.75 
20 42155.3±7576.9 104.90±21.21 79.9±14.36 
40 42755.0±2536.1 106.58±7.10 71.0±4.21 
60 36591.3±5626.4 89.32±15.75 58.7±8.92 
90 43260.3±3573.2 108.00±10.00 72.0±5.95 
120 41618.0±5919.8 103.40±16.57 68.9±9.80 
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Fig 53. Disrupted RSV-loaded liposomes after 2 hours of incubation with albumin. 
 
The amount of fluorescence in time is quite high, ranging from 65 to 88% for empty 
liposomes and from 58 to 85% for RSV-loaded liposomes, respectively. 
It seem that the effect of albumin was instant. As soon as albumine was added to 
liposomal dispersion, calcein can escape. 
 
III.3.3.3. Incubation with albumin coated beads 
 
Resveratrol has poor water solubility (Belguendouz L, 1997; Caddeo C, 2009), so it must 
be bound to proteins to keep it at a high concentration in plasma. The efficiency of a 
therapeutic substance is related to its affinity to bind protein transporters (Khan MA, 2002). 
In the transport of resveratrol, it can bind to serum proteins (Jannin B, 2004) and can 
passively diffuse through the plasma membrane (Lancon A, 2004).  
Resveratrol binds human serum albumin with association constant of K = 2.56 × 105  M-1.  
The resveratrol-protein binding  is mainly  through pigment H-bonding with polypeptide 
C=O, C-N, and NH groups. At low drug concentration, no major protein conformational 
changes occur, whereas at high pigment contents, an increase of protein α-helix and a 
decrease of β-sheet were observed. This is due to an additional stabilization of protein 
conformation induced at high resveratrol concentration (Soukpoé-Kossi CNN, 2006). 
 
Stability test of resveratrol-loaded long-circulating liposomes in presence of blood protein 
like albumin was performed in order to assess the capacity of albumin to extract 
resveratrol from the vesicles. The molar ratio between RSV and albumin were 1:1, 1:1.5 
and 1:2. 
For the molar ratio RSV:albumin 1:1, results derived from HPLC/PDA analysis: 
 
final RSV 
conc. (mg/mL) % 
Time of 
incubation with 
albumin 
sample 
0.42±0.04 100 0 
0.44±0.01 104.8±1.68 20 min. 
0.41±0.10 97.0±23.74 40 min. 
0.42±0.07 99.9±17.68 1 h 
RSV-loaded 
liposomes in 
PBS 
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0.40±0.04 95.0±10.78 2 h 
0.40±0.04 95.9±10.78 4 h 
0.37±0.04 89.3±9.09 6 h 
0.37±0.05 89.3±12.79 24 h 
0.32±0.08 77.0±18.35 48 h 
0.34±0.01 80.4±3.53 6 days 
0.42±0.04 100 0 
0.13±0.02 30.8±5.76 20 min. 
0.10±0.01 23.7±0.93 40 min. 
0.10±0.01 24.9±2.23 1 h 
0.09±0.01 21.7±0.37 2 h 
0.10±0.01 23.2±1.67 4 h 
0.09±0.01 22.1±1.29 6 h 
0.06±0.01 13.5±0.56 24 h 
0.04±0.00 9.4±0.00 48 h 
0.02±0.01 5.8±0.37 6 days 
RSV in albumin 
coated 
beads/PBS 50% 
v/v 
0.42±0.04 100 0 
0.19±0.03 44.6±7.24 20 min. 
0.16±0.01 37.5±3.20 40 min. 
0.17±0.03 42.9±3.95 1 h 
0.16±0.01 39.3±3.37 2 h 
0.13±0.02 32.3±2.77 4 h 
0.13±0.01 30.9±2.69 6 h 
0.09±0.01 22.4±0.68 24 h 
0.08±0.01 17.5±1.39 48 h 
0.04±0.01 9.57±1.68 6 days 
RSV-loaded 
liposomes in 
albumin coated 
beads/PBS 50% 
v/v 
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Fig 54. Stability test of RSV-loaded LCL in presence of albumin. Molar ratio between RSV and 
albumin was 1:1. 
 
For the molar ratio RSV:albumin 1:1.5, results derived from HPLC/PDA analysis: 
 
final RSV 
conc. (mg/mL) % 
Time of 
incubation with sample 
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albumin 
0.42±0.04 100 0 
0.43±0.03 102.5±7.91 20 min. 
0.41±0.03 97.3±6.23 40 min. 
0.41±0.02 96.9±5.72 1 h 
0.40±0.01 94.4±0.16 2 h 
0.43±0.04 101.9±10.44 4 h 
0.40±0.01 96.5±0.50 6 h 
0.39±0.02 93.9±4.21 24 h 
0.41±0.06 98.8±14.8 48 h 
0.29±0.08 70.3±19.9 6 days 
RSV-loaded 
liposomes in 
PBS 
0.42±0.04 100 0 
0.11±0.01 27.4±3.37 20 min. 
0.07±0.01 17.7±1.97 40 min. 
0.08±0.00 20.3±0.00 1 h 
0.08±0.01 18.3±1.12 2 h 
0.09±0.01 21.5±1.68 4 h 
0.08±0.01 18.5±3.08 6 h 
0.06±0.00 14.3±0.00 24 h 
0.05±0.00 11.1±0.00 48 h 
0.03±0.01 8.3±0.00 6 days 
RSV in albumin 
coated 
beads/PBS 50% 
v/v 
0.42±0.04 100 0 
0.12±0.03 28.2±6.23 20 min. 
0.10±0.01 24.3±1.70 40 min. 
0.10±0.01 23.0±2.15 1 h 
0.09±0.01 21.1±0.56 2 h 
0.11±0.01 25.6±2.52 4 h 
0.12±0.01 28.1±2.01 6 h 
0.10±0.01 23.8±0.68 24 h 
0.07±0.01 17.7±0.27 48 h 
0.05±0.01 11.9±3.37 6 days 
RSV-loaded 
liposomes in 
albumin coated 
beads/PBS 50% 
v/v 
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Fig 55. Stability test of RSV-loaded LCL in presence of albumin. Molar ratio between RSV and 
albumin was 1:1.5. 
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For the molar ratio RSV:albumin 1:2, results derived from HPLC/PDA analysis: 
 
final RSV 
conc. (mg/mL) % 
Time of 
incubation with 
albumin 
sample 
0.42±0.04 100 0 
0.50±0.02 119.4±5.22 20 min. 
0.48±0.11 115.6±26.4 40 min. 
0.50±0.05 118.7±12.29 1 h 
0.45±0.06 107.4±14.14 2 h 
0.38±0.03 90.5±8.08 4 h 
0.46±0.05 110.2±13.13 6 h 
0.37±0.09 88.3±21.55 24 h 
0.36±0.06 85.5±13.81 48 h 
0.21±0.06 50.5±13.47 6 days 
RSV-loaded 
liposomes in 
PBS 
0.42±0.04 100 0 
0.08±0.01 20.0±0.75 20 min. 
0.06±0.01 15.5±3.33 40 min. 
0.06±0.02 13.4±4.09 1 h 
0.06±0.01 13.9±0.37 2 h 
0.07±0.01 17.9±2.24 4 h 
0.06±0.01 14.7±0.74 6 h 
0.05±0.01 12.9±1.87 24 h 
0.04±0.01 10.8±3.35 48 h 
0.04±0.01 8.9±1.48 6 days 
RSV in albumin 
coated 
beads/PBS 50% 
v/v 
0.42±0.04 100 0 
0.11±0.01 26.5±1.84 20 min. 
0.09±0.02 21.4±4.14 40 min. 
0.08±0.00 19.5±0.00 1 h 
0.09±0.01 21.8±0.37 2 h 
0.08±0.01 18.7±0.37 4 h 
0.09±0.01 22.4±1.12 6 h 
0.09±0.00 21.6±0.00 24 h 
0.09±0.01 20.5±2.23 48 h 
0.06±0.01 14.2±1.49 6 days 
RSV-loaded 
liposomes in 
albumin coated 
beads/PBS 50% 
v/v 
 
 
 113 
RSV:acb 1:2
0
20
40
60
80
100
120
140
160
0 5 10 15 20 25 30
hours
%
RSV-loaded liposomes in
PBS
RSV in acb/PBS 50% v/v
RSV-loaded liposomes in
acb/PBS 50% v/v
 
Fig 56. Stability test of RSV-loaded LCL in presence of albumin. Molar ratio between RSV and 
albumin was 1:2. 
 
In the experiment with the molar ratio RSV:albumin 1:1, resveratrol in contact with albumin 
coated beads/PBS 50% v/v had a residual percentage of 30.8% after only 20 minutes. Its 
level was manteined around 20% within 6 hours. 
If encapsulated in liposomes, it was reduced to 44.6% after 20 minutes. Its content was 
manteined around 40% within 2 hours and around 30% within 6 hours. 
In the experiment with the molar ratio RSV:albumin 1:1.5, resveratrol in contact with 
albumin coated beads/PBS 50% v/v was reduced to 27.4% after only 20 minutes. Its level 
was manteined around 20% within 6 hours. 
If encapsulated in liposomes, it was reduced to 28.2% after 20 minutes. Its content was 
manteined around 20-25% within 24 hours. 
In the experiment with the molar ratio RSV:albumin 1:2, resveratrol in contact with albumin 
coated beads/PBS 50% v/v had a residual percentage of 20.0% after only 20 minutes. Its 
level was manteined around 10-15% within 48 hours. 
If encapsulated in liposomes, it was reduced to 26.5% after 20 minutes. Its content was 
manteined around 20% within 24 hours. 
The results indicated  appreciable  destructive  effects  of  serum  albumin  on  the  
liposomal  content after only 20 minutes. 
 
III.3.4.  In vivo activity: tumor growth 
 
Liposomes containing polyethylene glycol (PEG) derivatives (Blume G, 1990; Klibanov AL, 
1990; Allen TM, 1991; Maruyama K, 1992; Woodle MC, 1992; Yuda T, 1996) are not 
readily taken up by the macrophages in reticuloendothelial system (RES), and hence 
remain in the blood circulation for a relatively long period of time.  
The addition of polyethylene glycol (PEG) is the most common and preferred method of 
“masking” nanoparticles from immune recognition (Gref R, 2000; Peracchia MT, 1999; 
Owens DE, 2006). It has been shown to decrease interactions of various nanoparticles 
with blood proteins and help avoiding recognition by the RES, in essence prolonging blood 
circulation (Gref R, 1994; 2000; Peracchia MT, 1999; Paciotti GF, 2004; Lemerchand C, 
2006; Kim HR, 2007). 
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Particularly, PEG-modified liposomes have been utilized as a particulate carrier for anti-
tumor therapy due to their long circulation time (Jun-ichi Y, 2008). The capillary 
permeability of the endothelium in newly vascularized tumors is significantly greater than 
that of normal organs and the integrity of the endothelial barrier is perturbed, via EPR 
effect: enhanced permeability and retention effect (Gabizon A, 1992; Jang SH, 2003).  
Studies with radiolabels entrapped in PEG liposomes have indicated that PEG liposomes 
can selectively extravasate in inflammatory tissues, by virtue of the increased permeability 
of the local vascular endothelium (Laverman P, 1999; Dams ET, 2000). 
So, long-circulating PEG liposomes are preferentially delivered and accumulated into the 
tumors which provides a great opportunity for passive targeting into tumor tissues (Maeda 
H, 2000; Luigi C, 2003).  
  
III.3.4.1. In vivo experiment: tumor growth 
 
Balb/c nude female mice were inoculated with 1 x 106 14C-tumor cells (the head and neck 
squamous-cell carcinoma line 14C). Palpable subcutaneous tumors was developed over a 
period of 2-3 weeks. The tumor was measured with a digital caliper in order to calculate 
the tumor volume. When the tumor measured 30 mm3, mice were treated with resveratrol-
loaded long circulating liposomes with an initial concentration of resveratrol of 1 mg/mL 
intravenously (0.102 µg of resveratrol in 200 µL of injected liposomal dispersion). During 
the whole experiment the tumor size was measured twice weekly. When the tumors 
reached the humane endpoint (1000 mm3) the mice were sacrificed one by one.  
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diameter 
(nm) 
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EE (%) 
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Fig 57. Tumor growth after administration of RSV-loaded LCL. 
The tumor volume was reduced in an impressive way in comparison with the vehicle 
(empty liposomes without resveratrol). 
 
III.3.4.2.  Tumor: microscopy 
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Laser Scanning Confocal Microscopy or fluorescence microscopy can be used to 
determine binding of fluorescence labeled liposomes in histological samples (Cavalletti G, 
2009). Tumors were saved with the perspective to do that. No results yet. 
 
III.3.5.  In vivo activity: biodistribution profile 
 
Our understanding of the bioavailability, metabolism and tissue distribution of this 
compound is limited. Orally  ingested trans-resveratrol is extensively metabolized in the 
enterocyte (Gonzalez-Pons E, 2004) before its entry into blood and target organs (Baur 
JA, 2006). To  improve  our understanding of the mechanism of action of trans-resveratrol, 
it  is  necessary  to  know  if  this  compound  or  its metabolites  are present in the body 
and in which organs they are found. A methodology of extraction and quantification of 
trans-resveratrol and its metabolites was performed after  the  intravenous  administration 
of 15 mg/kg to healthy rats (Juan ME, 2009). Because of the limited information on the 
distribution available at present, we modified the existent method for  simultaneous  
determination  of  trans-resveratrol  and  its metabolites in homogenized mice blood and 
tissues. The tissues that we analised were brain, liver, lungs, testis and kidney. 
 
III.3.5.1. Recovery of trans-resveratrol from plasma 
 
Blank plasma samples were spiked with the amount of RSV of 0.4 µg. 
Results derived from HPLC analysis for the isocratic method: 
 
Sample recovery (µg/mL) 
Organic solvent RT 2.16 
Organic solvent -20°C 7.55 
Organic solvent -20°C and salts 9.68 
 
III.3.5.2. Recovery of trans-resveratrol from tissues  
 
Blank brain, testis, liver, lungs and kidneys were spiked with the final concentration of 10 
µmol/g tissue. The samples were than analysed by two different HPLC methods. 
Results derived from HPLC analysis for the isocratic method: 
 
Sample recovery (%) 
liver 1 93.1±9.79 
liver 2 103.0±2.27 
kidney 1 82.1±7.11 
kidney 2 98.6±6.85 
lung 1 85.1±8.22 
lung 2 95.4±2.47 
testis 96.3±6.26 
brain 89.3±5.84 
 
Results derived from HPLC analysis for the gradient method: 
 
Sample recovery (%) 
liver 1 60.6 
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liver 2 77.8±3.79 
kidney 1 61.1±0.00 
kidney 2 67.0±3.05 
lung 1 60.6±2.21 
lung 2 76.9 
testis 79.9±21.33 
brain 71.1 
 
III.3.5.3. In vivo experiment: biodistribution profile 
 
Blood and tissues were saved for defining a biodistribution profile. No results yet. 
 
III.4.   Future perspectives 
 
Tumors will be observed by Laser Scanning Confocal Microscopy or fluorescence 
microscopy to determine binding of fluorescence labeled liposomes in histological samples 
(Cavalletti, 2009). 
Blood and tissues from treated mice were saved in order to assess a biodistribution profile 
after parenteraly administration of resveratrol-loaded PEGylated liposomes.  
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Concluding remarks 
 
During my PhD, innovative formulations were developed in order to try giving answers to 
different therapeutic emergencies.  
 
First of all, malaria, a neglected illness, which continues to be one of the major public 
problems to solve in Africa, Asia and Latin America. The World Health Organisation 
(WHO) has recommended that all the antimalarial drugs must be combined.  In particular,  
artemisinin and its derivatives are suggested as first line treatment against malaria but only 
in combination therapy (ACT) (Ioset JR, 2009; Eastman RT, 2009). Recently, it has been 
reported that curcumin, a very safe natural polyphenol, is active against malaria and  it has 
synergistic effects if administered with artemisinin.  In view of their abundance and safety, 
further investigations related to their combination to develop low-cost antimalarial 
therapies are mandatory (Reddy RC, 2005; Nandakumar DN, 2006). Several innovative 
formulations containing artemisinin were developed and were testing for their stability. 
In vivo studies showed improved pharmacokinetic parameters of artemisinin-loaded  
liposomes and PEGylated liposomes. These results are encouraging and, in a preliminary 
investigation, liposomes have been also positively tested in Plasmodium berghei infected 
mice for their antiplasmodial activity. In the future also the PEGylated liposomes, having 
the best pharmacokinetic performance, will be compared with conventional liposomes for 
the antimalarial activity. Subsequently, artemisinin-curcumin loaded liposomes have been 
developed with the aim of producing an appropriate formulation to be suggested as an 
artemisinin-based combination therapy.  
 
Secondly, neuropathic pain, is a widespread disorder induced by autoimmune diseases, 
drug or toxin exposure, infections, metabolic insults or trauma and it is defined by OMS as 
an untreatable disease. The underlying molecular mechanisms of neuropathic pain are still 
not completely understood, and as a consequence, treatments are unsatisfactory in mostly 
of the cases (Syndrup SH, 1999). There is an urgent need to develop novel therapeutics 
for an effective treatment of this disease. From our study it was found that a β-cyclodextrin 
formulation containing verbascoside 300 mg/kg showed the same antihyperalgesic profile 
of 300 mg/kg verbascoside saline solution when orally administered in a chronic 
constriction injury of the sciatic nerve and in an intra-articular injection of sodium 
monoiodoacetate in the rat paw-pressure test. Conversely, a liposome formulation 
containing verbascoside 100 mg/kg administered i.p. showed a longer lasting 
antihyperalgesic effect in comparison with a 100 mg/kg verbascoside saline solution. To 
the best of our knowledge no study has been reported on the activity of verbascoside on 
neuropathic pain, neither free nor formulated. 
In addition, stability studies revealed that vesicles were physically stable for 90 days and 
neither verbascoside leakage or degradation nor vesicle size alteration occurred during 
this period.  
 
Finally, a model of  tumor (Human Head and Neck Squamous Cell Carcinoma in BALB/c 
nude mice) was treated with resveratrol-loaded PEGylated liposomes. Although the 
stability of PEGylated liposomes containing resveratrol in presence of blood protein, like 
albumin, seemed scarce, in our in vivo experiments, the tumor growth was strikingly 
reduced by resveratrol-loaded PEGylated liposomes  in comparison with the vehicle. 
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